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Cardiovascular disease is the principal cause of death worldwide. Common manifestations are 
peripheral arterial disease (PAD) and coronary heart disease (CHD), which develop as a 
consequence of the critical atherosclerotic narrowing of supplying arteries. Prompt restoration 
of downstream blood flow is essential to avoid the onset of chronic or acute of both pathologies.  
 
Cell therapy has been explored as solution to promote revascularization for patients with severe 
condition of PAD in which surgical revascularization is not suitable, but this approach showed 
limitations with regards of delivery and efficacy of cell homing. 
On the other hand, coronary artery bypass grafts (CABG) remains the preferred therapy for the 
majority of patients with CHD. Autologous vessels, such as the saphenous vein and internal 
thoracic artery, represent the gold standard for grafting small-diameter vessels. However, they 
require invasive harvesting and show low long-term patency rate due to intimal hyperplasia and 
imposed atherosclerosis.  
 
This thesis aims to reach two principal goals: 1) design and manufacture composite hybrid 
scaffolds cellularized with human vascular cells for perivascular promotion of arteriogenesis in 
a murine model of limb ischemia; 2) generation of three-layered small-size vascular graft (VG) 
resembling the complexity of an artery to address the unmet clinical need and shortage of 
natural arterial grafts. Aiming at overcoming the limitation of traditional clinical approaches, 
multi-scale composite scaffolds developed in this work have proven the capability to deliver 
efficiently pro-angiogenic cells in the target ischaemic area and to improve the process of 
collateral formation. This thesis also provides the evidence of the success of the hybrid-VG 
fabrication approach which led to the development of a prototype of biocompatible living 
vascular conduit using innovative cellularization techniques. In fact, the capability to generate a 
graft which possesses distinct and well organized cellular layers, matching the structure of the 
native artery, provides the potentiality to integration and remodelling in a physiologic manner 
following implantation in vivo.  
 
The evidences shown in this thesis, centred on Tissue Engineering approaches, may represent 
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1  Introduction: Vascular Tissue Engineering 
1.1  Cardiovascular diseases 
Cardiovascular disease is the principal cause of death worldwide. Common manifestations are 
coronary heart disease (CHD) and peripheral arterial disease (PAD), which develop as a 
consequence of the critical atherosclerotic narrowing of supplying arteries. The worldwide 
annual incidence of deaths related to cardiovascular disease, is expected to rise to 23.3 million 
by 2030 (Criqui and Aboyans, 2015). In the UK alone, more than 2 million people suffer from 
CHD. Moreover, there are 188,000 hospital episodes attributed to a myocardial infarction (MI) 
each year. 
Peripheral artery disease (PAD) is a pathology consisting in the occlusion of the arteries lumen 
in the abdomen or the legs due to the formation of atherosclerotic plaques. Insufficient blood 
supply to the limbs is initially asymptomatic then, with the atheroma thickening, pain occurs 
followed by intermitted claudication, non-healing wounds, gangrene and limb loss at the final 
stage. PAD is one of the most prevalent, morbid and mortar disease. It has been estimated more 
than 200 million people affected by PAD worldwide (Marrett et al., 2013).  Approximately 12 to 
20% of people over the age of 60 develop PAD and many of them manifest critical limb ischemia, 
which is associated with a poor quality of life and high risk of amputation and death (Townsend 
et al., 2015).  
The possible treatments are chosen depending on the PAD severity. If early stage of the 
pathology could be treated with pharmacological administration, more severe forms of PAD, like 
the critical limb ischemia (CLI), are treated with surgical interventions. Two main approaches are 
followed: endovascular revascularization or bypass. However, both endovascular and bypass 
treatments are subjected to durability issues and the need of intervention repetition 
(Swaminathan et al., 2014). Despite technical advances, graft occlusion may occur up to 50% of 
lower extremity bypasses (Foley et al., 2016). Depending on the failure term, the occlusions can 
be classified as: early (less than 3 months) from mechanical failure due to technical 
imperfections or hypercoagulable state, mid-rem (from 3 to 24 months) due to proliferative 
neointimal hyperplasia and late (more than 24 month) which is related to the progression of the 
underlying pathology (Oresanya et al., 2014). In addition, in the most severe CLI, patients are 
not suitable for surgical revascularization due to multiple occlusion and lack of autologous 
replacement. Recently, novels approaches based on cell and gene therapy have been 
experimented. Several biologic components, like protein, genes and cells have been used to 
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stimulate angiogenesis. Several therapies are at the trial stage and have given encouraging 
results (Swaminathan et al., 2014). 
Coronary Heart Disease (CHD), according to the WHO, is the main cause of death worldwide 
and this data reflects also on European Union in which CHD is the leading single cause of 
mortality responsible for 862,000 deaths a year, which represent the 19% of all deaths 
(European Cardiovascular Disease Statistics 2017, 2017; Mozaffarian et al., 2016; Townsend et 
al., 2015). 
The CHD is the pathological accumulation of atherosclerotic plaques in the coronary arteries 
resulting in the narrowing of the lumen until occlusion in the most compromised cases. As a 
result, there is a decrease of the blood flow to the myocardium occurs and provokes tissue 
hypoxia. The first symptom is the unstable or stable angina, a temporary or constant chest pain, 
culminating in myocardial infraction as a consequence of the complete occlusion of the 
epicardial coronary artery and the resulting myocardial tissue death.  
The main options are represented by the pharmacological therapy, which is mainly carried out 
with fibrinolytic drugs to disintegrate the blood occlusion, or the interventional approach. This 
procedure is employed to restore the blood flow and can be carried out through percutaneous 
coronary intervention (PCI) or surgical bypass of the occluded segment, also called coronary 
artery bypass grafting (CABG) (Sur et al., 2014). 
The PCI is a non-surgical procedure consisting in a preliminary catheterization to visualize the 
occlusion followed by an angioplasty with a balloon catheter placed in the obstruction site and 
inflated to open the artery. Before retracting the instrumentation, a stent is release in the 
occlusion section to help keeping it open; bare metal or drug-eluting (DES) stent are available. 
Second generation drug eluting stents, have also decrease the thrombosis rate, which was an 
issue brought by the DES due to the drug effect that slows down the re-endothelialisation 
(Stettler, 2007). 
Coronary artery bypass grafting is the favourite way of intervention and consists in the complete 
replacement of the clogged coronary segment. Many studies have stated that, due the patient 
short and long term outcomes, is preferable to PCI for several pathology complications, such as: 
high main coronary stenosis, multi-vessel occlusion, recurrent myocardial ischemia refractory to 
medical therapy, life threatening ventricular conditions and patients with unsuccessful PCI 
(Sipahi et al., 2014; Sur et al., 2014). Nowadays autologous replacement, like the saphenous vein 
(SVG) (which represent the gold standard), cephalic vein, basilic vein and internal mammary vein 
(IMA), are considered the most suitable for this purpose. However, limited availability of tissue 
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or donors and limited long-term patency represent the main limitation of the current techniques 
(Harskamp et al., 2013). 
1.2 Process of vascular regeneration 
Prompt restoration of tissue perfusion is pivotal for preventing heart failure in patients with CHD 
and for helping the repair of ischemic limbs. Spontaneous vascular repair comprises two major 
mechanisms: (1) Hypoxia-driven angiogenesis, in which capillaries (cellular tubes formed of 
endothelial cells and lacking other typical wall cells like smooth muscle cells or fibroblasts) 
sprout and organize in networks. Depending on the strength of this process, the newly formed 
capillary plexus can potentially re-establish local tissue perfusion but lacks the potency to 
transport bulk blood flow. In fact, only the growth of arteries can compensate for flow deficits 
caused by arterial occlusions. (2) This latter process, named arteriogenesis, consists of the 
growth of functional arteries from pre-existing collateral anastomoses and the maturation of 
provisional capillaries into arteries through the recruitment of mural cells. Arteriogenesis can 
proceed independently from hypoxia, being triggered by physical forces, such as changes in 
shear stress (Figure 1-1) (Heil et al., 2006), or biochemical signals. 
 
 
Figure 1-1: Scheme of the ischemic hindlimb model. 
The femoral artery is ligated distally to the bifurcation of the A. profunda femoris causing low 
blood pressures distally to the ligation side. Blood flow is now redistributed along the blood 
pressure gradient, thereby recruiting pre-existing collateral anastomoses. In addition, 
arteriogenesis is promoted via maturation and muscularization of capillaries. From Hell et al. 
(Heil et al., 2006) 
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In fact, these processes of spontaneous revascularization involve several cells, like the 
endothelial cells, endothelial tip cells, smooth muscle cells and pericytes, under the regulation 
of angiogenic factors, such as fibroblast growth factor (FGF), platelet derived growth factor 
(PDGF), and vascular endothelial growth factor (VEGF).  
Stem cells or progenitor cells have been proven to have the potential to differentiate into many 
tissue types of the body, including the those belonging to the cardiovascular system, like the 
endothelial cells or the smooth muscle cells.  
Chang et al. showed that injection of Endothelial Progenitor Cells (EPCs) reduced myocardial 
infarct size and decreased ischemia-reperfusion injury (Chang et al., 2013). Furthermore, an 
increase of localized myocardial contraction was assessed. Promotion of in vivo angiogenesis 
was also demonstrated in another study, in which reperfusion was stimulated in mouse model 
of hindlimb ischemia after injection of EPCs in the ischemic limb (Kiewisz et al., 2016; O’Neill et 
al., 2019). Another cell type that acquired high interest in the recent years is induced Pluripotent 
Stem cells (iPSCs). In various studies iPSC-derived progenitor cells (Ja et al., 2016) and iPSC-
derived cardiomyocytes (Chow et al., 2017; Liao et al., 2019) showed potential for treatment of 
ischemic diseases.  In model of myocardial infarction these cells demonstrated a higher capacity 
of stimulating angiogenic processes, reduction of infarcted area and engraftment compared 
with iPSC derived cardiomyocytes (Ja et al., 2016).   
However, most research groups believe that the benefits brought by the stem cells are due to 
their paracrine influence on the surrounding tissues, which includes the release of cytokines and 
grow factors, rather than differentiation of the stem cells themselves.  
Below, I illustrate the spectrum of vascular cells that have been considered for far for 
cardiovascular regenerative medicine and tissue engineering. 
 
1.2.1 Sources of vascular cells 
1.2.1.1 Endothelial progenitor cells 
Asahara et al. (Asahara et al., 1997) identified a source of CD34+ cells in the peripheral blood, 
which also expressed the vascular endothelial growth factor receptor Flk1 and had the ability to 
form tube-like structures when seeded on fibronectin-coated plates. These cells were found to 
differentiate into endothelial cells in vitro, expressing the endothelial markers Flk1, CD31 and 
eNOS and were therefore defined as peripheral blood EPCs (Asahara et al., 1997). In vivo, 
injection of EPCs into the tail vein of a mouse model of limb ischaemia (LI) caused these cells to 
mobilize to the area of ischaemia and appeared to promote vasculogenesis (Asahara et al., 
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1997). Subsequently, Ingram et al. (Ingram et al., 2005)  demonstrated EPCs that could be 
isolated from the umbilical vein and Zengin et al. (Zengin, 2006) identified a source of CD34+ 
cells that residing in the vascular wall, located between the smooth muscle and adventitial 
layers. These cells were negative for CD31 but expressed VEGFR2 and Tie2. In vitro, these cells 
expressed endothelial cell markers VE-cadherin and occluding and like circulating EPCs, formed 
tube-like structures when cultured in collagen gel (Zengin, 2006). Whilst there is some discussion 
as to how to truly identify an EPC (reviewed in Madonna et al. (Madonna and De Caterina, 
2015)), there has been a number of publications demonstrating EPCs can promote 
neovascularization in vitro and in vivo (Asahara et al., 1997; Chang et al., 2013; Xin et al., 2008). 
The advantages of using EPCs for cell therapy are that they are easily isolated using a minimally 
invasive procedure and the cells collected can be used as an autologous cell source. However, 
EPCs are relatively scarce (Case et al., 2007) found that only 0.0084% of cells from peripheral 
blood were EPCs) and this may mean that it is difficult to acquire the required number for cell 
therapy. 
1.2.1.2 Mesenchymal stem cells 
MSCs can be isolated from the bone marrow or found in other tissues such as heart (Avolio et 
al., 2015), blood (Manca et al., 2008), skeletal muscle (Crisan et al., 2008), adipose tissue (Uccelli 
et al., 2008) and blood vessels (Campagnolo et al., 2010). They are a heterogeneous subtype of 
stromal cells. In order to distinguish a clear criteria for defining stem cells of mesenchymal origin, 
the International Society for Cellular Therapy issued a position statement in 2006 (Dominici et 
al., 2006) to address this issue. It was proposed MSC populations must express CD90, CD105 and 
CD73 at >95% of the total cell population when quantified by flow cytometry (Dominici et al., 
2006). Additionally, MSC must be capable of differentiating into multiple lineages, including 
adipocytes, chondrocytes and osteoblasts (Dominici et al., 2006). Obtaining MSCs from patients 
involves processes of varying invasiveness. MSCs can be easily isolated from blood, umbilical 
cord or bone marrow with minimum disturbance to the patient, whereas collection of blood 
vessels would involve a surgical procedure. Once collected, cells are isolated from tissue by 
enzymatic digestion, followed by magnetic sorting to only select MSCs, then expansion ex vivo. 
Therefore, MSCs can be either autologous or allogeneic. In vivo injection of MSCs into animal 
models of MI promotes a reduction in infarct size and improved vascularization (Katare et al., 
2013). Additionally, it has been proposed that some MSCs also have the potential to 
differentiate into vascular smooth muscle cells. Both Hu et al. (Hu et al., 2004) and Rodriguez-
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Menocal et al. (Rodriguez-Menocal et al., 2009) provided evidence that suggests MSCs found in 
the vascular adventitia can also differentiate into vascular smooth muscle cells. 
1.2.1.3 Adventitial progenitor cells 
In our laboratory, we have identified a source of vascular progenitor cells—adventitial 
progenitor cells (APCs), which express typical pericyte (NG2, PDGFRβ), mesenchymal (CD44, 
CD90, CD105) and stemness (c-kit, GATA-4) markers (Campagnolo et al., 2010). These cells are 
isolated from saphenous vein remnants from coronary artery bypass surgery (Campagnolo et 
al., 2010). Our team has a plan to use these cells as an autologous source of stem cells for 
treatment of refractory angina as APCs play an important role in angiogenesis and vascular 
stabilization, are easily isolated from tissue and expand well in vitro. We have demonstrated 
injection of APCs into mouse models of LI or MI results in increased angiogenesis (Campagnolo 
et al., 2010; Rajesh et al., 2013). Injection of APCs into the LI model caused a significant increase 
in the time to recover vessel perfusion and increased numbers of capillaries and arterioles when 
compared to controls (Campagnolo et al., 2010). Similarly, in the mouse MI model injection of 
APCs resulted in increased myocardial blood flow and increased numbers of capillaries and 
arterioles 14-days post-MI when compared to controls. A decrease in vascular permeability was 
also observed. Furthermore, Dil-labelling of the APCs revealed the cells to be found beside 
capillary endothelial cells (Katare et al., 2011). Currently, we are refining the cell isolation 
protocol so we are able to isolate APCs to conform to Good Manufacturing Practice (GMP) in 
preparation for use in a first-in-man clinical trial (Spencer et al., 2015). Using the same protocol, 
we have identified and expanded a similar cell population from the heart of children undergoing 
repair of congenital cardiac defects. These cells express the previously described pericyte, 
mesenchymal and stemness markers and can differentiate into vascular smooth muscle cells. In 
vitro experiments demonstrated a pro-angiogenic response when co-cultured with endothelial 
cells (Avolio et al., 2015). 
1.2.1.4 Other cell sources 
Other sources of cells with vasculogenic potential have been identified. In particular, bone 
marrow-derived multipotent stem cells are a widely investigated cell type due their ease of 
extraction, autologous nature and ability to differentiate into a number of vascular cell types—
endothelial cells, pericytes and smooth muscle cells (Chang-Hwan et al., 2010). Pre-clinical 
studies have demonstrated their pro-vasculogenic potential (Ascione et al., 2015; Chang-Hwan 
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et al., 2010) and already a number of clinical studies of regenerative medicine have been 
performed with these cells. 
1.2.1.5 Mechanism of action 
The mechanism of therapeutic action for stem cells is still a matter of some debate (Gnecchi et 
al., 2012; Madonna and De Caterina, 2015). Proposed mechanisms  include the direct 
incorporation of these cells into tissues and their differentiation into the appropriate cell type 
(F. and J., 2004), paracrine action of pro-angiogenic factors secreted by transplanted cells that 
stimulate the local micro-environment to promote neovascularization (Gnecchi et al., 2005; 
Katare et al., 2013) and the recruitment of resident stem cells to the site of injury (Elisa et al., 
2015). Some in vivo studies have reported a significant reduction in number of transplanted 
stem cells at the site of delivery post-injection (Li et al., 2009; Martin et al., 2005), therefore 
giving more weight to the paracrine action theory. A number of papers have described 
expression of secreted factors that could promote neovascularization or recruitment of other 
cells (Gnecchi et al., 2012; Katare et al., 2011, 2013); however, the full secretome produced by 
these cells remains largely unknown. More recently, it has been suggested that the paracrine 
action is not just restricted to secretion of soluble factors, but also the action micro-RNAs (small 
nucleotide sequences capable of modifying gene expression) secreted from the transplanted 
cells. Katare et al. (Katare et al., 2011) demonstrated secretion of miR-132 by vascular-derived 
stem cells enhanced angiogenesis in a mouse model of LI. De Luca et al. (De Luca et al., 2015) 
recently demonstrated the existence of MSC-derived cellular vesicles that are capable of 
transporting micro-RNAs that can influence gene expression in surrounding cells, whilst Teng et 
al. (Teng et al., 2015) have shown injection of MSC-derived exosomes (small vesicles secreted 
by cells, thought to play a role in cell–cell communication by transporting RNA or protein) in a 
mouse of model of MI reduced infarct size and increased capillary density. These recent findings 
demonstrate significantly that more work is required to elucidate the exact mechanism of action 
of transplanted stem cells. 
1.3 Cell-based strategies for regenerative medicine and tissue engineering 
Due to the crucial role of cells during vascular regeneration, cell-based strategies have been 




i) Cell injection: direct transplantation of the cells on the injured site to promote tissue 
repair, 
ii) Carrier vector for cell delivery: the fabrication of scaffolds with proper surface 
morphology and chemistry, able to attract the cells from the implantation site and drive 
their behavior.  
iii) Medical revascularization: combination of cells into scaffold to create tissue engineered 
vascular grafts (TEVGs) for surgical revascularization. 
1.3.1 Cell injection 
In light of the recent developments in stem cell therapy for the treatment of patients with MI, 
the interest in cell delivery techniques is increasing day by day. Many pre-clinical and clinical 
trials have delivered cells by direct injection into the heart (intra-myocardial injection), which 
allows for a targeted approach, but still may involve open heart surgery (Elisa et al., 2015; 
Gnecchi et al., 2005; Tao et al., 2015). Other trials have used intra-coronary infusion of cells (H. 
et al., 2013). This technique is less complex, offers a more repeatable procedure and avoids the 
risk of ventricular arrhythmia that is associated with intra-myocardial injection. However, this 
technique does require the migration of cells into the myocardium. Currently, these mechanisms 
of delivery are not efficient enough to ensure the desired retention and survival of cells in the 
target area. A number of studies have demonstrated a significant decrease in cell number after 
transplantation, some in as little as 48 hours (Li et al., 2009; Y. et al., 2012). Additionally, the 
presence of the transplanted cells has been found in other various organs, e.g. liver, lungs and 
kidney in addition to the target organ (Yan et al., 2013).  
1.3.2 Scaffold for cell delivery 
Pre-clinical studies are focusing on new cell delivery systems by exploiting the interdisciplinary 
methodologies of cell therapy, nanotechnologies and tissue engineering to achieve the 
therapeutic goal of revascularization and vessel regeneration. Many methods of delivery are 
based on cell encapsulation, in which cells are suspended in microparticles of a viscous polymer 
solution. Pericytes encapsulated in alginate beads have been demonstrated in vitro to stimulate 
vessel structure formation mediated by the release of paracrine factors (Andrejecsk et al., 
2013b).  In vivo trials using MSCs (H. et al., 2013; Katare et al., 2013) and EPCs (Kim et al., 2014) 
encapsulated in alginate or arginine-glycine-aspartic acid conjugated alginate demonstrated an 
increase in arterial collaterals and activation of vascular endothelial growth factor or hepatocyte 
growth factor pathways. There is however concern about this technique based upon the large 
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modification of the injection area due to the high volume of micro-particles required to reach a 
beneficial number of cell release. Other studies have focused on innovative approaches 
consisting of attaching stem cells on to a delivery platform made by pre-designed scaffolds or 
injectable hydrogels. Synthetic polymers have been utilized, in particular polycaprolactone (PCL) 
fibres and PCL nanofibres conjugated with fibronectin, to deliver EPCs (Singh et al., 2011) and 
MSCs (Kim et al., 2014). Naturally occurring scaffolds have also been utilized. Mesenchymal 
progenitor cells (MPCs) have been combined with the natural scaffold from decellularized 
myocardium and fibrin hydrogel (Godier-Furnémont et al., 2011) resulting in the basal recovery 
of left ventricular (LV) dimensions and the formation of a micro-vasculature in the infarcted area. 
Alternatively, researchers are also testing the ability of commercially available prosthetic 
patches, already used is surgery, as cell carriers. The patches are impregnated with cells then 
stitched into the damaged area, allowing specific delivery of the therapeutic cells, but also 
potentially encouraging migration of resident cells (Avolio et al., 2015). Meanwhile, the number 
of papers in literature concerning injectable scaffolds is rapidly increasing due to the potential 
to be easily delivered with the use of catheter. Bone marrow-derived stem cells have been used 
for treatment of MI delivered in injectable materials such as polyethylene-glycol (PEG) (Wang et 
al., 2009), fibrin glue (Nakamuta et al., 2009) and polysaccharides-based chitosan hydrogel (Lu 
et al., 2008), whilst Portalska et al. (Portalska et al., 2013) recently showed the beneficial effect 
of dextran-hyaluronic acid hydrogel combined with MSCs for the treatment of ischaemic 
disease. At first glance, the pre-designed scaffolds represent only a solid carrier for the delivery 
of cells. However, they offer many other potential benefits such as mechanical properties, 
chemical cues, and shape and surface patterning, which can vary widely depending on 
regenerative aim. The intention being the hydrogels or scaffolds will stimulate vasculogenesis 
as well as deliver cells.  
1.3.3 Medical Revascularization 
Spontaneous processes of revascularization are important. In fact, their deterioration caused by 
underpinning comorbidities can worsen the outcome after an ischemic event. Nevertheless, 
they are generally not sufficiently potent and rapid to impede the damage of the ischemic tissue. 
Therefore, prompt reperfusion needs to be realized through medical procedures. Current 
revascularization techniques consist of angioplasty, placement of a stent, or surgical bypass 
grafting. In the United States, an average of 400,000 coronary artery bypass grafting (CABG) 
interventions are recorded annually (Epstein et al., 2011; Pashneh-Tala et al., 2015). Moreover, 
the number of invasive lower-extremity vascular procedures for patients with PAD has doubled 
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over the last decade. As introduced in the previous paragraph, the surgical bypass grafting 
mostly involves the use of autologous vessels, such as the saphenous vein and internal thoracic 
artery. Though representing the gold standard for small-diameter (<6mm) vascular replacement, 
these vessels require invasive harvesting and are often unsuitable for use. For instance, in 
patients needing primary revascularization of the lower extremities, as many as 30% lack a 
suitable autogenous vein. This number increases to 50% in those patients requiring a secondary 
bypass procedure. Furthermore, venous grafts can develop neointimal hyperplasia in the peri-
anastomotic regions. Patency rates for saphenous vein grafting remain limited, with both 
coronary and femoro-popliteal reconstructions showing failure rates of approximately 50% at 
10 years (Collins et al., 2008; Goldman et al., 2004; Harskamp et al., 2013; Kim et al., 2008; van 
Dijk et al., 2007). Surgical revascularization with implantation of conduits made of non-
biodegradable polymers, including Polytetrafluoroethylene (PTFE), Gore-Tex, and Dacron, prove 
to be effective when replacing large vessels. However, when used in the application of small-
diameter vascular grafts, they were complicated by the occurrence of thrombotic occlusions 
(Jackson et al., 2000; Takagi et al., 2010; van Det et al., 2009). 
1.3.4 Tissue Engineering 
Considering the limitations of current vascular bypass conduits (Gui and Niklason, 2014), a 
tissue-engineered vascular graft (TEVG) embedded with cells to generate a living material 
capable of physiological remodeling represents a potential solution for the future of vascular 
surgery. In this introductive chapter, I provide a summary of methodologies and solutions 
adopted in recent years that aim to create functional small-diameter TEVGs. Halfway through 
the twentieth century, the first autologous saphenous vein was used as a vascular graft in a 
clinical application by Kunlin (1951) (Kunlin, 1951). By the end of the 1970s, synthetic material 
such as Dacron (De Bakey et al., 1958) and PTFE (Campbell et al., 1976; Soyer et al., 1972; Tellis 
et al., 1979), were introduced for aortic and lower extremity bypass, respectively. As mentioned 
above, the low patency rate over a long period of implantation was the common limitation of 
these vascular grafts. 
Tissue engineering aims to provide alternative and innovative solutions for small diameter 
vascular replacement, and an interdisciplinary approach could offer the chance to design a graft 
for any specific target tissue and clinical needs. The first commercially available acellular TEVG 
from bovine and human origin, such as Artegraft (North Brunswick, NJ) (Hutchin et al., 1975), 
Procol (Hancock Jaffe Laboratories Inc., Irvine, CA) (Hatzibaloglou et al., 2004), and Cryovein 
(CryoLife, Kennesaw, GA) (Madden et al., 2004), appeared on the market toward the end of the 
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1970s. Nevertheless, the flourishing number of techniques and innovative approaches finds its 
definitive turning point with Weinberg and Bell in 1986, who first tried to fabricate a biological 
vascular graft with xenogenic cells embedded to circumvent the limited availability of 
autologous cells (Weinberg and Bell, 1986). A collagen gel was used as a substrate on which they 
cultured bovine fibroblasts, vascular smooth muscle cells (VSMCs) and endothelial cells (ECs), 
thereby recreating the adventitia, media and intima layers of the vessel, respectively. This 
attempt led to the fabrication of a vessel-like structure with poor mechanical properties, that 
required a Dacron mesh to act as a structural support. Despite its apparent failure, this 
pioneering study drew a new path in TEVG development. From then on, many attempts have 
been made, ultimately leading to a standardized set of quality control criteria for TEVG 
fabrication, that is based on the performance of the actual “gold standard” [for example the 
saphenous vein (SV) or internal mammary artery (IMA)]. The ideal TEVG, therefore, should have 
anti-thrombogenic properties preferentially conferred by a fully autologous endothelium. 
Another important quality requisite is the similarity of TEVG mechanical properties to the native 
tissue, with a recommended minimum burst pressure of 1700 mmHg (Konig et al., 2010; Wise 
et al., 2011), together with a fatigue resistance of 30 days to cyclic loading in vitro (L’Heureux et 
al., 2007) and a level of compliance necessary to avoid excessive stress. A mechanical mismatch 
is acknowledged as a key determinant in the loss of long-term patency, resulting in aneurysm 
formation and implant at failure. The living cell component within the TEVG is critical to provide 
remodeling potential and biochemical signaling (G et al., 2015) while being devoid of 
immunogenic activity. To achieve clinically valuable outcomes, the manufacturing process has 
to take into account other fundamental aspects, such as the capability of the TEVG to be stored 
and delivered ready for the intervention as well as to be easily manipulated during the 
implantation. 
TEVGs can be mainly categorized into self-assembled vascular grafts and scaffold-based 
approaches, using synthetic, natural or hybrid materials. Natural polymers can then be further 
categorized into extracellular matrix (ECM)-based material and decellularized natural matrices. 
1.3.4.1 Scaffold-based TEVG 
The scaffold-based approach represents the most diffuse strategy to build TEVGs. The popularity 
of this methodology is justified by the fact that the presence of physical support enables the 
cells to follow a pathway during their colonization and proliferation. As introduced previously, 
the study performed by Weinberg and Bell pioneered the development of the scaffold-based 
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methodology which during the last 30 years, saw the introduction of many variables and the use 
of a great variety of manufacturing techniques and materials. 
 Synthetic materials 
Synthetic polymers have been widely used for the fabrication of TEVGs. The advantage is that 
the final properties of the graft can be tuned to meet the clinical needs, choosing the 
appropriate fabrication technique and specific material. However, the required higher level of 
technologies and the long period involved in the process of manufacturing constitute significant 
obstacles to clinical translation. Other prominant disadvantages shown by these materials are 
the lack of cell binding sites and the necessity to ensure an anti-thrombogenic property of the 
lumen, as required in the case of PLGA. A variety of polymers and copolymers have been tested. 
The most studied comprise degradable polyesters, like polyglycolic acid (PGA) (E. Niklason and 
S. Langer, 1997; Hoerstrup et al., 2006), poly-lactic acid (PLA), poly-l-lactic acid (PLLA) (Yokota et 
al., 2008), their copolymer poly (lactide-co-glycolide) (PLGA) (In Jeong et al., 2007), and 
polycaprolactone. Among the biodegradable polymers, polyurethanes (PU) (Hashi et al., 2007; 
Nieponice et al., 2010; Sharifpoor et al., 2011) and Poly(glycerol-sebacate) (PGS) (Wu et al., 
2012), which are bioabsorbable elastomers, possess good biocompatibility properties allowing 
proliferation of endothelial cells (ECs) onto the luminal side and parietal infiltration of VSMCs 
(Gao et al., 2006; Rai et al., 2012). Hemocompatibility testing sees PGS having a low platelet 
adhesion and inflammation (Motlagh et al., 2006) and stimulating the production of elastin (Lee 
et al., 2011). However, the main issue was represented by the lack of mechanical properties, 
with a burst pressure of 200 mmHg (Lee et al., 2011). Various TEVG models fabricated with 
synthetic polymers have been assessed in preclinical small and large animal models. Both PU 
(Nieponice et al., 2010) seeded with mouse-derived MSCs and bone marrow-derived stem cells 
(BMDSCs) seeded onto PLA (Hashi et al., 2007) vascular grafts were used in a rat model and 
showed patency rates of 50 and 100% respectively, after several weeks from implantation. PGA 
is the most extensively explored material having been used in sheep (Brennan et al., 2008; 
Cummings et al., 2012), dogs, pigs (Quint et al., 2011) and primate models. Acellular electrospun 
PCL conduits, implanted into a mouse carotid model, allowed complete endothelium formation 
in 28 days. However, neointimal formation was detected, in particular at the anastomoses (Chan 
et al., 2017). Electrospinning microfabrication technique is often used to generate tubular 
structures composed of nanofibers from different polymers. Composite scaffolds made of 
PCL/poly(ethylene oxide) (Wang et al., 2016b) and PCL/PLGA (Ong et al., 2017) have been tested 
in animal models with the later acellular graft having been evaluated in an ovine bilateral 
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arteriovenous shunt model. Such a model showed good results in term of patency (66%) and 
endothelialization of the lumen after 4 weeks of implantation, but the graft eventually dilated 
as a consequence of inadequate elastin content (Ong et al., 2017). 
Despite the great variety of preclinical studies, very few assessed the clinical utility of this type 
of TEVGs. One key study involving synthetic biodegradable polymers has been carried out by 
Niklason et al. using PGA seeded with VSMCs to create a small diameter TEVG (E. Niklason and 
S. Langer, 1997). The graft was conditioned with pulsatile flow for 8 weeks to achieve full 
maturation, through deposition of collagen matrix. At the end of the in vitro culturing, the 
structure showed a burst pressure of 2150 mmHg (Niklason, 1999; Niklason et al., 2001). These 
engineered blood vessels, named Humacyte (Humacyte Incorporated, RTP, NC), were tested in 
a series of small and large animals models, showing 100% patency after 24 days and 88% after 
6 months in dogs and baboons, respectively (Dahl et al., 2011, 2013). These promising results 
led to a clinical trial that got underway in 2012, in which the acellular PGA scaffolds were used 
for vascular access in patients with end-stage renal disease (Gui and Niklason, 2014; Lawson et 
al., 2016). This study involved 60 patients recruited in Poland and the US with an average of 
follow-up period of 16 months, during which 4 patients died, although none were associated 
with the failure of the graft (Lawson et al., 2016) (Table1). Additionally no immune response or 
aneurysm formation was detected. In term of efficacy, the TEVGs were successfully patent (63%) 
at 6 months, while the patency rate dropped to 28% after 12 months. This led to numerous 
interventions of thrombectomy to restore the patency (Lawson et al., 2016). 
  Natural Materials 
ECM-based grafts 
The lack of bio-activity of synthetic scaffolds prompted researchers to investigate natural 
polymers obtained from ECM as a possible alternative option. Proteins derived from the ECM 
have the benefit of maintaining the natural binding sites for cell adhesion, improving biomimetic 
and biocompatibility properties of the material and stimulating the colonization and 
proliferation of recruited cells. Collagen, gelatin, elastin, fibrin, and silk-fibroin are the most 
extensively used in tissue engineering. Different manufacturing techniques can be selected to 
produce a TEVG of this kind. Typical fabrications procedures consist of electrospinning (Soffer et 
al., 2008), freeze-drying (Engbers-Buijtenhuijs et al., 2006; Zhang et al., 2006), and mold casting 
(Boccafoschi et al., 2007; Schutte et al., 2010) (Figure 1-2-C). Electrospun meshes of gelatin 
(Elsayed et al., 2016) have been used, usually in combination with a polymeric structure, to 
improve the surface conjugation with cells, while silk-fibroin nanofibers tubes have been used 
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alone (Marelli et al., 2010) or as a support matrix for coating hydrogel such as collagen (Marelli 
et al., 2012) and gelatin (Marcolin et al., 2017). The feasibility of the approach has been proven 
in vitro, with the tubular scaffold showing encouraging mechanical properties (burst pressure of 





Figure 1-2: Schematic illustration of TEVG manufacturing process.  
A,B) Tissues obtained from biopsies of patients are treated and cells are isolated and expanded 
in vitro. (C) Microfabrication techniques, such as freeze-drying and electrospinning, can be used 
to treat natural and synthetic materials in order to obtain a porous scaffold. Another approach 
sees the casting of a suspension of gel and cells into a mold to produce a tubular structure. 
Vascular and non-vascular tissues, obtained from allogeneic or xenogeneic sources, are used as 
TEVGs after being decellularized by using detergents and enzymes. (D) The TEVG undergoes 
cellularization with the expanded autologous cells before moving to dynamic conditioning into 
bioreactor which allows the maturation of the structure. (E) The manufactured TEVG is 
implanted into the patient (Carrabba and Madeddu, 2018). 
 
Following the Weinberg and Bell study in 1986, most of the studies focusing on natural materials 
have used a gel-based approach. This consists of casting a mixture of the desired gel and cell 
suspension in a tubular mold made of a polypropylene tube. The first period of incubation and 
cell growth is followed by a period of maturation in dynamic conditions to confer properties of 
a vascular tissue (Weinberg and Bell, 1986). Tranquillo et al. achieved the fabrication of a tubular 
structure using a fibrin gel with human dermal fibroblasts, but the burst pressure after 3 weeks 
was still far below (543 mmHg) the SV values (Huynh and Tranquillo, 2010). Natural gels, based 
on collagen and fibrin, have been evaluated as a possible artificial arterial conduit in animal 
models. The above mentioned fibrin-based structure with fibroblasts was implanted into the 
femoral artery of sheep. Cyclic deformation in addition to pulsatile flow conditioning improved 
mechanical properties of the graft (Syedain et al., 2011). To further improve the mechanical 
properties of the TEVG, a suspension of ovine dermal fibroblasts were added to the fibrin and 
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the gelled structure was cultured for a total period of 5 weeks (the first 2 in static conditions and 
the remaining 3 under pulsatile flow stimulation) (Syedain et al., 2014). At the end of the 
conditioning period, the structure was decellularized. This process led to obtaining a TEVG with 
around 4200 mmHg burst pressure, able to remain patent for 24 weeks and with a concentration 
of collagen and elastin close to the natural values (Syedain et al., 2014). In another study, VSMCs 
were used to colonialize the fibrin gel and ECs were seeded on to the luminal side before 
implantation into an ovine model (Liu et al., 2007; Swartz, 2004). This graft showed good results 
in terms of integration with the native vessel but, on the other hand, it displayed poor 
mechanical properties. 
Silk fibroin-based materials were considered as an alternative (Enomoto et al., 2010) and Kaplan 
et al. implanted a graft of this kind in the abdominal aorta of rats (Lovett et al., 2010). No 
thrombosis was seen, and implants remained patent, with the absence of occlusion or ischemia 
detected at the 1 month follow-up. 
Collagen-based vascular grafts were recently tested in vivo and assessed for the feasibility of the 
system to hold microsurgical sutures. Dehydration of crosslinked collagen allowed to create a 
small-diameter TEVG (diameter ≤ 1 mm) with a burst pressure of approximately 1313 mmHg, 
compliance of 1.7%/100 mmHg (comparable with mammalian vein), but the strength of the 
anastomosis at the interface between the rat femoral artery and TEVG was still lower than the 
one between two portions of explanted rat femoral artery (Li et al., 2017). Natural polymers are 
acknowledged to be valid alternatives in the production of small diameter TEVGs, due to their 
higher biocompatibility and capability to remodel in vivo. Nonetheless, natural polymers 
generally offer reduced mechanical strength compared to their synthetic counterparts and can 
be more susceptible to degradation, which, if not carefully controlled, may lead to rupture and 
aneurysm formation. 
Decellularized natural matrices 
The mismatch of mechanical properties, in terms of strength, elasticity, long-term resistance, 
and fatigue, between the fabricated scaffold and the native vessel led to development of grafts 
with a structure more similar to the biological ones, but available as an off-the-shelf product. 
This need was reflected by further attempts to employ decellularization of tissues harvested 
from allogenic or xenogeneic sources (Figure 1-2). The elimination of cells is needed to avoid an 
immunological reaction from the recipient, but agents employed to this scope should have 
properties allowing preservation of the structure and function of the ECM. These techniques 
typically use detergents, like sodium dodecyl sulfate, octylglucoside, sodium deoxycholate, and 
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enzymes, like dispase II, nucleases, phospholipase, and thermolysin, often in combination with 
mechanical and physical methods to accelerate the process (Crapo et al., 2011). 
The approach based on natural matrices to obviate the problems associated with autologous 
grafts, led to the commercialization of a variety of decellularized products, such as Procol 
(Hancock Jaffe Laboratories Inc., Irvine, CA), the SG 100 SynerGraft® vascular graft, (CryoLife, 
Kennesaw, Georgia, USA) and the already mentioned Artegraft (North Brunswick, NJ). To 
improve the properties of these grafts, autologous ECs and VSMCs obtained from differentiation 
of bone marrow-derived cells were seeded in decellularized matrices and then tested in ovine 
(Tillman et al., 2012) and canine models (Cho et al., 2005). 
Decellularized vascular grafts derived from bovine have been widely experimented in clinical 
trials (Chemla and Morsy, 2009; Katzman et al., 2005) in which their performance was compared 
with the classical PTFE graft in arteriovenous fistula (AVF) and bypass procedures (Butler et al., 
1977). Despite the investments, the grafts maintained high costs, showed low patency and 
multiple cases of immunogenic response due to the inefficacy in the decellularization process. 
Sumitran-Holgersson et al. performed the first human study on a single pediatric patient (Table 
1-1), using a decellularized human iliac vein seeded with autologous cells (Olausson et al., 2012). 
The outcomes were promising, with patency up to 2 years even if applied in a low-flow district. 
A recent long-term study (2002–2017) showed the application of a bovine carotid artery graft 
(Artegraft) in lower extremity bypass surgery (Lindsey et al., 2017). Follow-up of 5 years of 
primary endpoints showed positive results for patency (66.7%) and salvage limb rates (81% of 
treated cases) (Table 1-1). 
Among the non-vascular tissues, swine or bovine pericardium have been tested in the past, but 
porcine small intestinal submucosa (SIS) was the first to be assessed as a valid tissue source 
(Sandusky et al., 1995). SIS, used as an arteriovenous shunt in a sheep model, showed burst 
pressure of around 1200 mmHg and the cellularization of the graft improved the anticoagulation 
properties with a lower rate of platelet aggregate formation (Peng et al., 2011). The 
decellularization process has many disadvantages. In fact, the main cause of failure is related to 
immune response induced by leftovers of foreign cellular material. Although the biological origin 
of the tissue reduced the gap between the properties of the native vessel and the built graft, a 
persistent limitation consists of the divergent behaviour under long-term stress. This difference 
leads to failure of the graft and possible creation of an aneurysm. In addition, decellularized 
grafts originating from non-vascular tissue, even if more reliable, are unsuitable for applications 
in which the scaffold has the necessity to adapt and grow with the patient, as in the case of 
correction of congenital vascular defects. In these patients, atherosclerotic and fibrotic 
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remodelling and calcification are the most common consequences of poor integration of the 
graft with the surrounding tissue, resulting in stenosis and graft failure and requiring multiple 
interventions for substitution (Gössl et al., 2012; Shetty et al., 2009; Woo et al., 2016). 
 
 











Decellularized human iliac vein 
seeded with autologous cells 
No commercial product 
Sumitran-Holgersson 
and colleagues 
(Olausson et al., 
2012)  
 
   
Lower extremity 
bypass surgery 
Decellularized bovine carotid 
artery graft 
Commercial name: 
Artegraft, (North Brunswick, NJ) 
Lin and colleagues 
(Lindsey et al., 2017) 





(AV) shunt for 
heamodyalisis  
Decellularization of PGA 




Incorporated, RTP, NC) 
Dahl/Niklason and 
colleagues (Lawson et 
al., 2016) 
   
Self-assembled 
TEVG 
AV shunt for 
heamodyalisis 
access 
Cell-sheet of human fibroblast in 
a shape of conduit. ECs were 
seeded in the graft after 
devitalization of the luminal side. 
Commercial name: 






   
AV shunts for 
hemodialysis 
access 
Cell-sheet of human fibroblast in 
a shape of conduit, without further 
endothelialisation. Dehydrated 










Table 1-1: TEVG in human studies. 




 Hybrid Scaffolds 
Natural and synthetic polymers can be used together to create a composite scaffold in order to 
improve the characteristics that each category possess on its own. In recent years, initially 
positive results led to investment in this approach. A three-layered TEVG has been fabricated 
overlapping nanofibers of PCL, collagen, and PLLA (Haghjooy Javanmard et al., 2016). PCL has 
also been used blended with collagen (Bertram et al., 2017; Tillman et al., 2009), gelatin (Jiang 
et al., 2017) and elastin (Wise et al., 2011) to improve surface adhesion features, while a PLCL 
porous scaffold was coated with nanofibers of silk fibroin (Henry et al., 2017) or alternatively 
with a layer of hMSCs/ECs (Ahn et al., 2015; Pangesty et al., 2017). 
PEG-fibrin hydrogel, with murine smooth muscle progenitor cells, was reinforced with an inner 
layer of electrospun PU fibers (McMahon et al., 2011). in vivo experiments with composite 
TEVGs were performed in the last decade demonstrating the feasibility of the hybrid approach. 
Murine models have been used to evaluate TEVGs composed of nanofibers of PCL blended with 
spider silk and chitosan (Zhao et al., 2013), and the scaffold showed maintenance of the patency 
for up to 8 weeks. A more recent experiment involved a decellularized rat aortic vessel in which 
the lumen was coated with heparin. Aiming at preventing the vessel weakening and consequent 
aneurysm formation, the decellularized structure was externally reinforced with PCL (Gong et 
al., 2016). This hybrid scaffold was easily sutured and displayed improved mechanical properties 
compared to rat autografts, with a burst pressure of 2060 mmHg and patency rate of 100% after 
10 weeks implantation. In a large animal model, Poly(L/D)lactide (P(L/DL)LA) coated with fibrin 
gel was used as an interposed carotid artery graft in sheep (Koch et al., 2010). Autologous ECs, 
VSMCs, and fibroblasts were encapsulated in the fibrin gel and cast around the synthetic 
polymer before the bioreactor conditioning for 21 days to allow for the maturation of the cells. 
The TEVG was then implanted and after 6 months it showed the absence of thrombus and full 
patency. A study was recently performed on a large animal, grafting a PCL/collagen scaffold 
seeded with autologous ECs and VSMCs as arterial interposition. Computed tomography (CT) 
scan and ultrasonography showed no stenosis and structural integrity of the TEVG at 6 months 
follow-up (Ju et al., 2017). Though the hybrid approach offers an opportunity of exploiting the 
qualities of natural and synthetic polymers, a typical drawback is a need for long conditioning 
and the requirement of high technological skills during the manufacturing process. 
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1.3.4.2 Scaffold-free and Self-assembled TEVG 
Despite the improvements achieved in fabricating TEVGs based on scaffolds, some research 
groups believed that scaffolds would force the cells to grow in an unnatural assembly, and 
therefore decided to test the tissue engineered self-assembled (TESA) approach. Self-assembled 
TEVGs are based on the concept that cells, placed in a 3D environment and with the right stimuli, 
would be able to organize themselves in a complex tissue. Currently, three main strategies have 
been investigated: cell-sheet assembly, micro-tissue aggregation, and cell printing (Figure 1-3). 
Different cell sources have been considered suitable to generate a cell-sheet tissue engineered 
graft. Human adipose-derived stromal cells (Vallières et al., 2015) and dermal or SV fibroblasts 
(Bourget et al., 2012) were used to create a scaffold-free graft and, after in vitrocharacterization, 
displayed good mechanical properties and the ability to produce ECM proteins, including 
collagen type I, III, and IV, laminin and fibronectin, which are necessary to give structural support 
to the vessel. The development of this novel scaffold-free approach finds its origin in the success 
of the first trial by the pioneer L'Heureux. In 1998, L'Heureux et al. first documented the 
feasibility of implanting a cell-sheet graft in a canine model (L’Heureux et al., 1998). The 
technique consisted of peeling off a confluent culture of VSMCs and fibroblasts and carefully 
shaping the cell sheet with all the released ECM into a tubular structure (Figure 1-3). 
Conditioning in a bioreactor represents a crucial step to allow the maturation of the cells by 
fusion of the wrapped layers in a unique vascular structure. After the extended conditioning (8 
weeks) under dynamic conditions, the graft showed a burst pressure of around 2600 mmHg, 
which is higher than that of SV. Relevant to the physiological maturation of the graft, the authors 
showed the production of ECM proteins typical of the vasculature and the recruitment of ECs 
onto the luminal surface. Nonetheless, at 7 days post-implantation, the grafts exhibited bleeding 
and detachment of the layers leading to the failure of the implant. To overcome these 
limitations, a new study to fabricate scaffold-free TEVGs was performed, involving only human 
fibroblasts and increasing the period in dynamic culture (L’Heureux et al., 2006). The new grafts 
showed greater performances from the point of view of mechanical properties (burst pressure 
of 3468 mmHg) and were used as an arterial interposition in primate models. The grafts were 
shown to be resistant, did not form aneurysms and were fully patent after 8 weeks. Overall, the 
main limitation of the technique is the time to produce the graft which, considering the duration 
between the formation of a confluent sheet and the fusion throughout the bioreactor 
conditioning, was assessed to be around 28 weeks (L’Heureux et al., 2006). Scaffold-free grafts, 
containing autologous mesenchymal stem cells (MSCs), were tested by Zhao et al. during pre-
clinical studies in a rabbit model (Zhao et al., 2012). The TEVG, used to replace a section of 
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carotid artery 1 cm in length, was fully patent and completely endothelialized after the 4 weeks 
from implantation. An assessment of histology showed a full integration of the cell-sheet graft 
and a more complex remodeling in the laminated structure after the period of implantation. 
 
 
Figure 1-3: Schematic representation of techniques to manufacture scaffold-free vascular grafts. 
A, B) Tissues obtained from biopsies of patients are treated and cells are isolated and expanded 
in vitro. (C) Microfabrication techniques, such as freeze-drying and electrospinning, can be used 
to treat natural and synthetic materials in order to obtain a porous scaffold. Another approach 
sees the casting of a suspension of gel and cells into a mold to produce a tubular structure. 
Vascular and non-vascular tissues, obtained from allogeneic or xenogeneic sources, are used as 
TEVGs after being decellularized by using detergents and enzymes. (D) The TEVG undergoes 
cellularization with the expanded autologous cells before moving to dynamic conditioning into 
bioreactor which allows the maturation of the structure. (E) The manufactured TEVG is 
implanted into the patient (Carrabba and Madeddu, 2018). 
 
In the meantime, the scaffold-free engineered graft developed by L'Heureux et al., patented 
with the name of Cytograft (Cytograft Tissue Engineering, Inc., Novato, CA), was used at the 
beginning of the 2000s in a clinical trial involving 10 patients that suffered from end-stage renal 
disease (McAllister et al., 2009). Fibroblasts obtained from biopsies of the patient were used to 
create the autologous TEVG. The fabrication procedure, illustrated above, was completed with 
the devitalization of the luminal side of the graft, and subsequent seeding of autologous ECs. 
The period of time required to produce these grafts turned out to be around 7.5 months. 
Excluding one patient that died for a cause not related to the graft, the other 3 failures of the 
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self-assembled blood vessel were related to dilatation, thrombosis, and aneurysms. After the 20 
months trial, the overall results of the study were promising. Grafts had 78% patency rate at the 
time point of 1 month and 60% at 6 months. In this study, McAllister et al. demonstrated the 
feasibility of long-distance graft delivery after fabrication in insulated and sealed conditions for 
long distance (McAllister et al., 2009). L'Heureux's group further improved the production of an 
off-the-shelf graft attempting to define a procedure to store the graft after the manufacturing 
process. The cell-sheet based scaffolds were devitalized to be frozen and at the moment in which 
the patient required the implantation they were thawed, rehydrated and autologous ECs were 
finally seeded on the luminal side (Wystrychowski et al., 2011). The new allogenic Lifeline™ 
(Cytograft Tissue Engineering, Inc.), without the seeding of the autologous ECs, was also used in 
patients as shunts for hemodialysis (Table 1-1). The mechanical properties of the graft were not 
affected by the thawing procedure and no immune response was detected (Wystrychowski et 
al., 2014). 
Microtissue aggregation represents a variation among the TESA strategies, in which, to 
circumvent mechanical stress, the cells are not peeled from the culture surface and the post-
culturing manipulation to shape the graft is avoided using a growing template. In this approach, 
a temperature–responsive poly(N-isopropylacrylamide) is used as culturing surface, allowing the 
easy detachment of the cell aggregate when the culture is confluent (Asakawa et al., 2010). 
Alternatively, high density hanging drop cells are deposited in the mold for in situ merging by 
secretion of ECM, representing building blocks for vascular-like structures  (Marga et al., 2012). 
Kelm et al. obtained a tubular structure by the aggregation of human artery-derived fibroblasts 
and HUVECs (Kelm et al., 2010) (Figure 1-3B). Fourteen days of conditioning with dynamic 
pulsatile flow allowed the fusion of the multiple blocks in a unique tissue with layered tissue 
formation. 
One typical constraint of the TESA technique is the limited shape that the graft can assume. In 
fact, the inability of the cell aggregation to self-sustain, forced the researcher to keep the 
geometry as simple as possible. The possibility to rectify this limitation was recently proposed 
by the use of Bioprinting, which may have the refined capability to build a patient-specific 
arterial vessel (Figure 1-3C). Bioprinting is currently used to create constructs for growth factor 
delivery (Gao et al., 2015), in vitro microvacularized constructs (Bertassoni et al., 2014; Cui and 
Boland, 2009; Gao et al., 2015; Kamei et al., 2006; Kolesky et al., 2014; Miller et al., 2012) and 
myocardial patches (Gaebel et al., 2011; Gaetani et al., 2012, 2015). Some studies have focused 
on providing a proof-of-concept for manufacturing vascular structures with the intention to be 
used as small-diameter TEVGs (Borovjagin et al., 2017; Duan, 2017). A novel approach exploited 
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the concept of self-assembly through the fusion of cell spheroids forming a unique tubular 
structure (Mironov et al., 2009b). Norette et al. performed an initial study attempting to bioprint 
a complex vascular tree (Norotte, 2009). The high flexibility of this approach allowed the 
fabrication of tubular structures by aggregation of spheroids, with connected branches of 
accurate diameter and wall thickness. On the other hand, this strategy showed limitations in 
terms of sterility and its time-consuming nature. Maintaining the integrity of the environment 
during the assembling of the vascular tree is challenging, and a minimum of 7 days is required 
to allow for the fusion of the spheroids on to the tubular surface. To overcome some of these 
disadvantages, Norette et al. reduced the complexity of the system and succeeded in the 
creation of a tubular structure by deposition of human umbilical vein VSMCs and skin fibroblasts 
(Norotte, 2009). Additionally, mouse embryonic fibroblasts have been used by Kucukgul et al. to 
fabricate a scaffold-free arterial construct (Kucukgul et al., 2015). A bioprinted vascular graft 
suitable for implantation and delivery to any large in vivo model or clinical trial has not been 
developed, mainly due to the lack of mechanical properties and the long period required to 
produce a stable structure. 
The necessity to find an alternative to autologous vascular grafts led to the development of 
TEVG, which, exploiting the combination of multiple approaches, holds promise to match the 
minimal requirement of current autologous vessels. Many improvements have been awarded in 
the recent past and results from in vivo experiments showed encouraging outcomes. 
Nevertheless, initial clinical trials did not always confirm the experimental findings, thus 
suggesting there is still room for improvements in the translational process. 
Failure of TEVG could occur at different time points after the implantation and, accordingly, can 
be classified as early, midterm and late failures (Pashneh-Tala et al., 2015). Acute thrombosis is 
the main cause of early failure (within 3 months after implantation) and it is a coagulation 
reaction driven by platelet adhesion on collagen, which in the native vasculature is avoided by 
the anti-thrombotic properties of the endothelium. Acellular and decellularized TEVGs are 
mostly affected by this issue. Biodegradable TEVGs, cellularized or based on hybrid approach, 
shielding the scaffold lumen from the bloodstream, show a reduction in thrombus events. 
Multiple solutions have been explored, combining different synthetic and natural materials and 
performing chemical functionalization of the surface to improve anti-thrombogenic properties 
(Seifu et al., 2013; Tara et al., 2014). Furthermore, biodegradable polymers offer the possibility 
for the cells to colonialize the porous structure and thereby stimulate the production of ECM 
proteins. On the other hand, if the properties of the polymers are not well tuned, the intimal 
thickening can reduce the patency caused by the excessive migration and proliferation of cells. 
24 
 
Lumen occlusion due to anastomotic intimal hyperplasia typically characterizes the midterm 
failures (from 3 months to 2 years). Late term failure is associated, instead, to recurrent 
atherosclerotic disease and is a common problem with all the current approaches. It is mainly 
due to the loss in consistency of the graft or poor in vivo integration. 
1.3.4.3 Advantages of cellularization 
So far, decellularized native tissues are the most successful in vivo approach, although post-
implantation thrombus events are the main limitation for low long-term patency. Moreover, 
decellularization is still a topic of debate because the incompleteness of the process may lead 
to an immunogenic reaction by the recipient, whereas an excessive chemical treatment can 
provoke the loss of mechanical properties and aneurysmal dilatation (Shojaee and Bashur, 
2017). 
On the other hand, recent improvements in biodegradable TEVG production, offering a wider 
range of physical properties and the capability to remodel in vivo, might represent a potential 
solution to generate a valid TEVG. New microfabrication technologies allow patient-specific 
manufacturing of the TEVG, eliminating the dimension mismatch at the anastomosis site. This 
approach is particularly suitable for correction of congenital related diseases. Nevertheless, 
patency rate is still drastically lower than autologous grafts, with in vivo animal experiments no 
longer than 2 years. 
For the category of cellularized TEVGs, the cell source represents a much discussed topic. As 
described in the previous paragraphs, an extensive variety of cells have been tested, both to 
build the core of the graft (in the case of a scaffold-free approach) and to cellularize the scaffold 
in the pre-implantation stage. Autologous mature vascular cells, like VSMCs, ECs, and fibroblasts, 
have been used to cellularize TEVGs with success. Here, the main limitation is represented by 
the extraction from a patient biopsy, thereby leading to insufficient expansion (G et al., 2015). 
Adult stem cells, such as BM-MSCs have been used in consideration of their high proliferative 
property. The time-consuming process of fabrication, cellularization or chemical treatment is 
often not compatible with the urgent need of patients suffering severe pathology. This can only 
be solved through the adoption of an off-the-shelf TEVGs. In this approach, standardization of 
the fabrication process, preservation of sterile conditions and delivery represent the main 
challenges. However, the potential of having a ready to use graft, with advantages for patients 




1.4 Economics considerations 
Owing to the growing target-population for tissue engineering technologies/products under 
development for cardiac and vascular indications, as well as the major healthcare costs 
associated with existing treatments, the potential financial figure for these products is in the 
range of multibillion-dollar volume. In the U.S. alone, the total potential market for tissue 
engineering and cell transplantation technologies is expected to exceed USD 22.8 billion in the 
year 2019. Furthermore, the global vascular graft market is expected to reach USD 3,626 million 
by 2022, according to a new study by Grand View Research, Inc. There is a positive prospect that 
rising healthcare expenditure, favourable reimbursement policies, and technological 
breakthroughs will boost growth in the vascular graft market over the next 10 years. At present, 
TEVGs contribute a minimal part of these financial figures, however, a number of positive factors 





1.5 Aim of the Thesis 
In the following chapters, I illustrate the results of my work during the PhD studentship. The 
goals of this project were twofold.  
i) The first goal was to address the unmet need of vascular patients in which a classical 
revascularization approach is not achievable. 
With regard to the heart, nearly a quarter of ST-elevation MI (STEMI) patients in the UK are 
not amenable to revascularization or receive revascularization later than the recommended 
time target, resulting in larger infarcts, frequent angina attacks, and increased risk of heart 
failure and death. In the United States alone there are ≈850,000 patients who suffer angina 
unresponsive to maximal medical therapy, and there are 100,000 new refractory angina 
cases per year in Europe. It is now well recognized that these patients have microvascular 
disease, with impaired endothelium-mediated vasorelaxation and reduced coronary flow 
reserve. Currently, the treatment of refractory myocardial ischaemia remains a major clinical 
challenge. Moreover, around 30% of patients with CLI present with non-reconstructable 
disease, a situation particularly critical for diabetic patients, due to calcific and fibrocalcific 
disease in the distal vasculature (Norgren et al., 2007). As a consequence, there is a 4-fold 
increased risk for diabetic patients diagnosed with CLI to develop tissue necrosis and/or 
gangrene as compared with patients without diabetes (Lévigne et al., 2013; Tobalem et al., 
2015). In chapter 2 and 3, we propose a solution consisting of the perivascular delivery of 
composite scaffolds functionalized with vascular cells to promote collateralization of 
occluded artery in a model of limb ischemia. 
ii) The second goal was to address the unmet need of small size vascular grafts. Autologous 
vessels, such as the saphenous vein and internal thoracic artery, represent the gold standard 
for grafting small-diameter vessels. However, they require invasive harvesting and are often 
unavailable. One third of patients undergoing primary revascularization of the lower 
extremities lack a suitable autogenous vein and this number doubles with secondary bypass 
procedures. Moreover, the patency rate remains suboptimal, with both coronary and 
femoro-popliteal reconstructions showing failure rates from 50 to 80% at 8-10 years' follow-
up (Angelini et al., 2009; Harskamp et al., 2013).  Arterial grafts have better patency rates 
than vein grafts, but they are underused because of the higher procedural complexity and 
risk of complications. Synthetic vascular grafts represent an alternative to autologous 
vessels. They have shown satisfactory long-term results for replacement of large- and 
medium-diameter arteries, such as the carotid or common femoral artery (Chlupac et al., 
2009),  but have poor patency rates when applied to small-diameter vessels (<6 mm), such 
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as coronary, infra-inguinal, and infra-geniculate arteries (Pampaloni et al., 2007; Seifu et al., 
2013).  For these indications, autologous bypasses remain superior to synthetic prostheses 
(Ballotta et al., 2003).   
Considering the limitations of current bypass conduits, a tissue-engineered vascular graft 
(TEVG) with the ability to grow, remodel, and repair in vivo presents a potentially definitive 
solution. Synthetic conduits decorated with autologous endothelial cells (ECs) showed 
improved patency rate, but this improvement did not suffice to surpass autologous grafts 
(Deutsch et al., 2009). In particular, none of the so far fabricated TEVGs possess the 
properties of a natural artery, including proper compliance, resistance to burst pressure, and 
anastomotic strength .Chapter 4 describes my attempt to generate a novel small-size TEVG 
constructed by innovative fabrication techniques (Pashneh-Tala et al., 2015) and 







2 Design, fabrication and perivascular implantation of bioactive 
scaffolds engineered with human adventitial progenitor cells 
for stimulation of arteriogenesis in peripheral ischemia 
2.1 Rationale and aim of the study 
In this chapter, I report the first therapeutic preclinical trial of human adventitial progenitor 
cells-engineered scaffold implantation in a murine model of unilateral limb ischemia. The results 
of this study have been published in the journal Biofabrication (Carrabba et al., 2016).  
Enlargement of pre-existing arterial collaterals and formation of new conduit vessels through 
neo-arteriogenesis are essential requisites for reperfusion of ischemic limbs and hence 
represent a rational target for novel therapeutic strategies.  
We hypothesize that these processes can be fostered by the perivascular implantation of pro-
angiogenic/arteriogenic cells. We also propose that the incorporation of these cells into a 
biodegradable scaffold will improve their homing and paracrine activity. Furthermore, seeding 
the cells into the scaffold according to a defined topographical pattern will confer the 
engineered product with enhanced therapeutic precision.  
Therefore, the general objective of the preclinical trial was to implant a bioactive material 
favouring the formation of aligned arterial collaterals able to bypass the occluded femoral 
artery. The expected outcome was that the new formed collaterals would confer the limb tissue 
below the site of occlusion with proper blood perfusion. The scaffold is biodegradable, thus 
allowing the re-establishment of the regular anatomy at the completion of the reparative 
process. 
2.2 Comparison with competitive approaches and conceptual novelties 
The proposed approach can potentially surpass traditional therapeutic angiogenesis. Usually, 
the scope of therapeutic angiogenesis is to enhance the microvascular bed of ischemic tissues 
by muscular injection of growth factors or cells. The strategy proposed here is intended to 
potentiate major collaterals, which would increase perfusion but also serve as a stream for 
extended delivery of cell-derived paracrine factors to the distal part of the limb. This would 
result in potentiation of both proximal arteriogenesis and muscular micro-angiogenesis.  
There are distinctively innovative aspects in this study, namely the unprecedented use of human 
adventitial progenitor cells for tissue engineering, the manufacturing of a biocompatible, 
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degradable composite scaffold, the combination of cells and scaffold according to a coherent 
patterning, and the perivascular application of the cell-engineered scaffold around the occluded 
femoral artery. Here, we provide more in depth details of innovation. 
Cell product. As a cellular source for scaffold functionalization, we used adventitial progenitor 
cells isolated/expanded from remnants of saphenous vein of coronary artery bypass graft 
surgery. This is a convenient source of regenerative cells, readily available to us, under Ethical 
Approval and Patient’s Consent, from the Bristol Heart Institute - University Hospitals Bristol. 
However, any other vascular tissue could be used for adventitial progenitor cell derivation, 
according to the patient’s needs. Adventitial progenitor cells are attracting considerable 
attention for applications of cardiovascular regenerative medicine (Avolio et al., 2017). They are 
ideally suited to the scope of this project owing their topical proangiogenic properties and native 
acquaintance with the perivascular niche. Human adventitial progenitor cells have been 
developed to a clinical-grade cell product in our laboratory (Campagnolo et al., 2010). However, 
considering the high costs associated with clinical-grade cell manufacture, here we used a 
laboratory-grade protocol of cell derivation and expansion.  
Scaffold. The novel bio-engineered scaffolds were manufactured to provide a temporary 
artificial extracellular matrix (ECM) to support cell engraftment and guide the formation of a 
well-aligned arterial collateralization. Woodpile- or channel-shaped polycaprolactone (PCL) 
scaffolds were fabricated using a computer-assisted writing approach (pressure assisted micro-
syringe square (PAM2) (Tirella et al., 2011), which allows the precise configuration of a 3D 
architecture at the microscale level and thus confers greater control of cell organization. This 
step was followed by electrospinning deposition of nanofiber of the natural polymer gelatin (GL), 
which provides integrin binding sites for improved cell adhesion (Mano et al., 2007). The 
electrospinning system uses a high voltage field to launch a jet of GL strand onto the scaffold, 
thereby forming a nanofibers network with adhesive features similar to those of the natural 
ECM (Yeo et al., 2011). Two crosslinking agents, γ-glycidoxypropyltrimethoxysilane (GPTMS) and 
Genipin (GP), were used to increase scaffold durability.  
Delivery system. We wished to overcome the limits of delivery methodologies, which as yet are 
not efficient enough to achieve optimal distribution of therapeutic cells (see also Introduction). 
In the case of peripheral ischemia, the intra-arterial route is unsuitable for patients with multiple 
occlusions, as cells will not reach the ischemic tissue by blood flow. Intra-muscular delivery of 
dispersed cells results in stimulation of patchy microvascular angiogenesis below the occlusion 
site, which may be insufficient to promote an efficient reperfusion. An innovative method 
consists of transplanting stem cells perivascularly, e.g. along the blocked limb arteries, with the 
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intention to increase the formation of arterial collaterals bypassing the obstruction. Delivery of 
stem cells embedded in scaffolds or microparticles has been proposed for improving cell 
viability, tolerogenicity and paracrine activity (Goren et al., 2010; Montanucci et al., 2011; 
Weber et al., 2010). We have recently documented the advantages of combining the two 
approaches. In a mouse model of limb ischemia, perivascular delivery of microbeads filled with 
human mesenchymal stem cells (MSCs) stimulated the growth of arterioles alongside the 
occluded femoral artery, thereby improving perfusion, oxygenation and limb salvage (Katare et 
al., 2013). The tributary microvascular bed was also enhanced, as documented by increased 
counts of capillaries and arterioles in the ischemic adductor. Therefore, the method allows for 
additive implementation of proximal collateralization and distal microvascular angiogenesis. 
However, cell delivery by microbeads has also limitations. First, microencapsulated cells are 
unavailable for direct participation in vascular reparative remodeling. Second, random 
distribution in the target tissue does not ensure the development of an ordered 
neovascularization. The use of a composite scaffold as a method to deliver proangiogenic cells 




2.3 Work-packages of the preclinical study 
The present study comprises four main work-packages, illustrated in Figure 2-1: (1) fabrication 
of 3D scaffolds made of PCL and gelatin, (2) functionalization of scaffolds with human adventitial 
progenitor cells, (3) in vitro testing of cellularized scaffolds, and (4) in vivo perivascular 
transplantation of cellularized scaffolds in a mouse model of limb ischemia.  
 
Figure 2-1: Work-packages Chapter 2. 












2.4 Materials and methods 
2.4.1 Cell biology materials and methods 
2.4.1.1 Adventitial progenitor cells isolation and culture 
Cells were obtained from vein leftovers from Coronary Artery Bypass Graft (CABG) surgery, using 
a standard operating protocol as previously described (Campagnolo et al., 2010). Clinical 
characteristics of the patients are not reported due to limited access to the data imposed by the 
ethical approval. In brief, saphenous veins were carefully dissected from surrounding tissues 
using a sterile scalpel and then thoroughly washed in PBS. Veins were manually minced prior to 
4 hours incubation with 3.7 mg/mL Liberase 2 (Roche Technologies). Single cell suspension was 
ensured by passing the dissociated material through a 30 μm cell strainer. The suspension was 
then depleted of ECs using anti-CD31 conjugated beads (Miltenyi Biotech), followed by positive 
selection for CD34+ cells by anti-CD34 beads (Miltenyi Biotech). The immunosorted CD34+ cells 
were then plated on gelatin/fibronectin (10μg/mL) coated plates in presence of Endothelial 
Growth Medium 2 (EGM2) medium (PromoCell) supplemented with 2% FBS. Adherent colonies 
were passaged to new culture dishes once they reached 60-70% confluence. Cells were washed 
with PBS and incubated for 5 min in a solution of 0.05% (w/v) trypsin to detach them from the 
culturing surface. The trypsin activity was neutralized adding a solution of 10% FBS at the ratio 
of 1:2, and the whole suspension was centrifuged at 400g for 10 minutes. At the end of 
centrifuging period, the supernatant was discarded and the adventitial progenitor cell pellet was 
re-suspended in 1 ml of EGM2 (cat#: C-39211, PromoCell). Cells were counted and seeded in a 
new culturing plate at the density of 10,000 cell·cm-2. All in vitro experiments were set up with 
cells at P7. Purity of the preparations was determined by flow cytometry using combinations of 
the following antibodies to confirm typical phenotype: anti-CD44 (ebioscience), anti-CD-105 
(Life Technologies) and anti-CD90 (BD biosciences). After staining, fluorescence was analyzed 
using a FACS Canto II flow cytometer and FACS Diva software (both BD Biosciences). Flow-
cytometry analysis indicates that >95% cells express the surface antigens CD105, CD44 and 
CD90.  
2.4.1.2 Cell cryopreservation and resuscitation 
For cell storage, a cell-specific freezing media was prepared: 50% EGM2, 40% FBS and 10% 
dimethyl-sulphoxide (DMSO). Adventitial progenitor cells detached from the culturing plate, 
were suspended in 1ml freezing media and pipetted into a cryovial (Thermofisher). This latter 
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was immediately stored at -80°C in a dedicated container which allows the freezing of the cells 
at the rate of -1°C·min-1. The following day, the cryovial was moved into a liquid nitrogen tank 
for long term storage. During the process of cells resuscitation, the cryovial was immerged in a 
37°C water-bath for 1 min to allow the gradual thawing. The cell suspension was immediately 
pipetted into a 15ml Falcon tube containing 3 ml of EGM2. The tube was centrifuged at 400g for 
10 minutes and, after discarding the supernatant, the pellet was resuspended and transferred 
into a culturing flask and incubated at 37 °C and 5% CO2.  
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2.4.2 Scaffolds material and methods 
2.4.2.1 Use of polycaprolactone (PCL) as a polymer in the PAM2 fabrication of 
the multi-layered scaffold backbone 
In this study, I used PCL (average Mn 80,000, cat:440744, Sigma-UK) to manufacture different 
geometries of the 3D scaffold where cells are expected to migrate from gelatin nanofibers and 
organize following the different topographic patterns. The choice of this polymer was based on 
preliminary research of data from literature indicating PCL has excellent biocompatibility, 
biodegradability, workability, and both mechanical and chemical properties (Hollister, 2005; 
Hutmacher et al., 2004); characteristics that made the synthetic polymer Food and Drug 
Administration (FDA) approved.  
PCL is an aliphatic polyester obtained from the polymerization of the open cycle of ε- 
caprolactone. Its linear aliphatic structure confers the ability to degrade in the physiological 
environment due to the easy interaction that the aliphatic ester bond has with water molecules. 
This mechanism of degradation activated by chemical hydrolysis allows the PCL to be counted 
as one of the main representatives of the class of biodegradable polymers (Mondal et al., 2016). 
The process of degradation has a relatively slow rate, between 6 and 24 months, following in 
vivo implantation under physiological conditions. 
2.4.2.2 Use of gelatin (GL) as a natural agent to provide additional physical and 
chemical biocompatibility features instrumental to initial cell 
engraftment into the scaffold  
I employed GL type A from porcine skin (G1890-500G – Sigma Aldrich) to generate a 
nanofibers layer allowing initial homing of seeded cells.  
GL is the product of thermal denaturation or disintegration of insoluble collagen. The 
denaturation is a process in which a protein loses its 3D structure but keeps its sequence of 
amino acids (primary structure). It can be carried out either physically, through freezing or 
heating, or chemically, with the addition of reducing or oxidising agents. A third way is 
possible through enzymatic digestion. The most widely used types of GL are bovine and 
porcine skin gelatines owing to the large availability. GL has the main property of forming gel 
when dissolved in hydrogen bond friendly solvents with a concentration usually larger than 2% 
w/v and below gelation transition point of 30°C. In this condition, the GL molecule aggregates 
forming a 3D interconnected network, property that has been widely explored for tissue 
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engineering. GL, in fact, has been used as a cell interactive coating and microcarrier for drug 
delivery. Moreover, GL has attracting interest as a biomaterial because it provides physical and 
chemical signals (like the RGD sequence) to drive cell attachment and proliferation, is 
biocompatible, biodegradable and relatively cheap compared with other biomaterials.  
2.4.2.3 Use of crosslinking agents γ-glycidoxypropyltrimethoxysilane (GPTMS) 
and genipin (GP) 
In tissue engineering applications, crosslinking agents are generally used to provide tensile 
strength. In this work, I have employed γ-Glycidoxypropyltrimethoxysilane (GPTMS) (Sigma 
Aldrich, Milan, Italy) and Genipin (GP) (Challenge Bioproducts Ltd., Taichung, Taiwan) to 
crosslink GL, thereby delaying its degradation in an aqueous environment. This would otherwise 
liberate cells too prematurely after in vivo implantation, before they could be incorporated into 
the core of the scaffold. 
GPTMS is a silane-coupling agent, in which the oxirane ring reacts with the amino groups of the 
GL chains. The hydration of the trimethoxy groups on the GPTMS forms pendent silanol groups 
(Si-OH) through an acid catalyzed reaction. Then, Si-O-Si bonds are formed thanks to the 
condensation of two silanol groups during the solvent evaporation step in the fabrication 
process. The Si-O-Si linkages provide inter-chain covalent bonds, resulting in a more stable 
crosslinked structure (Chao, 2008; Ren et al., 2002).  
GP is a naturally occurring agent that can be used as a coupling agent for amino containing 
materials. GL indeed is chemically crosslinked through the creation of bonds between functional 
groups of amino acids. Crosslinking mechanism of GP with GL consists of two reactions, involving 




2.4.3 Design and fabrication of multi-scale scaffolds 
The scaffold was manufactured according to a multi-scale and multi-material approach in the 
attempt to mimic the hierarchical organization of the native ECM. In particular, the focus of 
fabrication was on topography, biocompatibility, and mechanical properties. To this aim, I have 
considered specific microfabrication techniques allowing the generation of different geometry 
and scale of interaction of material with cells. In particular, the use of a composite scaffold was 
intended to combine the mechanical properties of the synthetic material PCL with the 
biochemical cues from GL to improve cell adhesion.  
In this thesis, I will refer to this type of scaffold as composite-planar scaffold. The fabrication of 
the composite-planar scaffold was carried out by the combination of two different techniques, 
PAM2 and Electrospinning, which are described in the following paragraphs. 
2.4.3.1 Pressure Activated Microsyringe2 (PAM2) fabrication system 
The Pressure Activated Microsyringe2 (PAM2) is a microfabrication technique entirely developed 
and fabricated by the bioengineering research group at Research Centre "E. Piaggio", Faculty of 
Engineering, University of Pisa. It belongs to the family of Rapid Prototyping techniques and It 
allows the manufacturing of scaffolds made of a wide range of biomaterials and with a well-
defined architecture (Cei et al., 2014; Tirella et al., 2011, 2012; Vozzi et al., 2012). Here, we 
describe the principal components of the system. 
The motorized component (Figure 2-2) allows the movement of a pressure syringe system 
extruding liquid material according to orthogonal XYZ axes. The XY plane moving with respect to 
the Z-axis draws the trajectories for the formation of each slice. The Z-motor drives the 
movement of the syringe (connected to the Z-stage) in Z-direction, allowing the deposition of 
additional layers. The vertical increment (ΔZ) made by the Z-stage after the deposition of every 




Figure 2-2: Image of the motorized system configuration; (Tirella et al., 2012) 
 
The computerized system and dedicated software controls and manages the whole 
microfabrication process, according to a CAD/CAM approach (Computer Assisted Design/ 
Computer Assisted Manufacturing) described previously (Tirella et al., 2011).  
In brief, the control panel of the software allows the operator to select the main parameters of 
polymer extrusion (Figure 2-3): namely, speed and air pressure. The interface enables also to 
choose and design the drawing path. A high level of accuracy is needed when dealing with 
complex geometry in order to avoid points of multiple extrusion and consequent uneven 
accumulation of material. Accordingly, the adopted system uses an approach called “direct 




Figure 2-3: PAM2 Software.  
A) the Image shows the main page of the PAM2 control software. Highlighted in the images, the 
pattern (1), the speed (2) and the air pressure controls (3). B) single layer of extruded PCL 
material with defined geometry; C) multiple-layer deposition of PCL. 
The Pressure Activated Micro-syringe incorporated in the PAM2 system drives the extrusion of 
low-viscosity solutions. The pressure is controlled through a pneumatic valve connected to the 
syringe of the device, and the solution is extruded through glass needles of micrometric 
dimensions (with a diameter of 80μm) (Figure 2-4). 
 
 
Figure 2-4: Syringe system of the PAM2 and all its components 
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2.4.3.2 PAM2 working parameters set-up 
During this stage of the work, I carried out the calibration of the PAM2 initially set up at the 
Research Centre "E. Piaggio", University of Pisa. The PCL solution was prepared by dissolving the 
polymer in chloroform at a concentration of 10% (w/v) using a magnetic stirrer. The first test 
with PAM2 was the assessment of line width deposited with speed (5-10mm·s-1) and pressure 
(8-16kPa) variables. The structures have been evaluated by measuring the width of the lines 
deposited through an optical microscope (AX70, Olympus, Tokyo, Japan).  
After tuning of the deposited line of a PCL single layer, I proceeded to set up an optimal protocol 
for the layer-by-layer fabrication of the 3D scaffold. The process of precise stacking requires the 
addition of a sacrificial material to allow the deposition of a polymer layer on top of this layer 
avoiding the fusion of the two layers (Figure 2-5). The presence of the solvent in the extruded 
material, in fact, would melt the new layer with the underlying one. To circumvent this problem, 
I used a 4% solution of Hydrolene® (LTF/K, Ecopol Italy), which is a polymer support soluble in 
water. The Hydrolene solution was added before every layer deposition and allowed the piling 
of PCL up to 7 layers. 
 
Figure 2-5: Schematic representation of layers stacking process. 
 A) The deposition of the first PCL filament, is followed by the deposition of Hydrolene. Then, a 
subsequent filament of PCL is extruded without risk of melting of the layers; B) Comparison 
between the aspect of the extruded filament of PCL with (on the left side) and without 
Hydrolene (right side). 
2.4.3.3 Patterns of polymer fabrication 
The morphology of the seeding surface is strictly related to the migration and colonization 
behaviour of cells. To assess the effect of the geometry, in this work I fabricated and tested two 
distinct patterns (Figure 2-6): 
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1) Woodpile is a multilevel structure composed of 6 layers of biodegradable PCL (Figure 2-6A). 
The final organization is the result of alternation of serpentine rotated 90° from each other. This 
allowed the structure to have a well-defined organization of interconnected pores with size of 
200μm per side and 100μm wide lines. The final height was of around 70μm. 
2) Channels derived from overlapping 6 layers of extruded PCL (Figure 2-6B). Structures were 
formed that were 150–200μm wide, 70μm high, and arranged around 100μm wide lines. The 
bottom part of the channel was composed of a grid layer built using the PAM2 technique, with 
the aim of avoiding channel structure collapse at the time of detachment from the deposition 
plate. 
 
Figure 2-6: 3D pattern of PAM2 fabricated scaffold. 
3D render of the PAM2 microfabricated scaffold: A) channels, B) woodpile 
2.4.3.4 Electrospinning fabrication system 
 Electrospinning is a fabrication technique used to create thin fibres for many purposes, from 
clothing to filters and, as shown here, tissue engineering. The general working principle involves 
producing an electric field between two electrodes to extrude nanometer fibres (Figure 2-7). 
One of the electrodes is attached to a syringe loaded with the polymer solution, while the second 
one is attached to a designed collector for the deposition of the fibres. Due to the high voltage, 
the polymer solution on the needle tip of the syringe is stretched to form nanometer fibres, 




Figure 2-7: Schematic representation of the Electrospinning technique. 
 
An advantage of the electrospinning technique is its flexibility. The variation of main parameters, 
like voltage, flow rate, distance between collectors and viscosity of the solution, allows the 
fabrication of fibres with wide range of dimensions, from micrometers to nanometers. 
Moreover, it produces different shaped final products by simply changing the geometry of the 
fibre’s collection plate.  
In the scaffold fabrication, electrospinning was used to generate a layer of GL to coat the PCL 
structure created with the PAM2. The result was a nanofiber coating of the 3D scaffold to create 
a hybrid structure on which cells are seeded and cultured before implantation in vivo. 
2.4.3.5 Electrospinning set-up and tuning 
The electrospinning process was performed using the electrospinning laboratory prototype of 
Linari Engineering S.r.l. (Italy) owned by the Research Centre "E. Piaggio", Faculty of Engineering, 
University of Pisa.  
The manufacturing process was carried out using a solution of GL from porcine skin (Sigma 
Aldrich) dissolved in 60/40% (v/v) acid acetic/distilled water at a concentration of 10% (w/v); 
the solution was then stirred at 50°C for 60 min.  
I performed the tuning of main parameters of electrospinning (voltage, process duration, 
distance between the needle tip and the collector, and flow rate) to achieve the optimal 
manufacture of the GL nanofibers, namely precise fibers size and porosity and minimal defects.  
Thickness of fiber section, fiber density and percentage of defects were evaluated after a 




• Distance between emitter and collector: 15, 20 and 30cm; 
• Voltage: 30, 40 and 50kV; 
• Flow rate: 1, 2 and 3ml·min-1.  
Scanning Electron Microscopy (SEM) was used to capture images of the mat of nanofibers.  In 
this work, I performed the SEM analysis at the Bioimaging Facility, University of Bristol. The SEM 
machinery used was the Quanta FEG model 200 (FEI, U.S.) (Figure 2-8).  The scaffold specimens 
were dried in a vented oven for 48 hours at 37°C, to avoid outgassed vapours during the SEM 
acquisition, and coated with a gold-palladium alloy, to have an electrically conductive surface 
that avoids deterioration of the images.  After the sputtering, samples were placed in a specimen 
stand within the SEM device. Pictures were captured at different magnifications.  
 
 
Figure 2-8: SEM system. 
A) The SEM device Quanta FEG model 200. B) A sample is placed on the machine stage. 
 
Image processing by the ImageJ software was used to evaluate the diameter of the section 








2.4.4 Use of crosslinking agents for preservation Gelatin nanofibers 
To address the needs of preventing GL nanofibers dissolving in water and preserving the specific 
biomimetic morphology two cross-linking systems were used, GPTMS and GP.  
I. GL was dissolved in 60/40 v/v acid acetic/distilled water at a concentration of 10 % (w/v) 
at 50°C. GPTMS cross-linked GL nanofibres were prepared by adding two different 
amounts of GPTMS. For the first test 200μl of GPTMS per gram of GL was added and the 
solution mixed 1h before spinning (Tonda-Turo et al., 2013). Then the samples were 
dried at 37°C for 24 hours. 
II. GL was dissolved in 60/40% (v/v) acid acetic/distilled water at a concentration of 30% 
(w/v) and stirred at 50°C for 60min. Then 60mg of GP dissolved in 0.5ml of ethanol and 
1 ml of phosphate-buffered saline (PBS) were added to 10 ml of the GL solution 
(Panzavolta et al., 2011). Thirty min later the mixture was ready to be electrospun. To 
complete the crosslinking, samples were soaked in 5% (w/v) GP solution in ethanol for 
7 days at 37°C. The mats were rinsed in 0.1 M PBS, pH 7.4, dried overnight at 37°C, then 
rinsed in ethanol and dried again. 
2.4.5 Combination of PAM2 and Electrospinning for fabrication of the composite 
scaffold  
A biological tissue holds a precise and dynamic hierarchical organization of its architecture, 
based on interactions at a macrometer scale (matrix support and/or structures trabecular for 
organs) down to the nanometer scale (interaction of a specific molecule with its receptor). In 
this respect, ECM provides essential cues to regulate cell functions including adhesion, 
proliferation, survival and differentiation. Aiming at replicating this complex and supportive 
conditions, I attempted to develop a new multi-scale and multi-material composite scaffold 
fabricated with PAM2 and electrospinning techniques.  
The matrix made by PAM2 involved a synthetic material, PCL, and was fabricated with a specific 
geometry. This first micro-structure has the ability to provide a physical support with 
appropriate mechanical properties and morphology. To complete the composite scaffold, 
electrospun nanofibers, made by a solution of GL, natural polymer, were used to coat the 
synthetic surface. GL fibers provided support at the nanoscale level and appropriate biochemical 
cues, displaying many integrin binding sites for cell adhesion and differentiation. 
As mentioned above, the development of multi-materials and multiscale scaffolds involves the 
combination of the two microfabrication techniques. The micrometer structures of PCL were 
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fabricated as previously described. At this stage, the 3D channels and woodpiles were uniformly 
fastened on the collector and the fibres were deposited on top of the surface, forming a mat of 
uniform thickness of randomly oriented GL nanofibers. Considering the small size of the 
microstructures, their presence does not alter the optimal electrospinning parameters for 
obtaining a uniform and controlled GL mesh. Thus, based on the process described in the 
previous paragraphs, PAM2 was set up with deposition plane velocity of 9 mm·s−1 and extrusion 
pressure of 8 kPa, and electrospinning parameters were set as follow: distance from the needle 
20cm; voltage 50kV; flow 1ml/hour; time of spinning 12min. The final step of the production of 
the composite planar scaffold consists in the cross-linking treatment of the GL layer with both 
GPTMS and GP. 
2.4.6 Mechanical characterization of the composite scaffold 
A material that is subjected to an external force undergoes deformation, i.e. changes in shape 
and size. These changes depend on the applied force, the characteristics of the material, and 
the morphology of the object. In this study, I tested the composite planar scaffolds in a uniaxial 
tensile assay, in which the specimens undergo traction, as a consequence of a force application 
in a single direction with constant displacement rate. Displacement, force, and time were 
recorded as endpoint of this experiments. In addition, any material has a different behaviour to 
traction and changes its dimensions in a reversible way, called elastic deformation. Once the 
force is removed, the material recovers its original dimensions. There is a force limit for this kind 
of deformation which is the elastic limit, beyond which the deformation is irreversible; this is 
named plastic deformation. Usually, when testing a material, it is appropriate to work on data 
that do not depend on the sample sizes. For this reason, the stress is used in place of the force 
and the strain is used instead of the displacement. The definition of the engineering stress is: 
𝜎 = 𝐹 𝐴0⁄  
where F is the tensile force and A0 is the initial cross section area or, in other words, the section, 
orthogonal to the direction of the force, that the sample has before starting the test. The strain 
is defined as:  
𝜀 = (𝑙 − 𝑙0) 𝑙0⁄  
where l is the length of the sample at a certain point of the test, l0 is the sample length before 




Figure 2-10: Schematic stress-strain graph with main features highlighted 
 
The stress-strain curve is indicative of the behaviour of the material (Figure 2-10), it is a diagram 
of the stress as a function of the strain and offers the possibility to extract some important 
parameters that characterize mechanically a material, such as:  
• the elastic modulus: the slope of the curve in the first linear segment of the stress-strain 
curve; 
• yield strength: the stress value as soon as the sample undergoes a plastic deformation;  
• maximum stress:  the maximum value of nominal stress reached in the stress-strain 
diagram;  
• breaking load: the stress value at which the sample rupture occurs;  
• elongation at break: the total displacement of the sample just before the rupture;  
• toughness: the area under the stress-strain curve.  
Mechanical properties of scaffolds were measured using a Zwick/Roell Z005 device (Zwick GmbH 
& Co, Germany). For the mechanical testing, samples of 16x16mm and a thickness of 70±10µm 
were prepared. The specimens were placed in the custom-made jaws of the testing device 
(Figure 2-11) with an initial separation of 9±1mm and stretched with a steady strain rate 
of (0.01% ∗ 𝑙0) 𝑠𝑒𝑐⁄  until breaking point. The channel scaffolds were tested both in longitudinal 
and transversal direction, while the woodpile one was tested in a single direction due to its 




Figure 2-11: Tensile test set-up. 
Image representing the tensile test performed on PCL structures and its magnification. 
2.4.7 Scaffolds sterilization 
The scaffolds used for the in vitro characterization were fabricated in squares of 6x6 mm to fit 
into a 48 multiwell-plate (CellStar – Sigma Aldrich), and immobilized on the well bottom using 
disposable inserts called CellCrowns (Sigma Aldrich). The structures underwent a process of 
sterilization before becoming in contact with cells. 70% v/v ethanol/water solution was added 
to the well. After 1-minute incubation, the ethanol solution was removed, the scaffolds were 
washed with PBS, and then exposed each side for 15 minutes to UV light. 
2.4.8 Cell culturing on the composite scaffold and assessment of biological 
functions 
Culturing conditions were maintained constant for each in vitro assay. After the process of 
scaffold sterilization, 250 µl of endothelial cell growth media (EGM-2, Lonza) were pipetted in 
each well (growth area of 0.95 cm2) containing the 6x6 mm scaffolds, carefully positioned with 
GL nanofiber layer facing up. Adventitial progenitor cells were seeded in each well at a density 
of 105 cells/well (~11,000 cells/cm2). Every 72 hours the cell culture media was changed, and the 
assays described below were performed after 7 days from seeding. 
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2.4.8.1 In vitro functional assays on cellularized scaffolds 
These tests allowed me to decide the best configuration scaffold allowing preservation of cell 
viability and biological functions. I also tested the alignment of cells according to patterning.  
2.4.8.2 Cell density assay 
Adventitial progenitor cells were incubated with Dil (Vybrant™ DiI, cat:V22885, Thermofisher) 
(1:1000 in PBS) for 20 minutes (5 min at 37 °C and 15 min in ice covered by light); 105 cells/well 
were then seeded in the 48-well plate in which contained the 6x6 mm scaffolds. This step was 
followed by culture for 7 days at 37°C, 5% CO2. After this period, the samples were washed twice 
in PBS and fixed in 4% (w/v) paraformaldehyde/PBS for 10 minutes at room temperature. After 
washing three times in PBS, the cellularized scaffolds were incubated for 1 minute with DAPI. 
After two washes in PBS the slides were mounted, and cell density was imaged using an Olympus 
BX41 microscope. 
2.4.8.3 MTS viability assay 
Cells were seeded onto scaffold in 48-well plate at a density of 105 cells/well and incubated for 
7 days at 37°C, 5% CO2. Prior to the assay the scaffolds were moved into a new 48-well plate to 
avoid the counting of cells not attached to the structures. Following manufactures instructions, 
MTS solution (CellTiter 96 AQueous One Solution Cell Proliferation Assay, Promega UK, ltd) was 
diluted 1:5 in PBS with 250μl solution added per well. After incubation at 37°C, 5% CO2 for 2 
hours, an aliquot of 100μl of supernatant was used to measure the absorbance (490 nm) using 
a Dynex Opsys MR 96 Well Microplate Reader. 
2.4.8.4 EdU proliferation assay 
Cell proliferation was evaluated using an EdU kit (Click-iT® EdU Assay, Invitrogen) as per 
manufactures instructions. The proliferation rate of the cells seeded onto scaffolds was 
evaluated after 7 days of incubation with culturing media. The percentage of the proliferative 
cells was given by the ratio between cells stained with EdU and the total amount of cells on the 
scaffold (stained with Dapi).  
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2.4.8.5 Differentiation assay 
The ability of adventitial progenitor cells to differentiate into ECs or VSMCs was tested following 
exposure to conditioned media (Campagnolo et al., 2010). Cells were seeded either onto glass 
coverslips or scaffolds at a density of 105 cells/well, 48 well plates. After 48 hours, EGM-2 
medium was substituted with differentiation media, with subsequent changes every 3 days, for 
14 days. The following differentiation protocols were used: (1) EC differentiation: cells were 
cultured with CFU-Hill Liquid Medium Kit (StemCell Technologies, UK); (2) VSMC differentiation: 
cells were cultured in basal medium (60% DMEM low glucose + 40% MCDB201) added with 20 
ng/mL human PDGF-BB (Pepro-Tech). As a control, adventitial progenitor cells cultured in EGM-
2 were included. 
2.4.8.6 Immunofluorescence microscopy assessment of seeded cells  
For immunofluorescent staining, cells were fixed with freshly prepared 4% (w/v) 
paraformaldehyde for 20 minutes at room temperature (RT), washed with PBS and 
permeabilized with 0.1% (v/v) Triton X100 (Sigma-Aldrich) diluted in PBS for 10 minutes at RT 
when detection of intracellular antigens was required. The following antibodies were used: (1) 
EC markers: VE-Cadherin (1:50, Santa Cruz), von Willebrand Factor (1:50, DAKO, UK) and CD31 
(1:50, DAKO); (2) VSMC markers: α-smooth-muscle actin (1:100, DAKO), α-retinol-binding 
protein 1 (1:100, Abcam), and α-calponin (1:100, Abcam). Primary antibodies were incubated 
for 16 hours at 4°C. Negative controls, without incubation with the primary antibody, were 
blocked with same species immunoglobulin G (IgG). 
Secondary antibodies were incubated for 1 hour at 20°C in the dark (1:200 goat anti-rabbit IgG 
Alexa 488, 1:200 goat anti-mouse IgG Alexa 488 (Life Technologies, UK). The nuclei were 
counterstained with DAPI (Sigma-Aldrich). Coverslips and scaffolds were mounted using 
Fluoromount-G (Sigma-Aldrich). 
2.5 In vivo study of scaffold implantation 
In this final study, I compared the performance of different cellularized scaffolds. CD1 mice 
underwent femoral artery occlusion by silk ligature and were randomly assigned to 3 
experimental groups (n=6 mice per group), given no treatment (control), perivascular 
implantation of scaffolds (properly dimensioned in 2x2 mm squares) without cells, or 
implantation of scaffolds seeded with adventitial progenitor cells (Figure 2-12). For this last step 
of the investigation, I used the channel-shaped scaffold with nanofibers crosslinked by GPTMS, 
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which showed the best in vitro characteristics, as described in the Results section. I personally 




Figure 2-12: Schematic representation of scaffold implantation.  
The image shows a schematic representation of the sequence of the scaffold implantation. The 
scaffold is cellularized, wrapped around the femoral artery of a CD1 mouse and placed exactly 
between the two ligations. 
2.5.1 Laser Doppler flowmetry as a follow up of blood flow recovery 
Hemodynamic recovery was followed up using Laser Doppler flowmetry (LDF). LDF is an accurate 
and reliable method for assessing blood flow. The basic principles of LDF are as follows: a laser 
beam is directed by an optical fiber to the probe head. When the probe head is applied to the 
skin, the light will penetrate. All blood cells traversing this volume will be struck by laser light, 
partly reflecting it, whereupon the light undergoes a Doppler shift. The light in the volume of 
tissue will be a mixture of unshifted and doppler-shifted components, the magnitude and 
frequency distribution of the latter being related to the number and velocity of moving blood 
cells within the volume of tissue. The illuminating light is back-scattered from the tissue and 
picked up by two optical fibers, which convey the back-scatter fraction to photodetectors. This 
one converts this fraction into electrical signals with the same mixture of frequencies as the 
light. Similar to the surgery, my role here was to assist Dr. C. Reni, in the hemodynamic 
measurements, which were performed in a blind fashion with respect to the treatment group. I 
then calculated the ischemic to contralateral limb blood flow ratio, made averages and 
performed statistics.   
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2.5.2 Preparation of tissues for histology 
At sacrifice, after the last Doppler measurement, I collected the adductor muscles and the area 
that includes the femoral artery and scaffold and fixed the tissues with paraformaldehyde (PFA) 
(4% w/v in PBS) overnight at 4⁰ C. The samples were then washed with PBS, placed in sucrose 
and embedded in mounting medium for microtomy (VWR international, Belgium). The frozen 
samples were finally placed in cryogenic microtome at −20 °C and sectioned into 5–8 µm thick 
slices. 
2.5.2.1 Immunohistochemistry (IHC) analysis of vascularization and 
inflammatory cell infiltration 
I then performed the analysis of microvasculature in a blind fashion. Vascular structures were 
recognized using IHC analysis. VSMCs have been identified using α-SMA-Cy3 (1:400, Abcam) 
while ECs were stained with Isolectin B4 Biotin Conjugated (1:10, invitrogen, Ltd., UK). Primary 
antibodies were incubated over night at 4°C. Secondary antibody was incubated for 1 hour at 
20°C in the dark (1:200 goat anti-rabbit Alexa 488, Life Technologies, UK). The nuclei were 
counterstained with DAPI (Sigma-Aldrich). Furthermore, infiltrating monocytes and 
macrophages were identified using antibodies against CD3-ε (1:50, DAKO) and F4/80 (1:50, Rat 
anti Mouse, SERPTEC), respectively. Secondary antibodies were incubated for 1 hour at 20°C; 
Streptavidin Alexa 488 (1:200, Life Technologies, UK) was used to stain monocytes (1 hour 20°C) 
and Alexa 568 (1:200 goat anti-mouse, Life Technologies, UK) was used for macrophages (1 hour 
20°C). 
2.5.2.2 Histology assessment of fibrosis  
To assess the presence of fibrotic tissue in the area of implantation, I used the Azan Mallory 
technique. This is a histological technique consisting of a chemical labelling for ECM. The samples 
were incubated with 0.1% Azocarmine G for 1h and, then 30 min at 56-60°C and after left to cool 
for 10 min. at this stage, samples were washed with distilled H2O, then incubated with 5% 
Phosphotungstic Acid for 2 h. Slices were washed with dH2O and Mallory solution was added for 




2.6 Statistical Analysis 
Experiments were performed using randomized/blinded protocols. Group identity was decoded 
only after the completion of analyses. Results are expressed as mean ± standard error. An initial 
test was performed to determine the normal distribution of data and the applicability of 
parametric or non-parametric tests. Analysis of laser Doppler blood flow recovery was 
performed using repeated measures Two-Way ANOVA followed by pair-wise comparison using 
the Holm-Sidak method. In other experiments, study endpoints were analysed using one-way 
ANOVA, followed by pair post-test comparison using Tukey test. When the normality test failed, 
differences between groups were analysed using Kruskal–Wallis test. A p-value of <0.05 was 




2.7 Experimental results and discussion 
2.7.1 PAM2 microstructure fabrication 
Previous study demonstrated that scaffold fabricated with PAM2 technique had optimal line 
width between 50-140µm (Cei et al., 2014). To achieve the fabrication of PCL scaffold with that 
specific feature, during this study, I performed the tuning of the parameters (deposition plane 
velocity and extrusion pressure).  The structures fabricated by the use of PAM2 were evaluated 
using optical microscopy. The assessment of the deposited lines demonstrated that the optimal 
parameters to generate structure with line with of 110±10µm were: plane velocity of 9mm s-1 
and extrusion pressure of 8 kPa. I also wanted to create a scaffold with a balance between 
polymeric material and interstitial space to have a high surface/volume ratio. For this reason, I 
fixed the distance between deposition lines at 200µm. At the end of the tuning stage, I 
manufactured the 3D PCL structures following the layer-by-layer deposition as described above. 
The extracted measurements confirmed the successful fabrication of robust and repeatable 
woodpile and channels architectures (Figure 2-13A-B). The PCL matrices have a thickness around 
60–75 μm. Woodpiles have holes of 200 μm, with a line of deposition between 100 and 120 μm. 




Figure 2-13: PAM2 microfabricated structures.  
A) 3D render showing the x and y axis of fabricated channel structures, and B) microphotograph 
(captured by optical microscope AX70 Olympus, Tokyo, Japan) of channel structures made by 
PAM2; C) render and C) microphotograph of woodpiles made by PAM2. 
2.7.2 Characterization of electrospun GL nanofibers  
The morphology, size and shape of the GL fibers deposited using different electrospinning 
parameters were verified by SEM. The dependence of the fibers features on the different 




Figure 2-14: Scanning electron microscopy microphotographs of GL nanofibers.  
Scanning electron microscopy microphotographs of GL nanofibres obtained varying the process 
parameters (d: distance; voltage; f: flow rate): (A) 15 cm, 40 kV, 1 ml h−1; (B) 15 cm, 40 kV, 2 ml 
h−1; (C) 15 cm, 40 kV, 3 ml h−1; (D) 15 cm, 50 kV, 1 ml h−1; (E) 15 cm, 50 kV, 2 ml h−1; (F) 15 cm, 50 
kV, 3 ml h−1; (G) 20 cm, 40 kV, 1 ml h−1; (H) 20 cm, 40 kV, 2 ml h−1; (I) 20 cm, 40 kV, 3 ml h−1; (J) 
20 cm, 50 kV, 1 ml h−1; (K) 20 cm, 50 kV, 2 ml h−1; (L) 20 cm, 50 kV, 3 ml h−1; (M) 30 cm, 50 kV, 1 
ml h−1; (N) 30 cm, 50 kV, 2 ml h−1; (O) 30 cm, 50 kV, 3 ml h−1. 
 
Results illustrated in Figure 2-15A indicate an inversely proportional dependence of the section 
diameter on the tip-collector distance (300±20 nm at 15 cm, 230±1 nm at 20 cm, and 200±10 
nm at 30 cm) and applied voltage (215±15 nm at 30 kV, 190±10 nm at 40 kV, and 165±8 nm at 
50 kV). Analysis of the influence of the feed rate showed that for low values of flow the diameter 





Figure 2-15: Results of GL nanofibers analysis: trend of diameter of nanofibers varying distance, 
voltage and flow.  
(A) Linear graphs showing the dependency of diameter of nanofibre section on electrospinning 
parameters: distance, voltage and flow rate. Values expressed as mean ± standard error. 
Analysis of nanofibres defects; (B) SEM micrograph of nanofibres; fibers show irregularity due 
to electrospinning process. (C) Defects are isolated by image processing and quantified in terms 
of number of pixel of defects. 
 
The voltage level of 50 kV showed the highest reproducibility as assessed by the standard error 
values. Therefore, this parameter was kept constant in further evaluation of fiber porosity and 
defects, when varying flow and tip-collector distance. The thin layer of nanofibres produced 
during the process (thickness lower than 10 μm) allowed the assessment of the area associated 
to pores by image analysis (Image J). Porosity was defined as the ratio between the number of 




) ∗ 100 
Typical defects illustrated in Figure 2-15 consist of irregularity due to formation of polymer 
beads or fusion of several fiber bundles leading to loss of morphological properties of the mat. 
SEM pictures were analyzed and defects quantified by imaging processing (Figure 2-15C). They 
were calculated by the ratio between the number of pixels associated with the defects and the 




) ∗ 100 
The percentage of defects (df) for flow of 1ml h-1 was significantly lower compared with higher 
flow rates. Both 1 and 3ml h-1 showed low level of defects and high and appropriate levels of 
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nanofibres porosity (around 80%) (Figure 2-16A-B). Porosity is among the most important 
features of scaffolds, providing cell communication, exchange of nutrients or waste elimination 
and increasing the surface area-volume ratio. This allows the presence of more sites for cell 
adhesion, spreading and bridging. In order to have an objective criterion for choosing the 
definitive working condition, the R1 parameter, defined as the ratio between the pixels 
associated to defects and pixels associated to fibers, was calculated (Figure 2-16C). The lowest 
R1 value was then chosen to denote the optimum flow rate. 
Figure 2-16D and Figure 2-16E illustrate that distances of 20 and 30cm reduced significantly the 
percentage of defects (below 1%) and yield the best porosity features. Likewise, R1 parameter, 
the ratio between the defects and fibers was determined for different distances to calculate R2 
(Figure 2-16F). The following parameters were then fixed for the setup of the electrospinning 
process: voltage 50 kV, distance 20 cm and flow rate 1ml h-1. Figure 2-17A shows the nanofibers 
obtained as result from tuning of the electrospinning system. From the image processing, they 
have the average diameter section of 210±49 nm. Layers of nanofibers fabricated with the 
chosen parameters showed a pore distribution ranging from 0.4 μm to around 4 μm in diameter 
(average: 0.95±0.04 μm, Figure 2-17B. Previous studies have reported that such range of pore 
size and fiber section are the most suitable to achieve good cell viability and proliferation on 
porous matrices (Christopherson et al., 2009; Min et al., 2004; Powell and Boyce, 2008; Tonda-
Turo et al., 2013). The final step of multi-scale microfabrication consisted of merging the two 
techniques to incorporate GL nanofibers within the PCL microstructure. Dimensions of PCL lines 





Figure 2-16:Percentage of defects and porosity of GL nanofibers graph bars. 
Bar graphs showing percentage of nanofiber defects (A) and porosity (B) in relation to flow rate. 
(C) Bar graph of variable R1 assessed by calculating the ratio between defects and fibers for 
different distance values. Bar graphs showing percentage of nanofiber defects (D) and porosity 
(E) in relation to tip-collector distance. (F) Bar graph of variable R2 assessed by calculating the 
ratio between defects and fibers for different flow rate. *P<0.05; **P<0.01; ***P<0.001. 




Figure 2-17: Pore diameter distribution and SEM images of GL nanofibers electrospun onto PCL 
channel-shaped structure. 
(A) Bar graph of pore diameter distribution of the nanofiber mat chosen after the tuning process; 
(B) scanning electron microscopy microphotograph of nanofiber mat obtained after tuning of 
working conditions; (C) scanning electron microscopy microphotographs showing structures 
obtained by combination ofPAM2 and electrospinning. 
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2.7.3 Mechanical characterization of composite scaffolds 
From the stress-strain curves, I next calculated the elastic modulus, ultimate stress and ultimate 
strain. The results showed that different types of structures have different rigidity (Figure 
2-18A): the elastic modulus of PCL channel structures was 10.2±4.9 MPa in x direction and 
2.0±0.6 MPa in y direction, while the value of the woodpile structure was 4.2±0.4 MPa. The 
failure strain was 43±16% and 47±2% for channels along x and y directions, respectively, and 
52±2% for woodpile. The highest failure stress was displayed by channels along the x direction 
(1.9±1.8 MPa), while for woodpiles and channels along y direction, respectively, the values were 
0.4±0.2 and 0.7±0.1 MPa.  
Results find support on the analysis of the scaffolds’ geometry. In fact, all layers of the channel-
shaped scaffolds have fibers oriented in the x direction, while the woodpile shaped scaffold have 
half of the layers with fibers oriented in the x direction and half in y direction. In line with this, 
results indicate a remarkable difference in mechanical characteristics between channels and 
woodpiles, and also denote the channel architecture anisotropy  
(Figure 2-18B-D). Significant differences were observed between PCL channels along x direction 
and the others in both elastic modulus (P<0.05) and failure stress (P<0.01). The comparison 
between channels in x direction and woodpile showed a ratio of 2.4 with respect to the elastic 
modulus and 2.8 with respect to failure stress. Woodpile and channels had comparable values 
in the x-direction. No significant differences were detected in failure strain between woodpile 
and channels along x and y directions. Noteworthy, the mechanical features of both fabricated 
structures were similar to biological values of blood vessels, considering that the elastic modulus 




Figure 2-18: Results of mechanical test. 
(A) Stress–strain curve of PCL structures comparing the three different structures: Channels in x 
direction (Ch-X), Channels in y direction (Ch-Y) and woodpile (W). Bar graphs summarize results 
of mechanical tests on PCL structures: (B) elastic. *P<0.05, **P<0.01 and ***P<0.001. Values 
expressed as mean ± standard deviation. n=3. 
 
2.7.4 Comparison of cellularized scaffolds in terms of cell biological functions 
Having achieved the fabrication of composite materials, I next moved to the following objective 
of the study, aimed at comparing the scaffolds capability to accommodate and be functionalized 
with human cells. The ability of cells to adhere on the surface of the scaffolds was assessed 
through the evaluation of cell density, counting the number of cells per mm2. Adventitial 
progenitor cells were seeded onto the scaffolds and maintained in regular culture medium. 
Seven days after seeding, I counted the density of cells identified by staining with Dapi (nuclear 
marker) and Dil (lipophilic membrane dye), while proliferation was assessed by EdU staining, a 
fluorescent nucleoside which is incorporated into DNA of cells in S-phase (Figure 2-19A). 
Comparison between different structures indicates that channels electrospun with GPTMS-
crosslinked fibers yield the highest cells density (Figure 2-19B). Next, I compared the bio-
scaffolds with regard to cell viability. Channels electrospun with genipin-crosslinked nanofibres 
conferred the best structural conditions to preserve viability (Figure 2-19B). Importantly, all the 
scaffolds showed the presence of proliferating cells, thus suggesting they have a good 
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biomimetic structure. Channels electrospun with GPTMS-crosslinked fibers yielded the highest 
proliferation index (Figure 2-19B). In order to select the best performant structure to be tested 
in vivo, I assigned a score calculated on the rank of each structure in the above biological tests 
(1 being the best score in each test). Channels-GPTMS scaffolds yield the best average score 
(mean 1.66, median 1), followed by woodpiles-GPTMS (mean 2.66, median 2), channels-genipin 
(mean 2.66, median 3), and woodpiles-genipin (mean 3, median 3). Therefore, the first of these 
structures was implanted perivascularly in a mouse model of limb ischemia.  
 
Figure 2-19: Results of in vitro assessment.  
(A) Representative fluorescent microscopy images of scaffolds seeded with Adventitial 
progenitor cells. Nuclei are stained blue with DAPI and cell bodies are labeled with Dil. 
Magnification image shows cells in the channels delimited by the wall (dotted line). Proliferating 
cells are stained pink by EdU. (B) Bar graphs summarize results of in vitro assays on Adventitial 
progenitor cells seeded on hybrid scaffolds. Gelatin nanofibers were crosslinked with genipin 
and GPTMS. *P<0.05, **P<0.01, ***P<0.001 and ****P<0.0001.  Values expressed as mean ± 
standard error. n=3. 
 
Before moving to this final step, I investigated if incorporation into a scaffold modify the 
differentiation capacity of adventitial progenitor cells.  After 14 days culture with inductive 
media, the expression of typical markers was evaluated by immunocytochemistry. Results 
confirm previous studies showing that adventitial progenitor cells maintain their original 





Figure 2-20: Immunofluorescent images of adventitial progenitor cells phenotype markers and 
differentiation assay. 
(A) Pictures show adventitial progenitor cells maintain typical markers expression, PDGFR-β and 
NG-2, from T0, the day in which cells were seeded on scaffold, to T14, the day in which cells 
were analysed by cytochemistry. (B) Pictures show the presence of endothelial markers in 
HUVEC while they are absent in adventitial progenitor cells seeded both on coverslips and 
scaffolds. 
 
In addition, the analysis of Z stack reconstruction acquired with confocal microscopy (Figure 




Figure 2-21: Adventitial progenitor cells distribution in channel and woodpile scaffolds. 
Z stack reconstruction of confocal microscopy images from channel scaffolds (A) and woodpile 
scaffolds (B). 
2.7.5 In vivo study 
The endpoints of in vivo studies using channel-shaped/GPTMS-crosslinked scaffolds were blood 
flow recovery, collateral formation around the occluded artery and distal angiogenesis in 
ischemic muscle. Two-way ANOVA indicated an effect of time (P<0.01) and scaffold implantation 
(P<0.05) on superficial blood flow recovery as assessed by laser Doppler flowmetry (Figure 2-22). 
However, there was no difference between scaffolds alone or scaffolds seeded with adventitial 
progenitor cells. 
 
Figure 2-22: Blood flow recovery assessed by laser Doppler flowmetry. 
 
 With regard to neovascularization of ischemic adductor muscles, arteriole density, but not 
capillary density, was increased by scaffolds with or without cells (P<0.01 versus vehicle for both 
comparisons, Figure 2-23B-C. Additionally, there was a remarkable increase in arterial collaterals 
in the space between the scaffold and femoral artery, with this effect being significantly greater 
in mice implanted with cell-engineered scaffolds (Figure 2-23A). The scaffold was still visible at 
3 weeks from implantation but appeared fragmented, which suggested initial degradation. 
Furthermore, a remarkable recruitment of F4/80 monocytes was observed, with no difference 
in cell infiltration between groups that received the scaffold alone or cell-engineered scaffolds. 
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Altogether, in vivo data indicate that the scaffold itself has the ability to promote an 
improvement in proximal and distal vascularization and that APC-engineering additively 
improves this capacity at the proximal perivascular site. Immunohistochemistry analyses 
excluded the presence of adventitial progenitor cells at 21 days from implantation, thus 
suggesting that paracrine mechanisms are mainly responsible for the improvement of 
arteriogenesis. There is no evidence of fibrotic tissue around the scaffold. 
 
Figure 2-23: Results of in vivo experiments. 
(A) arteriole density in the implantation site; bar graph and immunohistochemistry of 
vascularization around the femoral artery; (B) capillary and (C) arteriole density in limb muscles). 
(D)Nuclei stained blue by Dapi and vascular smooth muscle cells stained red by alpha-smooth 
muscle actin. Arrows indicate arterioles. S indicates the scaffold. *P<0.05 and ***P<0.001 versus 





Design of composite materials for tissue engineering 
The design of the scaffold is key in any tissue engineering application. The manufacturing 
strategy of scaffolds must be planned to create a temporary artificial ECM in order to support 
cell attachment and guide 3D tissue formation. In applications like bone tissue engineering 
(Turnbull et al., 2018), musculoskeletal system regeneration (Casanellas et al., 2018) and cardiac 
patches (Li et al., 2016; Liau et al., 2011; Zhang et al., 2013), 3D scaffolds demonstrated to 
reproduce better the complex native tissue as compared to 2D scaffold and traditional cultures.  
But producing a porous 3D structure is not enough. In fact, the native ECM is comprised of a 
complex network of structural and regulatory proteins that are arrayed into a composite 
structure.  
For this reason, in this project, I developed a composite scaffold with hierarchical organization 
that has the macrometric structure made by PCL to provide mechanical properties and physical 
support, and nanofibers layers of natural polymer GL to enhance binding and give chemical cues. 
Previous studies explored the possibility to fabricate hybrid scaffolds combining different 
manufacturing systems with promising results.  Rapid prototyping microfabrication techniques 
(like PAM2, 3D printing, Fusion deposition modelling, Solid free form deposition, etc.) were used 
in combination with electrospinning to generate composite scaffolds for in vitro culture of 
chondrocytes (Kim, 2008; Yoon et al., 2009). In another study, the electrospinning technique 
was substituted by electrohydrodynamic direct-jet to generate microfibrous bundles of collagen 
type-I to improve adhesion for osteoblasts (Yang et al., 2015). These works demonstrated an 
increased level of cell viability in composite scaffolds as compared the single material controls. 
In general, the application was focused on generating bone and cartilage in-vitro and often 
migration of the cells through the scaffold was not achieved. 
 
Milestones of the in vitro experiments 
At the best of my knowledge, the present study is the first attempt to incorporate human 
vascular cells within a multi-material, multi-scale scaffold. The resulting 3D biomaterial 
represents a candidate therapeutic product for promotion of reparative arteriogenesis.  
I succeeded in the establishment of a robust productivity process based on the combination of 
PAM2 and electrospinning microfabrication techniques. I also set up a consistent protocol for 
characterization of major physical properties of 3D scaffolds.  
The ability of pro-angiogenic cells to grow on 3D matrixes was tested in a previous work using a 
natural substrate (CorMatrix® ECM® (CorMatrix Cardiovascular,Sunnyvale, CA)) (Avolio et al., 
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2015). Here, the functional assays showed that all the four studied composite scaffold types 
have the ability to support the attachment and survival of adventitial progenitor cells. This new 
system represents a novel technological platform to study the reaction of adventitial progenitor 
cells as well as other reparative cells to changes in the physical parameters. In line with this, 
results extracted from in vitro assessments highlighted significant differences in viability and 
proliferation rate between different types of scaffolds. Like for the ECM, also scaffold’s micro- 
and nano-scale morphology (Jeon et al., 2014), and biochemical cues have impact on cell 
behaviour (Battista et al., 2005; Owen and Shoichet, 2010). In fact, the composition of the 
scaffold influences the rigidity and cell-matrix interaction, with direct effects on cell adhesion, 
migration and differentiation. Analysing these numbers, structures fabricated with the 
crosslinking agent GPTMS appeared superior to woodpiles in terms of proliferation and number 
of adhered cells. Furthermore, channel-shaped scaffold showed values of viability that out-
performed those expressed by scaffold using GP, convincing us to choose channel-
shaped/GPTMS-crosslinked scaffolds for in vivo testing in the murine model of limb ischemia.  
In a previous study, GPTMS was employed as a crosslinker with chitosan. The result showed that 
the Si-OH and Si-O-Si groups favour osteoblast-like cell attachment and differentiation (Liu et 
al., 2004; Shirosaki et al., 2009). In another work, GPTMS crosslinked GL nanofibers have proven 
to support in vitro adhesion, proliferation and survival of neonatal olfactory unsheathing cells 
(Tonda-Turo et al., 2013). From the analysis of our results, we observed a comparable value of 
adhered cells between the layer of nanofibers that Tonda-Turo et al. used and our composite 
scaffold. On the other hand, adventitial progenitor cells did not differentiate after the culturing 
period.  
It has been reported that GP is 5,000–10,000 times less cytotoxic than glutaraldehyde 
(Manickam and Elumalai, 2014). GP has been widely used as a crosslinking agent for natural 
polymers in tissue engineering and biomedicine. 
A comparative study on layer of GL nanofiber crosslinked with GP and GPTMS (Tonda-turo et al., 
2011) showed an opposite trend in cell proliferation, with an higher ratio or proliferative 
osteoblast-like cells on GL scaffold crosslinked with GP. This different behaviour could depend 
on cell-type specific behaviour and on the combination of pattern-crosslinking agent. In fact, the 
addition of morphologic patterns could influence and increase/decrease cell proliferation. 
 
In vivo vascular tissue engineering 
Tissue engineering provides a better scope for cell retention as compared with injection of 
dispersed cells. In previous studies, implantation of alginate beads (Andrejecsk et al., 2013a; 
68 
 
Katare et al., 2013) and hydrogel scaffolds (Kim et al., 2014) containing mesenchymal stem cells 
(MSCs) or endothelial progenitor cells (EPCs) resulted in improved arterial collaterals formation 
and activation of vascular growth factors (revised in Slater, Carrabba, and Madeddu 2016).  
 
Milestones of the In vivo study 
Here, I used two novel approaches: (i) A composite scaffold (channel-shaped/GPTMS-
crosslinked) as a novel carrier of therapeutic cells and (ii) A perivascular delivery method to 
promote arterial collaterals.   
After an arterial occlusion, pre-existing vessels enlarge and remodel through an arteriogenic 
process that is triggered by shear stress and involves soluble factors, cell proliferation, and ECM 
rearrangement. I found that the arteriogenic process is enhanced by perivascular implantation 
of cellularized scaffolds and, to a lesser extent, by the scaffolds themselves. This represents a 
significant improvement over conventional intramuscular cell therapy, which disperses cells and 
therapeutic mediators in an unpredictable manner. In addition, perivascular delivery of scaffolds 
enhanced the tributary microvascular bed in hindlimb muscles, as documented by increased 
counts of small arterioles in the ischemic adductor.  
It is clear that, despite this material being highly biocompatible, it still capable of invoking an 
inflammatory response. Inflammatory cells recruited in response to ischemia and presence of 
foreign material may contribute to angiogenesis via the release of cytokines and growth factors 
(Barrientos et al., 2008; Chen et al., 2018; Degen et al., 2014; Watt et al., 2013). The absence of 
human adventitial progenitor cells at the implantation site indicates that the scaffold is unable 
to preserve implanted xenogeneic cells from rejection due to ischemia and recipient’s immune 
response. Also the observed additive therapeutic benefit exerted by cells is likely to be ascribed 
to paracrine mechanisms (Campagnolo et al., 2010; Katare et al., 2013), which we reported play 
an important part in adventitial progenitor cells biological activities.  
In summary, the described methodology using composite biomaterials functionalized with 
adventitial progenitor cells may offer potential as a treatment for peripheral vascular disease, 
whereby administration of the cell-engineered material within the vicinity of diseased vessels 
could promote revascularization. Further improvements may make the approach particularly 
attractive for use in patients in whom interventional revascularization is not amenable because 
of multiple or distal obstructions. Moreover, perivascular cell therapy might be used as an 
adjuvant treatment in conjunction with or preparation to operative revascularization.  
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2.9 Study limitations 
From the analysis of the in vitro and in vivo assays some limitations emerged. The scaffolds were 
designed to have precise geometries able to influence cell distribution. Nevertheless, cells 
appeared to lose completely the initial organization given by the structure during proliferation 
and colonization of the matrix. Further work is necessary to create stronger physical anchorage 
of cells to the chosen geometries. The loss of precise organization might account for the 
formation of spatially disorientated collaterals not efficient in supporting blood flow recovery. 
This endpoint was examined by laser Doppler flowmetry, with animals under general anesthesia 
and without prior maximal vasodilation. The laser Doppler technique gives an indirect 
estimation of blood flow, therefore, additional studies using different methods such as 
distribution of fluorescent microspheres or tracers in rodents and large animals become 
mandatory. Anesthesia may contribute to obscure a perfusion improvement and increase 
variability of therapeutic endpoints due to differences in body temperature and oxygenation, 
although we tried to maintain constant these vital parameters by the use of thermostatic pads 
and intubation. Use of vasodilators may have revealed increased perfusion reserve by the newly 
generated collaterals, a possibility that also calls for additional studies eventually extending 
beyond the follow up period tested in the present study.  In addition, post-mortem analysis of 
the implant indicated that the PCL structure was still clearly visible, thus suggesting the scaffold 
degradation was too slow in relation to the revascularization process and potentially responsible 
for an extended inflammatory alteration of the implanted area. 
Another caveat in the interpretation of the muscular perfusion and angiogenesis data is that the 
low group size may have led to a false negative result (type II error), which occurs when the null 
hypothesis (H0) is falsely asserted as a consequence of a limited power rather than reality. This 
especially applies to the comparison of arteriole density in ischemic adductors, which was 
increased in both acellular and cellularized scaffolds vs. vehicle. One can decrease the risk of 
committing a type II error by ensuring the test has enough power. This can be done by ensuring 
the sample size is large enough to detect a practical difference when one truly exists. Increasing 
the number of experimental animals could be therefore necessary to reveal an additive effect 







3 Refinement and further characterization of the cellularized 
scaffold  
3.1 Introduction 
The first study was successful in some of the considered endpoints but failed to improve 
reperfusion of the ischemic limb. The fabricated scaffolds were created with a patterned 
macrostructure of PCL, which ensured mechanical strength, and with electrospun fibers of GL, 
which provided cells with binding sites and points of focal adhesions. Among the different 
combinations examined, the channel-shaped scaffold, in which GL was crosslinked with GPTMS, 
showed the best compatibility with adventitial progenitor cells in vitro and was therefore 
transplanted in a murine model of limb ischemia, comparing with the scaffold alone or vehicle. 
Primary endpoints were blood flow, as assessed by laser Doppler flowmetry, and 
angiogenesis/arteriogenesis, as evaluated by immunohistochemistry. The results from in vivo 
experiments suggested that the scaffold itself has the ability to promote an improvement in 
proximal and distal vascularization and that the adventitial progenitor cells-engineered scaffold 
additively implements this capacity at the proximal perivascular site. But, as mentioned above, 
there was no effect of the scaffold with or without cells on perfusion, a result that called for 
additional investigation and refinement. 
In this respect, we considered several potential limitations emerging from the analysis of the in 
vitro and in vivo experimentation. With regard to the fabrication, the scaffolds were designed to 
have precise geometries able to influence cell distribution. Nevertheless, during colonization 
and proliferative expansion within the synthetic matrix, cells showed to lose completely the 
initial organization given by the structure. One possible explanation is that the adopted seeding 
procedure -pipetting cells directly into the centre of the well with the scaffold already in place- 
is too rudimental and therefore needs further refinement in order to anchor cells to the scaffold 
more firmly. The synthetic material itself might be suboptimal in ensuring an ordered alignment 
of the cells. Moreover, adventitial progenitor cells might not be enough to promote 
neovascularization unless associated with other vascular cells. We hypothesize that these three 
factors could have contributed in the failure of the implanted scaffold to promote collaterals 
coaxial with the occluded artery, thereby precluding a reperfusion benefit to the ischemic limb. 
Another important aspect emerging from the histological analysis of the in vivo study is that the 
PCL structure was in part degraded but still clearly visible, thus suggesting the scaffold 
degradation was too slow in relation to the reparative process. This could have been responsible 
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for an extended inflammatory response in the implanted area, as suggested by the presence of 
monocytes in the ischemic muscles. 
Therefore, here, we decided to perform a refinement of the production process. Table 3-1 
illustrates the main refinements introduced in this study. 
 
Study 1 Limitation Study 2 Refinement 
Backbone PCL/GL Too long 
degradation 









 Effect on 
secretome 
not explored 






the 3D scaffold – 
cell interaction 
Seeding Pipetting Leaves cells 









anchoring of cells 
to the scaffold 
Cells APC Insufficient 
to the scope 
Cells APC+EC Cooperation in 
angiogenesis 
Table 3-1: Refinement of the production process.  
The first refinement consisted of the use of PLGA to obtain a scaffold with more tunable 
degradation time, but similar in morphological features (geometry and line width) and 
biocompatibility to PCL. The second refinement was to substitute the prototype PAM2 with an 
available bioprinter ensuring similar precision in the scaffold manufacture. The third refinement 
was to determine the effect of the 3D structure and specific polymer of gene expression and 
secretome of adventitial progenitor cells. The fourth refinement consisted of developing a 
scaffold with cells tightly patterned on its surface. This was investigated by bioprinting a cell-
laden gel or by use of ultrasound for trapping and patterning cells. In the final refinement step, 
a layer-by-layer approach was used for the scaffold assembling, where PLGA or PCL-based 
scaffolds coated with GL were cellularized with adventitial progenitor cells and then a mixture 
of adventitial progenitor cells and HUVECs were aligned onto the pre-formed cellularized 





3.2 Comparative and competitive approaches 
3.2.1 Effect of scaffold physical properties on cell behaviour 
In the interdisciplinary field of TE, scaffolds and cell sources represent the two main 
components. Around 1960s, when the field started developing, the scaffold built with inert 
materials were believed to represent the best candidate, avoiding any reaction from the body. 
Nowadays, researches are aware the that the ideal scaffold has to interact with the cells and the 
host tissue to create a unique living tissue. The success of any TE approach depends on the 
choice of the appropriate scaffold for the desired clinical or pre-clinical application. The design 
of the scaffold starts from the material. Cells behaviour, in fact, is strongly affected by gradients 
of biochemical cues (chemotaxis), biodegradability and stiffness (durotaxis) of the scaffold. 
Different concentration of binding sites around the surface of the scaffold showed to regulates 
the motility and proliferation of the cells (Eid et al., 2001; Griffith, 2002; Kuntz and Saltzman, 
1997; Palecek et al., 1997; Schense et al., 2000). Biodegradability and mechanical properties of 
the material are often strictly related. Biodegradable polymers are now widely used for TE 
application, because they fill the gap between natural and synthetic non-biodegradable 
polymers, providing tuneable physical support and avoiding multiple intervention for implant 
removal. Moreover, the ideal scaffold should possess degradation rate comparable to natural 
tissue growth (Stowell and Wang, 2018).  Cell proliferation and host tissue reaction are affected 
by different degradation rate (Babensee et al., 1998). Rohman et al. showed in a comparative 
study, that human urinary tract-derived cells had a higher level of growth on more 
biodegradable PLGA porous scaffold over the PCL one (Rohman et al., 2007). On the other hand, 
other studies demonstrated the reduction in cell viability cultured on PLGA scaffold, with a direct 
effect of the degradation on the culture environment (Sung et al., 2004). Faster degradation of 
PLGA compared to PCL led to the release in the culture medium of higher amount of acidic 
bioproducts, directly affecting cell behaviour.  
Mechanical properties of the scaffold also play a fundamental role. For in vivo study, mismatch 
of strength between host tissue and scaffold leads to implantation failure, like for vascular grafts 
(Carrabba and Madeddu, 2018). Furthermore, an in vitro validation has been proven that cells 
obtained from different tissue endure the difference of mechanical properties of the scaffold 
compared the origin tissue. Tissue-specific approach is then fundamental during the design and 
the choice of the material. Studies have proven that fibroblasts and epithelial cells showed 
higher level of viability on PCL scaffold over PLGA one (Baker et al., 2009; Sung et al., 2004).  PCL 
scaffolds had lower elastic modulus and better approximated the one of the native tissues. 
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During the in vivo assessment, PCL also showed higher inflammatory response which some 
studies correlated to higher level of angiogenesis (Sung et al., 2004). 
3.2.2 Patterning methods 
Cells are influenced by chemical, mechanical and morphological properties of the culturing 
surface. Hence, the scaffolds themselves should be designed to provide a specific spatial stimuli 
and drive cells in orientation depending on the target tissue. Typically, the methods to pattern 
cells are distinguished in two main categories: passive and active cell patterning. 
3.2.2.1 Passive Patterning:  
Techniques which belongs to the passive patterning category exploit chemical modification and 
functionalization of the surfaces to raise the level of adherence of cells in specific area of the 
culturing substrate. Stiffness (durotaxis) and chemical (chemotaxis) gradients are the most 
common way to induce spatial organization passively. Modulation of fibroblast and stem cells 
migration was achieved using, respectively, a polydimethylsiloxane-based substrate (Cortese et 
al., 2009) and   nanocomposite material with mechanical gradient (Wang et al., 2016a). A 
competitive approach was also proposed by Hadden et al., in which stem cells migration was 
oriented on stiffness gradient hydrogel by mechano-transduction (Hadden et al., 2017). 
Hydrogel have been also widely explored for their property of encapsulating molecules, like 
embedding norbornene biomolecules enhanced the pattern of fibroblasts seeded onto 
nanofibrous scaffold (Wade et al., 2015). In addition to the previous techniques, a geometry-
guided patterning  (Chen et al., 2012; Lo et al., 2000; Malkoc et al.) and selective surface 
modification (like micro-contact printing (Singhvi et al., 1993) and molecular imprinting 
(Criscenti et al., 2018; Vozzi et al., 2010). Despite the success demonstrated by these methods, 
they require complex fabrication procedure for the material and they are mainly limited for 2D 
application. 
3.2.2.2 Active Patterning  
Active methods use physical and geometrical boundaries or external forces for a direct cell 
manipulation. Microscale patterning saw the development of techniques that exploits electrical 




Among those techniques that exploits forces, acoustic manipulation has been recently explored 
as an alternative approach. The approach based on acoustic standing-waves uses acoustic 
radiation force (ARF) to manipulate microparticles (King and A, 1934). In fact, Piezoelectric 
transducers generate an acoustic field with regions of variable pressure. The pressure 
distribution allows particles to get trapped in this high or low peaks. Varying the values of 
frequencies that drive the transducers is possible to modify pressure field and range of particles 
used. 
The ability demonstrated in manipulating micro-particles  (Bernassau et al., 2011; Scholz et al., 
2014) was translated in tissue engineering for cell trapping . The approach showed the low 
impact on cell viability (Ankrett et al., 2013; Vanherberghen et al., 2010)  a and recently it was 
applied to align nerval cells (Gesellchen et al., 2014). 
Bioprinting has also been used to control directly the geometry of cell deposition. Belonging to 
rapid prototyping microfabrication techniques category, Bioprinting had an extraordinary 
development and increase in the number of applications, mainly due to the flexibility offered by 
this method.  In Tissue Engineering, it offers the capability to produce artificial three-
dimensional support for cell growth or to extrude directly cell-laden hydrogels with well-defined 
organization. In fact, Bioprinting is defined as “the use of computer-aided transfer processes for 
patterning and assembling living and non-living materials with prescribed 2D or 3D organization 
in order to produce bioengineered structures serving in regenerative medicine, 
pharmacokinetics, and basic cell biology studies” (Moroni et al., 2018).  
In relation with the topic of cell manipulation, Bioprinting has been implemented to control 
geometries in order to create 3D cellularised constructs. Bioprinting could be based on different 
approaches. 
Laser assisted bioprinting was successfully used to print mammalian cells maintaining the 
viability of cells (Grafts et al., 2011; Hopp et al., 2005). This methodology allows to work with 
high resolution and this was exploited to form vessel-like structure (Guillotin et al., 2010; Tsutsui 
et al., 2010). The main limitation is the presence traces of agents used for the fabrication 
process,  in the final scaffold or substrate (Guillotin and Guillemot, 2011). 
Ink-jet technology is also wide diffused. It exploits piezoelectric or thermal extrusion system that 
commercial printer has, but rather than extruding drops of ink it allows the extrusion of gel with 
cells. Viable fibroblast was printed (Saunders et al., 2008) and more recently in-vitro high 
resolution network was fabricated with Ink-jet technique (Villar et al., 2013). Nevertheless, this 




This limitation is overcome by extrusion-based bioprinting. The methodology allows the 
extrusion of cell aggregates and cell-laden gel and, even if it has lower resolution than the 
previous one, it offers the wide range of gels and shapes. The possibility to create complex 
geometries is another fundamental characteristic of bioprinting. Extrusion-based bioprinting is 
currently used to create constructs for growth factor delivery (Gao et al., 2015), in vitro 
microvacularized constructs (Bertassoni et al., 2014; Kamei et al., 2006; Kolesky et al., 2014; 
Miller et al., 2012) and myocardial patches (Gaebel et al., 2011; Gaetani et al., 2012, 2015). Some 
studies have focused on providing a proof-of-concept for manufacturing vascular structures with 
the intention to be used as small-diameter TEVGs (Borovjagin et al., 2017; Duan, 2017). 
Nevertheless, lack of mechanical properties represents the main limitation factor of this 
methodology. 
Ultrasonic and extrusion-based bioprinting patterning will be investigated in this part of the 
project to create a patterned scaffold able to stimulate organized angiogenesis in application of 
peripheral limb ischemia. 
3.2.3 Multiple cell-type therapy 
As tissues consist of more than one cell type, it may be that the greatest therapeutic benefit 
would be seen if two or more cells types were administered together. This may enhance 
regenerative capacities by allowing secretion of a mixture of growth factors, cytokines and/or 
miRNA that could be missing if one cell line is not present. Currently, there has only been two 
reports detailing the therapeutic benefit of using more than one cell type. Williams et al. 
(Williams et al., 2013)  administered both human MSCs and cardiac tissue-derived stem cells 
(CSCs) into a pig model of MI and found the combination cell therapy caused a 2-fold decrease 
in infarct size compared to when a single cell type was administered. Similarly, Avolio et al. (Elisa 
et al., 2015) have demonstrated co-delivery of human CSCs and APCs in vitro resulted in 
enhanced paracrine activities, whilst in vivo the combination of cells additively reduced the 
infarct size and promoted vascular proliferation, thus demonstrating combined cell therapy is a 





3.3 Work-packages  
As mentioned in the introductive paragraph, Chapter 3 describes the three main stages of the 
new refinement study (Figure 3-1).  
 
Figure 3-1 Schematic workflow of the study. 
(1) Bioprinting fabrication of a composite scaffold with PLGA matrix, covered by GL nanofibers, 
in substitution of PCL. Analyses comprised mechanical tests and electron microscopy. (2) 
Investigation of cell seeding methodologies, bioprinting of gel-embedded cells or Ultrasound 
trapping, to improve cell organization and adherence onto the scaffold. I also examined the 
impact of the change in polymer and the 3D structure on cell behaviour and expressional profile. 







3.4 Material and methods 
3.4.1 Work-Package 1: Fabrication of a 3D Poly (lactic-co-glycolic acid (PLGA) 
scaffold engineered with adventitial progenitor cells 
3.4.1.1  Cell biology material and methods 
 Adventitial progenitor cells 
For the cellular component, the reader is referred to Chapter 2, Paragraphs 2.4.1.1-2.4.1.2.  
3.4.1.2 Scaffold material and methods 
 PLGA as a polymer alternative to PCL for the 3D printing fabrication of 
the scaffold backbone  
PLGA is an aliphatic polyester co-polymer that can be prepared at different ratios between the 
two constituent monomers, the lactic acid (LA) and the glycolic acid (GA). The LA is semi-
crystalline, and GA is highly crystalline, while PLGA is generally amorphous. From the physico-
chemical point of view, the glass transition temperature (Tg) is reported to be above 37 °C, thus 
PLGA shows a fairly rigid (glassy) structure at room temperature. The Tg lowers with the 
decrease of the molecular weight and the increase of GA content in the copolymer (Middleton 
and Tipton, 2000). PLGA can be dissolved in many common solvents like chlorinates, 
tetrahydrofuran, acetone, or ethyl acetate. In this thesis, I used chloroform as a solvent.  
PLGA has been extensively used since 1970s. In the first applications, it served as a material to 
generate biodegradable sutures threads, subsequently approved by the US FDA. Afterwards, 
PLGA was employed for several other medical modalities, such as drug delivery, imaging, 
implantable medical devices, vaccination, and tissue engineering. 
In this work, PLGA has been chosen, among the other biopolymers, for the easy tuning of its 
degradation rate. The PLGA degradation occurs through de-esterification, and the monomers 
produced from the degradation following implantation in vivo are expelled from the body 
through physiologic metabolic pathways. 
Table 3-2 contains a comparative list of common biopolymers, such as PCL, PLA, and PGA, and 
PLGA copolymers. PCL and PLLA, which is a PLA made only of the L-form lactide acid, have the 
highest values in term of loss of mass, whereas the PLGA copolymer has a quicker degradation. 
The loss of mass time, which is the time to complete in vivo resorption, is smaller as the amount 
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of GA increases, reaching the minimum at the equal amount of the two constituent polymers. 
As mentioned above, the Tg follows the same trend and that is an issue to consider when 
manufacturing the scaffolds (Velasco et al., 2015). 
Figure 3-2 shows the half-life variation in relation to the relative amount of GA and LA. PLGA 
pellets with various mixtures of monomers were implanted in rats (Middleton and Tipton, 2000; 
Miller et al., 1977) and the degradation rate of PLGA is determined by several aspects, some of 
which have been already cited. Here the most important are listed: 
1. The molecular weight: increasing the MW from 10-20 to 100kDa, will increase the 
degradation time from weeks to months. 
2. The ratio of GA to LA: higher content of LA gives a PLGA less hydrophilic, consequently 
the degradation is slower; this is because of the presence of the methyl side group in 
PLA. An exception is the PLGA 50:50 which has the faster degradation rate. 
3. Stereochemistry: The rate of water penetration is higher in amorphous D, L regions, 
resulting in an accelerated degradation. 
4. End-group functionalization: polymers that are end-capped with esters, that couples the 
free carboxylic acid and gives longer degradation times. 
5. The shape of the device: the higher is the surface/volume rate, the quicker is the 





















8–2300 4.8 5–10 60–65 24–68 
poly(DL-lactide) 
PDLLA 
29–150 1.9 3–10 40–69 12–16 
poly(glycolide) 
PGA 
350–920 12.5 15–20 35–40 6–12 
poly(DL-lactide-co-
glycolide): (PLGA) 





















23 0.4 300–500 50–60 >24 
Table 3-2: Specifications of the most commonly used synthetic biodegradable polymers.  
The glass transition temperature is always well above the body temperature, except for the PGA, 
which must be considered carefully when design a biomedical application. Furthermore, the 
degradation rate column highlights the massive difference between PCL and PLGA (PLGA could 




Figure 3-2: Half-Life of PLA and PGA homopolymers and copolymers implanted in in rat tissue 






  Use of PCL as a polymer for 3D printing fabrication of composite scaffold 
backbone 
Details of PCL fabrication are provided in Paragraph 2.4.2.1, Chapter 2. 
  Use of GL crosslinked with GPTMS 
Details of GL crosslinking are provided in Paragraph 2.4.2.2, Chapter 2. 
3.4.1.3 Microfabrication technique for the manufacturing of PLGA-based 
composite scaffolds 
As indicated in Table 3-1, in this first part of the project, I substituted the original fabrication 
technique (PAM2) with a novel one, the Bioprinter. PAM2 is in fact a unique prototype that was 
developed at University of Pisa. It has very high resolution, but also difficult servicing and 
peculiar components. Therefore, I customized a commercially available 3D printer, converting it 
into a Bioprinter using all open-source technology. The Bioprinter was used to fabricate both 
the PLGA and PCL synthetic backbones of the composite scaffolds. PCL production was 
maintained as an internal control for the newly fabricated PLGA-based scaffold and to verify the 
consistently precise production by the new device, the Bioprinter, as compared to PAM2. 
 Bioprinter system for the fabrication of synthetic scaffold backbone 
The customization of a commercially available 3D printer (MandleMax3, Maker’s Tool Works, 
US) comprised the substitution of the commercial extrusion system, which is based on fused 
deposition, with a newly designed motorized piston approach. The customization process of the 
3D printer into a Bioprinter was carried out at the Biomedical Science, University of Bristol.  
Piston based syringe: the new extruder was designed with the Autodesk Inventor software and 
fully 3D printed, using Polylactic acid (PLA) (Ultimaker B.V., Netherland) with maximum infill to 
guarantee the stability of the tool while subjected to high stress during extrusion (Figure 3-3A). 
The system allows the allocation of two 5 ml disposable syringes, with the advantage of reducing 
the cost associated to the dedicated syringe used in PAM2 and increasing the level of sterility 
due to the aseptic packaging of the syringes. The motorised piston system was formed by two 
stepper motors NEMA 17 connected with the pistons. The motion of the motors was driven by 
the 3D printed motherboard and allowed the controlled extrusion of viscous solutions without 
requirement of additional pumping systems. 
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Motion system: I exploited the original MandleMax3 movement control to drive the syringes in 
XYZ directions (Figure 3-3B). The new extrusion system was fixed to the horizontal bar for the 
movement in X direction. To complete the motion on the XY plane, the Y-motor, allocated below 
the 3D printer case, moves the deposition plate in Y direction. Moreover, the deposition is 
regulated by an infrared height sensor and 2 stepper additional motors control the movement 
of the extruder in the Z direction.  
Similar to other rapid-prototyping techniques, the customized Bioprinter required a specific file 
format able to define its printing path and the related parameters (i.e. movement speed, 
extrusion speed, extrusion volume, etc…): this format file is a g-code. To build the final 3D 
bioprinted structure, two methods can be followed: 
I. The first method requires the operator to design the 3D model of the structure through 
a CAD software (Autodesk Inventor, Solidworks, CATIA, etc…). At the end of the design, 
the operator will obtain a file in stl format, which means that an additional software for 
conversion is needed. Slicing softwares (Cura, Slic3r, etc…) are used to generate a g-code 
file from a stl one: in this work Cura is used as a main software. This method has the 
advantage of giving a direct feedback of the model geometry during the design. 
Moreover, the software is easy and intuitive. The parameters of the process can be 
chosen with Cura, but they are not entirely amendable. 
II. The second method passes through the direct coding of a script using the Anaconda 
Python software, which will generate the final g-code file, directly. This method is less 
intuitive, due to the absence of a visual feedback. Despite this clear limitation, it does 
not require the transfer through a conversion software and offers the opportunity of 
having direct and more accurate control of the path and all the parameters of the 
process. 
Finally, the gel printing procedure follows the listed points: 
• Connect to the laptop and switch on the Bioprinter,  
• Open the MatterControl software to drive the printer, 
• Upload the g-code file generated in one of the methods described above on the 
MatterControl software, 
• Calibrate the position of the extruder selecting the HOME ALL command, 
• Place the syringe in the dedicated space, 
• Adjust the z-position moving up or down the height-sensor to avoid the needle to crash 
on the deposition plate, 




Figure 3-3: Customized Bioprinter  
A)3D render of piston based syringe system and its components; B) image of commercially 
available 3D printer MandleMax2. 
 
3.4.1.4 Fabrication of PLGA- and PCL-based composite scaffolds 
The fabrication of the composite scaffold followed the underpinning rationale of recreating the 
hierarchical organization of the native extracellular matrix. As said above, I substituted the 
backbone material of the scaffold, switching the PCL to the more biodegradable PLGA synthetic 
polymer. Instead, I maintained the GL nanofiber component crosslinked with GPTMS, as 
described in Chapter 2.   
 Set up of the Bioprinter working parameters 
I carried out the calibration of the new customized Bioprinter parameters, using both PCL and 
PLGA solutions, and attempting to reproduce the resolution achieved with PAM2. As mentioned 
in Chapter 2, my goal was to produce a synthetic polymer structure with line width between 50 
and 140µm. The PCL (Sigma) solution was prepared by dissolving the polymer in chloroform at 
a concentration of 10%(w/v) using a magnetic stirrer. PLGA 50:50 with inherent viscosity of 0.55-
0.75 dL/g (B6010-2, Lactel) was used at 10% (w/v) and 15%(w/v). The line width of the deposited 
solution extruded with the Bioprinter was evaluated using a 32gauge needle (108µm) and 
varying extrusion rate (0.3-1 ml·min-1) and speed of the syringe (2-18 mm·sec-1, with steps of 
2mm·s1). I verified the structures by measuring the width of the lines deposited using an optical 
microscope (AX70, Olympus, Tokyo, Japan).  
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 Patterns of polymer fabrication 
At the end of the tuning procedure, I fabricated the synthetic microstructures with two different 
geometries. The patterns were designed to replicate the ones drew using the PAM2 technique: 
woodpile and channels (Chapter 2, paragraphs 2.4.3.3). 
For the bioprinting of the scaffolds, I designed the scaffold patterns with Anaconda Python 
(Woodpile and Channels codes are shown in supplementary data B and C). The codes were then 
exported in g-code format to be uploaded on the MatterControl software, which I used to 
control the Bioprinter. The desired pattern was chosen (Figure 3-4A-B), and through 
MatterControl, the printing process was started (Figure 3-4C-D).  
 
Figure 3-4: 3D render of the PAM2 microfabricated scaffold 
 A) channels, B) woodpile; C-D) MatterControl graphic interface showing the selection of the 
designed patter (respectively channels and woodpile). 
 
3.4.1.5 Electrospinning System: fabrication of Gelatin nanofibers 
The procedure of microfabrication of GL nanofibers crosslinked with GPTMS follows the 
description of Chapter 2, paragraph 2.4.3.5-2.4.3.6. 
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3.4.1.6 Combination of bioprinting and electrospinning for the fabrication of the 
composite scaffold: PLGA-GL and PCL-GL composite scaffold fabrication  
At the end of the tuning procedure, the synthetic microstructures were fabricated with two 
different geometry.  
Based on the process described in the previous paragraphs, the Bioprinter was set up for PCL 
with syringe movement velocity of 14 mm·s−1 and extrusion rate of 0.4ml·min-1 while for PLGA 
14 mm·s−1 and extrusion rate of 0.5ml·min-1.  
For GL nanofiber fabrication, the electrospinning parameters were set as follows: distance from 
the needle 20cm; voltage 50kV; flow 1ml/hour; time of spinning 12min. The 3D channels and 
woodpiles were uniformly fastened on the collector and the fibres were deposited on top of the 
surface, forming a mat of uniform thickness of randomly oriented GL nanofibers. GPTMS was 
finally used for the cross-linking treatment of the GL layer. 
3.4.1.7 Mechanical characterization 
Mechanical tests were performed following the procedure extensively described in Chapter 2, 
Paragraph 4.6. Briefly, PLGA and PCL samples of 16x16 mm and a thickness of 70±10 µm were 
stretched with a steady strain rate of (0.01% ∗ 𝑙0) 𝑠𝑒𝑐⁄  until breaking point. The channel 
scaffolds were tested both in longitudinal and transversal direction, while the woodpile scaffolds 
were tested in a single direction due to their symmetry. Mechanical tests were performed on 
acellular scaffolds. In addition, to discriminate the bulk material properties from the scaffold 
ones, films with a thickness of 90μm were produced by casting, using the same bulk material of 
the scaffolds. In fact, the mechanical properties of an object are related to the composing bulk 
material and its manufacturing process.  
3.4.1.8 Scaffold sterilization 




3.4.1.9 In vitro assays on adventitial progenitor cells  
 Functional Assays 
These tests were performed to assess the dependence of cell behaviour on the 3D geometrical 
configuration of the scaffold and to compare the effect of PCL and PLGA on preservation of cell 
viability and biological functions.  
 Cell density assay 
The reader is referred to Paragraph 2.4.8.2, Chapter 2 for details. 
Adventitial progenitor cells were incubated with Dil (1:1000 in PBS) for 20 min (5 min at 37 °C 
and 15 min in ice covered by light); 105 cells/well were then seeded in the 48-well plate, in which 
the 6x6 mm scaffolds were contained. This step was followed by culture for 7 days at 37°C, 5% 
CO2. After this period, the samples were washed twice in PBS and fixed in 4% (w/v) 
paraformaldehyde/PBS for 10 min at RT. After washing three times in PBS, the cellularized 
scaffolds were incubated for 1 min with DAPI. After two washes in PBS, the slides were mounted, 
and cell density was imaged using an Olympus BX41 microscope. 
 Viability assay 
Viability assay was performed using the viability/cytotoxicity assay kit (Biotium Inc, US). Cells 
were seeded onto scaffolds in 48-well plate at a density of 105 cells/well and incubated for 7 
days at 37°C, 5% CO2. At the moment of the assessment, the culturing medium contained in the 
48-well plate was removed and samples were washed with PBS. The samples were then 
maintained for 30 min in the incubator with a solution of Calcein [1:2000], EthD-III [1:500] and 
Hoechst [1:100] in serum free medium. After incubation at 37°C, 5% CO2 for 30 min, the scaffolds 
were analysed by fluorescence microscopy. 
  EdU proliferation assay 
Refer to Paragraph 2.4.8.4, Chapter 2. 
In brief, cell proliferation was evaluated using the EdU kit (Click-iT® EdU Assay, Invitrogen) as per 
Manufactures’ instructions. The proliferation rate of the cells seeded onto scaffolds was 
evaluated after 7 days of incubation with culturing media. The percentage of the proliferating 
cells was given by the ratio between cells stained with EdU and the total amount of cells on the 
scaffold (stained with Dapi). 
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 Immunofluorescence microscopy assessment of seeded cells  
Refer to Paragraph 2.4.8.6, Chapter 2. 
 Expressional studies and assessment of paracrine factors 
In this part of the project, I investigated possible changes produced by the cells being embedded 
in a synthetic 3D structure. Endpoints were the expression of microRNAs, typical markers, and 
growth factors (assessed at mRNA and protein levels).  
RNA isolation, RT-PCR and qPCR 
Total RNA was isolated by standardized phenol-chloroform protocol using Qiazol and miRNeasy 
Mini Kit (Cat Nbr #217004, QIAGEN). In brief, scaffolds were washed once in PBS to remove non-
adhered cells, as done for the counterpart cell monolayers (hereafter referred as bi-dimensional 
(2D) counterparts), lysed in 1mL Qiazol, and quickly frozen to induce a mechanical disruption. 
Further blade homogenization was performed if necessary. RNA quality was tested by the ratios 
260/280 > 1.7 while ratios 260/230 were not considered given the low yields of RNA obtained 
from small samples. Total RNA (100 ng) was reverse-transcribed into single-stranded cDNA using 
a High Capacity RNA-to-cDNA Kit (Life Technologies, UK). The RT-PCR was performed using first-
strand cDNA with TaqMan Fast Universal PCR Master Mix (Life Technologies, UK) or using SYBR 
Green PCR.  
The catalogue numbers for the endogenous controls and target transcript were as follows: UBC 
(Hs00824723_m1, housekeeping), BAX (Hs00180269_m1,  BCL2 associated X, apoptosis 
regulator), BCL2 (Hs04986394_s1, pro-survival factor), CSPG4/NG2 (Hs00361541_g1, pericyte 
marker chondroitin sulfate proteoglycan 4), PDGFRβ (Hs01019589_m1, pericyte marker 
platelet-derived growth factor receptor beta), GATA4 (Hs00171403_m1, transcription factor 
GATA4), ANGPT1 (Hs00375822_m1, angiopoietin-1), VEGFA (Hs00900055_m1, vascular 
endothelial growth factor-A), DLL4 (Hs00184092_m1, Delta-like protein 4), BACH1 
(Hs00230917_m1, Transcription regulator protein BACH1 targeted by miR-532-5p).  
MicroRNA profile preservation was also demonstrated by Taqman assays using the following 
primers/probe: miR132 (has-miR-132-3p, assay ID 000457, Cat Nbr #4427975, TaqMan® 
MicroRNA Assays, Applied Biosystems, city, country), miR-532 (hsa-miR-532-5p, assay ID 
001518, Cat Nbr # 4427975, TaqMan® MicroRNA Assays, Applied Biosystems, city, country), U6 
snRNA (U6 snRNA NR_004394, assay ID: 001973, Cat Nbr #4427975 TaqMan® MicroRNA Assays, 
city, country).  
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Additional SYBR Green qPCR assays (Power SYBR® Green PCR Master Mix, Cat Nbr #4368706, 
Fisher, UK) were performed using premade primers QuantiTect Primer Assay (Qiagen, city, 
country) to assess the effect of three-dimensionality and scaffold composition on the expression 
of myofibroblasts markers such as: GAPDH (QT00079247, Hs_GAPDH_1_SG), ACTA2/SMA 
(QT00088102, Hs_ACTA2_1_SG), TGLN/SM22A (QT00072247, Hs_TAGLN_1_SG), COL1A1 
(QT00037793, Hs_COL1A1_1_SG), MYOC (QT00068327, Hs_MYOC_1_SG), and MYH11 
(QT00069391, Hs_MYH11_1_SG). 
 Quantitative PCR was performed on a QuantStudio Real-Time PCR system (Applied Biosystems, 
city, UK). All reactions were performed in a 5μL volume using two cell lines, assayed in triplicate. 
The mRNA expression levels were determined using the 2−Ct method and is expressed as 
fold-change. Bidimensional cell monolayers cultured on petri dish were used as experimental 





Gene Symbol Assay ID Gene Name 
Housekeeping gene   
UBC Hs00824723_m1 hCG1744180 Celera Annotation; 
ubiquitin C  
Viability/apoptosis markers   
BAX Hs00180269_m1 BCL2 associated X, apoptosis 
regulator 
BCL2 Hs04986394_s1 BCL2, apoptosis regulator 
Pericyte-like phenotype markers   
PDFGR-β Hs01019589_m1 platelet derived growth factor 
receptor beta 
CSPG4/NG2 Hs00361541_g1 chondroitin sulfate proteoglycan 
4 
GATA4 Hs00171403_m1 GATA binding protein 4 
Myofibroblast phenotype markers   
GAPDH QT00079247 glyceraldehyde-3-phosphate 
dehydrogenase 
ACTA2/SMA QT00088102 actin, alpha 2, smooth muscle, 
aorta 
TGLN/SM22A QT00072247 transgelin 
COL1A1 QT00037793 collagen, type I, alpha 1 
MYOC QT00068327 myocilin, trabecular meshwork 
inducible glucocorticoid response 
MYH11 QT00069391 myosin, heavy chain 11, smooth 
muscle 
Pro-angiogenic phenotype markers   
VEGF-A Hs00900055_m1 vascular endothelial growth 
factor A 
ANGPT-1 Hs00375822_m1 angiopoietin 1 
BACH-1 Hs00230917_m1 BTB domain and CNC homolog 1 
DLL4 Hs00184092_m1 delta like canonical Notch ligand 4 
Angiogenic microRNA  Assay ID Assay name 
miR-132 000457 hsa-miR-132 
miR-532 001518 hsa-miR-532-5p 
U6 snRNA 001973 U6 snRNA NR_004394 
Table 3-3: Primers function and target description 




Enzyme-linked immunosorbent assays (ELISA)  
ELISA techniques were performed to quantify the release of angiogenic factors such as Angpt1 
and VEGF in the medium (secretome profile), thus confirming qPCR-derived results and 
validating the preservation of the pro-angiogenic phenotype of adventitial progenitor cells upon 
transfer to different scaffolds. Quantities of secreted VEGF and Angpt1 (DY293B and DY923, 
respectively, both from R&D Systems, UK) were determined in cell conditioned media (CCM) 
from cultured adventitial progenitor cells bioengineered on PCL-GL and PLGA-GL scaffolds or in 
cell culture dishes at 37°, 5% CO2, 21% O2. Briefly, after 5 days of the bioengineering, the cell 
culture medium was substituted with fresh EGM2 media (without GF supplements) for 48h and 
the cell supernatant was then collected and centrifuged at 10,000 g for 3 min, 4°, to remove any 
cell debris. The resulting CCM was stored at -80° until batch analysis. CCM was diluted for ELISA 
purposes into reagent’s solution by a dilution factor of 5 or 1.5 for VEGF or Angpt1, respectively. 
ELISAs were performed following the Manufacturer's instructions.  
Patients matched 2D cell monolayers were used as a control to compare with the 3D systems. 
Concentrations of GFs were expressed after normalization to the volume and total RNA yields. 
The latter normalization was performed to obtain an estimate of the relative effect of the 3D 
architecture and polymer material on growth factor synthesis and release vs. transcription. A 
total number of two adventitial progenitor cells lines were assessed and experiments were 
performed in triplicate.  
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3.4.2 Work-Package 2: Refinement of cell seeding using the Bioprinter or 
Ultrasound trapping 
Here, I describe the next step in the refinement methodology (Table 3-1). Advancing from the 
initial seeding approach of manual pipetting, I used the bioprinter to print a mixture of vascular 
cells encapsulated into alginate/F127 Pluronic (AG/PL) gel onto the above described scaffolds. 
Alternatively, I used ultrasounds for trapping and aligning the cells according to a precise design.  
3.4.2.1 Cell biology material and methods 
This section describes vascular cells we used for cellularization of the polymeric scaffold, during 
the implementation of patterning procedure, namely Bioprinting using Alginate/Pluronic gel or 
ultrasound trapping which was performed directly on the PLGA-GL or PCL-GL scaffold.  
  Adventitial progenitor cells 
Refer to Paragraph 2.4.1.1-2.4.1.2, Chapter 2. 
  Human umbilical vein endothelial cells (HUVECs) 
Commercially available HUVECs (Lonza cat#:CC-2517, lot:460587) were cultured at 37 °C, 20% 
Oxygen, 5% carbon dioxide in EGM2 (cat#: C-39211, PromoCell) supplemented with 0.05 ml/ml 
Fatal Calf Serum (FCS), 0.004 ml/ml endothelial cell growth supplement, 10ng/ml epidermal 
growth factor, 90μg/ml heparin and 1μg/ml hydrocortisone. Cells were used between passage 
5-7. The expansion process split the cells once 70% confluence was reached. Cells were washed 
with PBS and incubated with a solution of 0.05% (w/v) trypsin at RT to detach them from the 
culturing surface. Cells were counted and seeded in new culturing plate at the density of 8000 
cell·cm-2. For cell storage, a cell-specific freezing media was prepared: 50% EGM2, 40% FBS and 
10% DMSO. 
3.4.2.2 Scaffold patterning material and methods 
 PLGA, PCL and GL crosslinked with GPTMS 
Refer to Paragraph 2.4.1.2.1-2.4.1.2.3, Chapter 3. 
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  Gel compounds: alginate and F127 Pluronic 
Alginate is a natural polymer extracted by seaweed by treatment with alkali solution, like NAOH 
(Clark, Green, and Kelco 1936; Smidsrød and Skja˚k-Br˦k 1990). The commercially available 
Sodium Alginate powder is finally derived by multiple process of filtration, purification and 
conversion of the original extracted compound. Hydrogels derived from Alginate attracted a lot 
of attention and with it many ways of manipulating it have been developed. Crosslinking 
methods includes thermal gelation, cell-crosslinking and chemical crosslinking (K. Y. Lee and 
Mooney 2012). However, the most diffused way of gelling is through ionic-crosslinking with 
CaCl2 as an agent (Crow and Nelson 2006). Due to its properties of biocompatibility and low 
costs, Alginate was widely explored in biomedical approaches such as delivery of small proteins 
(VEGF and PDGF) chemical drugs, and wound healing, which represent the main field of 
application and delivered many commercially available product (i.e. AlgiSite MTM 
(Smith&Nephew), AlgicellTM (Dema Sciences)) (Balakrishnan et al. 2006; K. Y. Lee and Mooney 
2012; K. Y. Lee, Peters, and Mooney 2003; Murakami et al. 2010; Silva and Mooney 2010). Cell 
delivery for Tissue Engineering application found its main limitation was the absence of cell-
specific binding sites and limited migration due to the average small pore sizes (5 µm) 
(Boontheekul, Kong, and Mooney 2005; K. Y. Lee and Mooney 2012). In our study we used 
Sodium Alginate in combination with F127 Pluronic. This compound undergoes reverse thermal 
gelation, becoming a gel at higher temperature, conferring better printability. It has also the 
function of sacrificial material when it is washed out, it will generate bigger pores that would 
improve cell interaction property. 
3.4.2.3 Cell patterning devices 
  Bioprinter 
In this part of the project, the customized MandleMax2 3D printer, described at the beginning 
of this Chapter, was used to extrude polymer solution and cell-laden gel.  
Gel production 
The production of the stock solution of gel was carried out following the protocol described in a 
previous work (Armstrong et al. 2016). Solution of PL F127 40%(w/v) (Sigma, UK) in serum free 
DMEM (Gibco, life TechnologiesTM) was made by adding powder PL, while stirring at 4°C to allow 
the solution maintaining the liquid state. The solution was sterilized by autoclave process and 
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kept in sterile condition up to 4 weeks. Stock solution of AG was freshly prepared the day before 
the experiment. The powder was placed onto a sterile petri dish and exposed to UV lights for 15 
min. Sodium AG 10% (w/v) in DMEM was added under a biological safety hood, to keep sterile 
conditions, and maintained in agitation for 30 min, at 37°C, under exposure of UV lights. The 
final working solution of 13% (w/v) F127 PL and 6% (w/v) Sodium AG was derived from the 
combination of these two highly concentrated stock solutions. The gel then was crosslinked with 
CaCl2 providing higher water resistance. 
Viability assay on AG/PL gel without specific patterns 
The possible damaging effect of the gel and crosslinking agent on cells was assessed performing 
a viability assay (viability/cytotoxicity assay kit, Biotium Inc, US) on gel samples loaded with 
HUVECs (Lonza) and adventitial progenitor cells. To this initial aim, tests were performed on 
extruded cell-laden gel without any specific pattern, without the presence of PCL-GL or PLGA-
GL scaffold. Different concentration of CaCl2 (5, 10, 20, 30, 50, and 100 mM) were used to test 
the viability of the cells exposed to the crosslinking agent. CaCl2 solution were prepared in 
Endothelial cell Basal Medium (EBM2, Promocell) and filtered with 0.22µm filters. 
Sterile AG/PL gels (13% (w/v) F127 PL and 6% (w/v) AG) were loaded respectively with adventitial 
progenitor cells and HUVECs, both at the concentration of 1 million·ml-1. Cell-laden gel were 
extruded onto sterile coverslips and placed into 48-well plates. After the extrusion the gel 
samples were incubated 10 min with the CaCl2-EBM2 at 37°C and 5% CO2. According to the 
protocol established by Armstrong et al., the CaCl2-solution was removed, samples were washed 
with PBS, and incubated for 24h with a fresh new solution of CaCl2 (5mM)(Armstrong et al., 
2016). This second step was demonstrated being important for long lasting shape preservation. 
After 24h, samples were washed with PBS and incubated 30min with a solution of Calcein 
[1:2000], EthD-III [1:500] and Hoechst [1:100] in serum free medium at 37°C and 5% CO2 and 
finally visualized with florescence microscopy. 
Viability assay on AG/PL gel with specific patterns 
I performed an additional analysis combining the assessment of the effect of different 
concentration of CaCl2 solution on shape maintenance and cell viability on Bioprinted gel with 
specific patterns. Gels were prepared as described before (two different gels for adventitial 
progenitor cells and HUVECs), loaded into a sterile 5ml syringe and allocated in the Bioprinter 
extrusion system. A square 10x10mm gel pattern was printed on a sterile coverslip and placed 
into a 24-well plate and incubated with different CaCl2-EBM2 solutions (5, 10, 20, 30, 50, and 
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100 mM). Following the procedure described above, the gels were washed with PBS and 
incubated again with 5mM CaCl2 solution at 37°C and 5% CO2. After 3 days, I performed the 
viability assay described above and the geometry of the gel was assessed under fluorescence 
microscopy.  
  Layer-by-layer cellularization by bioprinting  
Once verified the viability of the cells in the gel and optimized the crosslinking process, I 
developed and fabricated the prototype of a pattern-enhanced composite scaffold. The design 
of the scaffold aimed at creating a cellularized matrix, which can be distinguished in two parts: 
I) the main component is represented by the composite scaffold developed in the previous part 
of the work (Chapter 2 and Chapter 3, paragraph 4.1.). This consists in PLGA-based and PCL-
based scaffolds coated with GL nanofiber crosslinked with GPTMS cellularized with adventitial 
progenitor cells, which were seeded by manual pipetting. For this stage of the work, I fabricated 
only the channel-shape scaffolds, which showed the best performance in the first study.   
II) The second component is represented by a patterned layer of cell-laden gel. Specifically, the 
AG/PL gel is loaded with a co-culture of HUVECs and adventitial progenitor cells, and bioprinted 
onto the first layer described above. The presence of both these vascular cells is supposed to 
foster arteriogenesis better that using on single cell type. The feasibility of the patterned scaffold 
fabrication was carried out following the described stages. 
1) The Bioprinter was used to fabricate a channel-shaped PCL-based and Channel-shaped 
PLGA-based scaffold. The machine was set up with syringe movement velocity of 14 
mm·s−1 and extrusion rate of 0.4ml·min-1 for PCL while for PLGA 14 mm·s−1 and extrusion 
rate of 0.5ml·min-1. Subsequently the synthetic channel microstructure was coated with 
a layer of electrospun GL nanofibers crosslinked with GPTMS. The electrospinning 
parameters were set as follow: distance from the needle 20cm; voltage 50kV; flow 
1ml/hour; time of spinning 12min. 
2) Adventitial progenitor cells (passage 5-7) were seeded onto the PLGA and PCL-based 
composite scaffold by pipetting at the density of 11,000 cell·cm-2 and cells were 
incubated for 5 days at 37°C and 5%CO2. The period of culturing was chosen to allow the 
cells producing a uniform and confluent layer and starting the production of their own 
ECM. 
3) After 5 days of incubation of the scaffold, a new co-culture of adventitial progenitor cells 
and HUVECs (1:4) was loaded in AG/PL gel (13% (w/v) F127 PL and 6% (w/v)) with cell 
concentration of 4million·ml-1, gently mixed to homogenize the solution and transferred 
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into a 5ml syringe for bioprinting process. The cellularized scaffold was quickly placed 
on the deposition plate of the Bioprinter and the extrusion activated to allow the 
deposition of the cell-laden gel on the scaffold with the appropriate pattern. At the end 
of the extrusion, the scaffold was incubated with 100mM CaCl2-EBM2 solution for 10min 
and then the solution was removed and 5mM solution of CaCal2-EGM2 (supplemented 
with 1% P/S) was added. After additional 24h, the CaCal2-medium was changed with 
complete EGM2 and incubated for 24h. At the end of this period, the maintenance of 
the pattern and viability assay was performed. 
  Ultrasonic trapping 
In this stage of the study, ultrasound trapping was investigated as an alternative possible seeding 
technique. Previous studies established the capability to manipulate particles (Scholz et al., 
2014) and cells (Gesellchen et al., 2014) exploiting the pressure generated by standing acoustic 
waves. In line with this methodology, I used ultrasonic waves to trap cells in pressure nodes. 
  Ultrasonic cell trapping device  
I designed and developed an ultrasonic device aiming at producing a rapid alignment of cells 
during the seeding procedure and I assessed the effect that this method had on cells behavior. 
During the first trial, a glass cover slip (15x15 mm) was used as a seeding surface. The coverslip 
was positioned in the cavity of seeding chamber formed by a coverglass (Thermofisher (UK)) as 
a substrate and a 3-mm-thin poly-(methyl methacrylate) (PMMA) as walls (Figure 3-5). This 
PMMA frame (20 mm x 20 mm x 5 mm) separates the internal part of the chamber, in which 
cells are seeded, from the rest of the device thus reducing the probability of contamination. The 
PMMA component was designed with Autodesk OInventor and fabricated with laser cutter. Two 
parallel 0.975 mm × 15 mm × 2 mm lead zirconate titanate (PZT) transducers (NCE51, Noliac, 
Kvistgaard, Denmark), driven by voltage supplier, were placed in contact with the external and 
opposite faces of the PMMA. This part which was in direct contact with cells was fully sterilized 
with ethanol 70%. 
The transducers were fixed to a movable support component that allows the gently compression 
to the PMMA surfaces. These supports were themselves connected to a 3D printed, Acrylonitrile 
butadiene styrene (ABS) case, in which tracks are designed to allow the modification of the 
position of the support components. The transducers have three main natural frequencies 2.01 
MHz (λ1=738 μm), 6.77 MHz (λ2=220 μm), and 11.00 MHz (λ3=130 μm) (Scholz et al., 2014). As 
described in the introduction of this chapter, the ultrasound trapping uses exploits the acoustic 
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force generated by the transducers to push the cells in the area of low pressure, which 
corresponds to the nodes of the generated standing wave (orange lines in Figure 3-5D). These 
nodes have a specific distance, depending of the frequency and identified by (λ/2) (Figure 3-5E).  
I choose for my experiments to investigate λ1 and λ2 because these distances are comparable 
with the dimensions of our channels-shaped scaffold (~400 µm distance channel-channel) but at 
the same time bigger than the typical dimension of a cell (10-30 µm). To optimize the process of 
cell trapping, different voltage amplitudes were evaluated starting from 1 Vpp to 10 Vpp. 
 
 
Figure 3-5: 3D rendering of ultrasonic device. 
 A): (1) transducers supports 3D printed with ABS, (2) ABS case displaying tracks for movement 
and (3) PMMA support. (B: Frontal vision of the components. (C: three-dimensional vision of 
assembled device. 
  In vitro evaluation of cell patterning and proliferation assay on 
adventitial progenitor cells cultured on coverslips 
For the first test performed on coverslips, I used a single culture of adventitial progenitor cells. 
Before proceeding with the seeding of cells with the ultrasound device, the coverslips were 
treated with different coating solutions with the aim to enhance the cells adhesion. I compared: 
i) coating solution composed by Bovine gelatine (0.0025%), fibronectin (0.01%) in PBS; ii) poly-
L-lysine (Sigma- Aldrich); iii) GL 1% (w/v) type-A from porcine skin (Sigma-Aldrich).  
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Adventitial progenitor cells at P7 were seeded onto coated coverslips with a density of 105 
cells/well and aligned with US device for 30 min. The transducers were driven by both 2.011 
MHz and 6.77 MHz sine wave at an amplitude of 10 Vpp. The device was placed on the stage of 
an Olympus microscope (Olympus BX51, Olympus UK) for enhanced visualization. To improve 
the analysis and have information about the migration of the cells after the patterning, culture 
chambers were placed in incubator in the stage of a Lumascope live imaging device (Etaluma, 
US). In a parallel experiment, proliferation of adventitial progenitor cells after US seeding 
procedure was evaluated with EdU® kit (as described in the previous paragraph.), to assess the 
effect of US on cell behaviour  
 Ultrasound patterning of HUVECs and adventitial progenitor cells 
The feasibility of the patterned scaffold fabrication was carried out aligning co-culture of 
adventitial progenitor cells and HUVECs onto cellularised composite scaffolds. The first two 
steps of the procedure were maintained the same as described in previous paragraph (3.2.3.3). 
1) Fabrication of PCL and PLGA-based scaffold with GL nanofibers 
2) Traditional seeding of adventitial progenitor cells (passage 5-7) for 5 days.  
3) Endothelial cells were stained with DiO dye (Vybrant® DiO, cat:V22886,  Thermofisher) 
(5µl·ml in PBS , incubation in suspension for 20 min at 37°C) while adventitial progenitor 
cells with Dil dye  (Vybrant™ DiI, cat:V22885, Thermofisher) (1µl·ml in PBS, incubation in  
suspension for 5 min at 37 °C and 15 min in ice covered by light). Nucleus of both cell type 
with Hoechst (blue). The scaffold was positioned in the seeding chamber and EBM2 was 
added. The US device was activated at the frequency of 6.77 MHz and 10Vpp. Next, cells were 
added in the seeding chamber and aligned for 30 min by the US device driven by 6.77 MHz 
at an amplitude of 10 Vpp (like described previously in Figure 3-5C). The pattern was 
evaluated every 24h for 3 days to assess the alignment of the cells. At every time-point the 
patterned scaffold was removed from the culture, washed with PBS and fixed with PFA 4% 
(v/v). DAPI staining was added and the samples were finally mounted on coverslips for IF 
microscopy assessment. 
3.4.3  Work-package 3: In vivo study 
After the evaluation of the two different method for cell patterning, the Bioprinting approach 
was chosen as optimal to align cells on composite scaffold. Therefore, for the in vivo study, the 
PCL and PLGA based scaffolds patterned with bioprinted gel were selected. 
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3.4.3.1 In vivo implantation of scaffolds in a murine model of limb ischemia   
In this final study, I compared the performance of different scaffolds, cellularized with 
adventitial progenitor cells and HUVECs: channels PLGA-based scaffold with pattern enhanced 
by AG/PL gel vs. PCL-based scaffold with pattern enhanced by AG/PL gel. For simplification, in 
this chapter, I will name these scaffolds as PLGA-AG/PL and PCL-AG/PL, respectively. In this stage 
of the study a different strain of mice, C57, was used, while in the first in vivo experiment CD31 
mice were used. I needed to do this amendment because of the high aggressivity shown by CD31 
mice. A first batch of CD31 mice were purchased by us and soon after the arrival at the animal 
facility they showed sign of bites and scratches on the limbs and tail, which were often still 
bleeding. This behaviour would have introduced an unexpected variability with high risk of 
compromising the experiment. The company providing the animals confirmed these anomalies 
and redirected us to the alternative strain of mice, C57. 
C57 mice underwent femoral artery occlusion by silk ligature and were randomly assigned to 5 
experimental groups (n=8 mice per group), given (i) no treatment (control), (ii) perivascular 
implantation of PLGA-AG/PL (properly dimensioned in 3x3mm squares) without cells, (iii) PCL-
AG/PL without cells, (iv) PLGA-AG/PL with cells, and (v) PCL-AG/PL with cells. I personally 
prepared the scaffolds for the in vivo study and assisted Dr. A. Thomas during the in vivo surgical 
procedure.  
 Laser doppler 
Refer to Chapter 2, Paragraph 2.5.1. 
 micro CT imaging 
I attempted to set up a protocol for use of microCT scanning to measure collateral formation in 
vivo. I compared two different protocols. 
Protocol 1): microCT sample preparation 
At sacrifice, after the final laser Doppler measurement, mice were perfused via the left heart 
ventricle with ETDA (1 mM) (VWR) in sterile PBS for 60s and then with 1% PFA for 60s, followed 
by 10 ml of a mixture of 1g/ml Barium sulphate and 5 %(w/v) gelatin in dH2O. At the end, the 
animal was placed at 4°C for at least 30min to allow the solidification of the contrast agent.  At 
this point, the legs were dissected as appropriate (fur removed, tail removed, backbone cut 
above hips) and placed in 4% PFA solution for 24 h at 4⁰C. In order to maintain a steadier 
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anatomical integrity, we decided to dissect the mice at the level of the hips to keep the legs 
together. 
 
Protocol 2): microCT sample preparation 
At sacrifice, after the final doppler measurement, mice were perfused via left heart ventricle 
with ETDA (1 mM) (VWR) in sterile PBS for 60s and then with 1% PFA for 60s , followed by 10 ml 
of a mixture of 1g/ml Barium sulphate and 80%Neoprene Latex (Neoprene Latex, Mapei). After 
this step, I dissected the mice at the level of the hips to keep the legs together and placed the 
legs in Formic Acid (40%) to allow the crosslinking of the Latex and the dissolution of the bones. 
After 24h in formic acid, the legs were washed in PBS and placed 24h in 4%PFA at4°C for post-
fixation stage. 
 microCT scanner and processing 
Samples derived from both types of processing were delivered to University of Cardiff imaging 
facility to perform microCT scanning.  All images were acquired on a whole-body Mediso micro 
PET/CT scanner in a 3- dimensional (3D) list mode. Mice harvested legs were placed into the 
scanning machine. The set up as follow: 20 μm resolution, 35 kVp, 450 ms time of acquisition 
per frame, 2 bed rotations and 1440 projections. A post-processing reconstruction was 
performed with VivoQuant software, with the objective to create a 3D render of the vascular 
network. 
3.4.3.2 Statistical analysis 
Normal distribution of continuous variables was tested by simultaneous Kolmogorov–Smirnov Z 
normality test and Shapiro Wilk test and normality was assumed when p > 0.05. Continuous 
variables are shown either as mean ± standard error of the mean (SEM) if normally distributed 
or otherwise as median (interquartile, range, IQR). Categorical variables are presented as 
frequencies (percentages). Comparisons of the groups for continuous variables were performed 
with the unpaired t test for independent samples or the Wilcoxon/Mann–Whitney U test (as 
appropriate). For multiple groups comparisons corresponding T-test one-way analysis of 
variance (ANOVA) or Kruskal-Wallis as appropriate. Homoscedasticity was tested suing Levene’s 
test and variances were considered equal when p > 0.05. PostHoc analysis of ANOVA used in this 
work were either Tukey or Bonferroni for samples with equal variances, and Dunnet for not 
equal variances. Bonferroni adjustment of the p-value was used to perform PostHoc analysis of 
Kruskal-Wallis tests if necessary. A multivariate model and linear regression were performed to 
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determine the association of the blood flow recovery in animals with or without scaffold 
implantation. Statistical significance (understood as null hypothesis rejection) was accepted for 
p < 0.05. Analyses were performed using SPSS 19.0 for Windows (SPSS, Inc., Chicago, IL, USA) 




3.5 Experimental results and discussion 
3.5.1 Results Work-package 1 
3.5.1.1 Composite scaffold fabrication 
 Bioprinter/3D printer microstructure fabrication tuning results 
I performed the tuning of the parameters (syringe movement velocity and extrusion rate) aiming 
at achieving the deposition of polymers with width in the range of 50-140µm.  The structures 
fabricated using the Bioprinter were evaluated using optical microscopy.  
The analysis of the graph (Figure 3-6A) showed, as expected, a decrease of the line width with 
the increase of speed of the syringe and with the reduction of the extrusion rate. For the PCL 
solution, among the many settings tested, only the combination of parameters [0.4ml·min-1-
14mm·s-1], [0.4ml·min-1-16mm·s-1] and [0.3ml·min-1-14mm·s-1] produced lines with width within 
the desired range (highlighted by red dashes in Figure 3-6A). Moreover, the analysis of the 
images showed that for [0.3ml·min-1-14mm·s-1] or higher speed the extrusion of the polymer 
was unstable and discontinuous. This led us choosing [0.4ml·min-1-14mm·min-1] as set-up 
parameter for PCL fabrication with Bioprinter. 
As far as PLGA Bioprinting tuning is regarded, the solution of 10%(w/v) was too liquid for the 
dimension of the needle (108µm). For instance, 1ml·min-1 extrusion rate was not reported in 
Figure 3-6B because the excessive extrusion of the polymer led to the fusion of the lines. On the 
other hand, a reduction in extrusion rate resulted in the clotting of the needle. Due to those 
limitations, I decided to increase the concentration to raise the value of viscosity of the polymer 
solution (Figure 3-6C). A PLGA 15% (w/v) solution showed better printability properties. The 
combination of parameters that matched the designed range were: [0.5ml·min-1-14mm·s-1], 
[0.5ml·min-1-16mm·s-1].  
I finally defined the optimal extrusion parameters of [0.4ml·min-1-14mm·s-1] for 10%(w/v) PCL 
and [0.5ml·min-1-14mm·s-1] for 15%(w/v) PLGA solution. The two combinations allowed to 





Figure 3-6: Results from tuning of bioprinting extrusion of synthetic polymers.  
Graph showing the dependency of the extruded line width on extrusion rate and speed for PCL 
10% (w/v) (A), PLGA 10%(w/v) (B) and PLGA 15%(w/v) (C). Values expressed as mean ± standard 
deviation. n=3.  
 Combination of Bioprinter and electrospinning 
At the end of the tuning procedure, the synthetic microstructures were fabricated with the 
Bioprinter and the coating of PLGA and PCL microstructure was performed with GL nanofibers 
as described in Chapter 2. 
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3.5.1.2 Mechanical characterization and comparison of PCL-PLGA scaffolds 
I extrapolated elastic modulus, failure strain and failure stress from the mechanical 
measurements performed on composite scaffolds applying a constant displacement rate of 0.01 
min-1 until failure. Mechanical features of PLGA structure were analysed and finally compared 
with PCL, like shown in Table 3-4. 
 
  ELASTIC MODULUS 
(MPa) 
FAILURE STRAIN (%) FAILURE STRESS 
(MPa) 
PCL PAM2 W 4.2±0.4   52±2  0.4±0.2    
 Ch-X 10.2±4.9   43±16  1.9±0.18   +++ 
 Ch-Y 2.0±0.6     * 47±2  0.7±0.1      *** 
PCL 
BIOPRINTED 
W 4.76±1.72  58±9  0.38±0.12  
 Ch-X 5.37±0.37  64±14  0.45±0.12  
 Ch-Y 1.14±0.5       **   + 55±8  0.09±0.019  *   + 
PLGA 
BIOPRINTED 
W 25.8±1.21  #### 4.51±1.2  ### 0.57±0.29   
 Ch-X 32.9±9.19  ## 4.83±2.31 ### 0.78±0.16  # 
 Ch-Y 7.44±1.14 **   +     ### 7.13±1.36  ### 0.23±0.07  *   # 
Table 3-4: Summary of mechanical test 
 Table shows the values resulting from tensile testing of microfabricated scaffold. Data shown 
as: mean ± dev std (n=3). (*):  *P<0.05 and ***P<0.001 versus Ch-x.  (+): +++P<0.001, versus W; 
(#): #P<0.05, ###P<0.01, ###P<0.001 and ####P<0.0001 versus PCL Bioprinted. 
 
The new mechanical tests performed on the Bioprinted PCL-based scaffold showed no 
significant differences in values of failure strain, failure stress and elastic modulus, compared 
PCL-based scaffold fabricated with PAM2. The only exception was represented by the elastic 
modulus of channel-shaped scaffold in x direction, which decreased form 10.2±4.9MPa to 
5.37±0.37MPa. This could be linked to the small variation in lines width produced with the 
Bioprinter system rather that with PAM2. 
The ratio of elastic modulus between channels x-direction and channels y-direction had similar 
values for PLGA and PCL (respectively 4.4 and 4.7), and also the ratios of the elastic modulus of 
channels x-direction and woodpile had approximately the same values (1.3 PLGA and 1.1 PCL). 
This highlighted that the differences in mechanical properties between PLGA and PCL depend 
only on the use of different material and not related to the geometry or the fabrication. 
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Overall, results showed that PLGA woodpile and channels had lower strength and higher 
elasticity than the film of solid and uniform PLGA. The results on the microfabricated scaffold of 
PLGA are in line with the analysis of PCL scaffold, where the orientation of the fibers is a 
determinant of mechanical behaviour (Figure 3-7D-E). Significant differences were detected 
between PLGA channels in x direction and PLGA channels in y direction in both elastic modulus 
and failure stress (P<0.05). No statistical difference was found between channels x-direction and 
Woodpile, while Woodpile had significantly higher elastic modulus compared with channels y-
direction (P<0.05).  
Extending the analysis to the comparison between PLGA and PCL structure, the general trend 
observed was that PLGA structure had higher values of elastic modulus for woodpile and 
channels in both directions (Table 3-4). Together with a lower values of failure strain, this 
suggested the higher rigidity and the less elasticity of the PLGA structure, as confirmed from 
stress-strain curve showed in Figure 3-7F in which is confronted PLGA and PCL scaffold tested in 
x direction. Data from literature (Middleton and Tipton, 2000) and the use of higher 
concentrated polymer solution (15%(w/v)) confirmed this behaviour.  
In conclusion, elastic modulus of PLGA is higher than human femoral artery (1.2-4MPa), but we 
believe that, representing only a cell carrier vector and without structural support role, this 








Figure 3-7: Image representing the tensile test performed on PLGA woodpile. 
(A), PLGA Ch-x (B) and PLGA Ch-y (C) structures. D-F) Images show the Stress-strain curve 
comparing the different geometry of PCL (D) and PLGA (E). F) Shows the stress-strain curve of 




3.5.1.3 Cell biology results 
Next, I performed cells density and proliferation assays using 3 lines of adventitial Progenitor 
cells seeded at the density of 10,000 cells/well onto 6x6mm PLGA-scaffolds both channels and 
woodpile, previously sterilized and placed in a 48 well plate and cultured in EGM2. These tests 
were performed after 7 days of incubation with media changed every 3 days. In addition, I used 
a control consisting of PCL-based channel-shaped scaffolds, which showed the best 
biocompatibility in the initial study described in Chapter 2. 
Results showed no statistical difference in cell density between the different patterns of PGLA 
scaffolds (Figure 3-8A-C) and also as compared with the PCL-channel-shaped scaffold (Figure 
3-8E). It should be noted that the latter group showed higher numbers of adherent cells 
compared with the results shown in Chapter 2. The Live/dead assay (Figure 3-8E-H), 
demonstrated the high viability of the adventitial progenitor cells onto composite scaffolds with 
an average percentage of living cells of 90±2% for PLGA-channels, 93±3% for PLGA-woodpile and 
92±2% for PCL-channels scaffold (Figure 3-8I-K). Again, no difference was noted between 
groups. 
Results of the Edu assay on adventitial progenitor cells indicate PLGA-channel-shaped scaffolds 
have higher proliferative indexes than PLGA-woodpile-shaped scaffolds (Figure 3-8L-N) (Figure 
3-8O).  
Overall, the three assays indicate the good biocompatibility features of the newly fabricated 
PLGA scaffold. Moreover, channel-shaped structures performed better than woodpile, 
confirming the choice done in the previous part of the study. No difference between PLGA-based 
and PCL-based scaffolds was detected, allowing me to conclude that the two materials could 




Figure 3-8: Results from in vitro assays.  
A-C) Representative images of adventitial progenitor cells stained with Dil (red) and DAPI (blue) 
and cultured for 1 week onto PLGA-Ch (A), PLGA-w (B) and PCL-Ch (C). D-E) Results from cell 
counting. F-H) Representative images of adventitial progenitor cells stained with calcein (green), 
EthD-III (red) and Echoest (blue) for assessment of cell viability respectively on PLGA-Ch (F), 
PLGA-w (G) and PCL-Ch (H). I-K) Results of percentage of living cells after 1 week of culture; F-H) 
Representative images of proliferative adventitial progenitor cells stained with EdU (green) and 
DAPI (blue) for assessment of cell preoliferation; PLGA-Ch (L), PLGA-w (M) and PCL-Ch (N). I-L) 
Results of percentage of proliferative cells after 1 week of culture (O-P); data shown as mean ± 






3.5.1.4 Effect of three-dimensionality on gene expression and pro-angiogenic 
profile of adventitial progenitor cells seeded on PCL and PGLA scaffolds 
We have previously characterized the expressional signature of adventitial progenitor cells 
cultured on 2D platforms. These cells express and secrete pro-angiogenic biomolecules including 
VEGF, angiopoietin-1, and leptin, but also pro-angiogenic microRNAs, such as miR132 and 
miR532. We also reported this expressional signature is modulated by exposure of cells to 
hypoxia. Here, I wanted to determine if this signature is modified in cells embedded in the 3D 
scaffolds. This is an important point as it can influence the ability of the cells to stimulate 
angiogenesis and arteriogenesis after implantation in vivo. 
3.5.1.5 Expression of markers of viability/apoptosis 
First, I measured the expressional levels of the pro-survival BCL2 and pro-apoptotic BAX: mRNA 
levels were quantified by qPCR in comparison with each 2D counterpart and then BAX/BCL2 
ratios were calculated. Results indicate a significantly higher BAX/BCL2 ratio in adventitial 
progenitor cells bioengineered on PCL (2.49 ± 0.58-fold change vs. 2D counterpart, p = 0.014) 
but this was not seen in cells on PGLA (1.48 ± 0.19-fold change vs. 2D counterpart, p = 0.45) 
(Figure 3-9A).  
3.5.1.6 Preservation of the pericyte-like phenotype of adventitial progenitor cells 
bioengineered on PCL or PLGA scaffolds 
Next, I tested by qPCR the expression of genes encoding for CSPG4/NG2 and PDGFRb. 
CSPG4/NG2 was similarly expressed in the different conditions under study, but PDGFRb was 
reduced under 3D conditions (PCL: 0.40 ± 0.162-fold change vs. 2D, p = 0.017; PLGA: 0.39 ± 
0.147, p = 0.013 vs. 2D). No difference was seen with respect to GATA4, SOX2 and NANOG mRNA 
levels. Differences in gene expression between PCL and PLGA conditions were not detected 
(Figure 3-9B).  
I further studied if the change in PDGFRb was associated with the acquisition of a myofibroblast-
like phenotype. For this purpose, I measure the mRNA levels of ACTA2/SMA, TGLN/SM22A, 
COL1A1, MYOC and MYH11 by qPCR. MYOC was barely detectable and is not further discussed. 
Interestingly, mRNA levels of ACTA2/SMA, TGLN/SM22A, COL1A1 and MYH11 were significantly 
down-regulated in both PCL and PGLA scaffolds in comparison with the 2D control counterparts, 
thereby suggesting that no myofibroblast-like phenotype might be induced by our scaffolds. 
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3.5.1.7 Preservation of the proangiogenic phenotype of adventitial progenitor 
cells bioengineered on PCL or PLGA scaffolds 
Adventitial progenitor cells are an important source angiogenic molecules including Angpt-1 
(pro-angiogenic and endothelial cell stabilization), VEGF (network formation) as well as miR132 
(indirect regulator of VEGF expression) and miR532 (indirect regulator of Angpt1 expression 
towards BACH1 inhibition). Therefore, mRNA levels of those molecules were additionally 
assessed in this work.  
Expression of the angiomiR miR132 and miR532 was evaluated. No effect was observed on the 
expression of miR132 neither for PCL (0.95 ± 0.10-fold change vs. 2D, p = 0.422) nor PGLA (0.96 
± 0.10-fold change vs. 2D, p 0.55). On the other hand, miR532 was found down-regulated by 
both scaffolds, significantly only by PLGA-based one (PGLA: 0.76 ± 0.02 vs. 2D, p = 0.003). BACH1, 
which is a negative regulator of Angpt1 and hemeoxygenase, was downregulated in both 
polymers (PCL: 0.39 ± 0.03-fold change vs. 2D counterparts, p = 0.029; PGLA: 0.52 ± 0.129-fold 
change vs. 2D counterparts, p = 0.013) (Figure 3-9C).  
Interestingly, adventitial progenitor cells bioengineered on scaffolds showed an upregulation of 
VEGF mRNA in both PCL (3.92 ± 1.16, p = 0.047 vs. 2D) and PGLA (3.85 ± 0.57, p =0.002 vs. 2D).  
On the other hand, Angpt1 expression was significantly down-regulated in cells seeded on both 
3D structures (PCL: 0.44± 0.039 vs. 2D, p = 0.001; PGLA: 0.45 ± 0.1 vs. 2D, p = 0.006) 
Those results were further verified by assaying the adventitial progenitor cells-derived 
secretome (Figure 3-9D). All conditions were standardized to be equal in term of growing 
surface, starting number of cells seeded, and volumes of sample (hereafter referred as cell 
conditioned media or CCM). Concentration of VEGF or Angpt1 (pg/mL) was additionally 
normalised by the total RNA yields obtained from each scaffold and condition. Similar results 
were obtained either expressing the results as pg/mL or total RNA yields normalization (pg 
growth factor/ug total RNA), therefore supporting our conclusions. In brief, VEGF was found 
significantly up-regulated in both PCL (4.11 ± 0.53 pg/mL fold-change vs. 2D, p = 0.004; or 6.54 
± 1.06 pg/ug fold change vs. 2D) and PGLA (5.07 ± 0.99 pg/mL fold-change vs. 2D, p = 0.015; or 
7.33 ± 0.21 pg/ug fold change vs. 2D). As per qPCR results, Angpt1 levels were significantly 
diminished in PLA (0.36 ± 0.02 pg/mL fold-change vs. 2D, p < 0.001; or 0.58 ± 0.04 pg/ug fold 
change vs. 2D, p < 0.001) but not in PGLA (0.70 ± 0.35 pg/ug fold change vs. 2D, p = 0.441; or 
0.91 ± 0.33 pg/ug fold change vs. 2D, p = 0.802). The two groups of 3D structures of PCL and 




Figure 3-9: Effect of 3D culture on PCL-GL and PLGA-GL-based based scaffold on adventitial 
progenitor cells expression and secretion. 
Bar graphs show the average of two biological replicates comparing the 3D conditions to the 2D 
monolayer culturing of petri dish. A-B) Expression of apoptotic (BAX/BCL2), differentiation 
(PDGFRB, ACTA2/SMA, TGLN/SM22A, COL1A1 and MYH11) and angiogenic (miR132, miR532 
and miR210-3p, BACH-1) molecules. C-D) Finally the bar graphs show the expression (C) and the 
secreted level of protein in the conditioned media of VEGFA and Angpt1. *p < 0.05 **p < 0.01 
and ***p < 0.001 vs. vs. 2D. Values expressed as mean ± standard error (n=2). 
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3.5.2 Results Work-package 2: Cell patterning 
3.5.2.1 Cell Bioprinting 
 Cytotoxicity assay 
Here, I assessed the viability of adventitial progenitor cells and HUVECs in AG/PL gel to verify the 
possible cytotoxic effect of the crosslinking agent. Samples of cell-laden gel were incubated with 
different solution CaCl2 (5, 10, 20, 30, 50, 100mM). The analysis of the graph (Figure 3-10) 
showed that both HUVECs and adventitial progenitor cell have good rate of viability (around 




Figure 3-10: Assessment of HUVECs and adventitial progenitor cells viability encapsulated into 
AG\PL gel. 
A) Bar graph showing viability percentage of adventitial progenitor cells (black bars) and HUVECs 
(grey bars) depending on the concentration of CaCl2 content. B-C) Representative fluorescence 
images of cells stained with live/dead kit showing viability of adventitial progenitor cells (B) and 
HUVECs (C) incubated (from left to right) with 5mM, 20mM and 100mM. Values expressed as 
mean ± standard deviation. n=3. 
 Assessment of extrusion pattern 
Next, I verified whether the crosslinker concentration influences the shape of the gel. I 
bioprinted a gel grid (10x10mm) with HUVECs and assessed, after 5 days of incubation, the 
morphology of the hydrogel structure. From immunofluorescence images, I observed that 
structures incubated with concentration of CaCl2 above 20mM have better resistance to 
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degradation and shape maintenance (Figure 3-11). A concentration of 100mM was established 
as the experimental concentration for the crosslinking agent.  
 
Figure 3-11: Bioprinting, CaCl2 effect on shape maintenance of gel extruded pattern. 
A) negative control, AG/PL gel without cells crosslinked with 20mM Ca2; B) Gel crosslinked with 
CaCl2 20mM; C) Gel crosslinked with CaCl2 100 mM. HUVECs stained with Calcein (green) and 
EthD-III (red) to stain viable and dead cells. Panels D-I) show highly magnified fields of control 
(D) 20mM (E) and 100mM (F) crosslinked gel. (D) and (G) show the absence of unspecific stain 
in the gel without cells. (E) and (F) show the living cells stained with calcein (Green) while (H) 
and (I) show dead cells stained with EthD-III (red). 
 Assembly of the pattern enhanced composite scaffold 
For the final assembly of the pattern-enhanced composite scaffold, I bioprinted a serpentine of 
AG/PL gel loaded with co-culture of adventitial progenitor cells and HUVECS [1:4] with a total 
concentration of 4 million·ml-1 (Figure 3-12A-B). The resolution of the bioprinted lines could not 
achieve the resolution of the synthetic polymers. Considering the higher viscosity of the gel and 
also to avoid loading the cells with too much pressure, I decided to use needles with larger 
diameter (30gauges, 159 µm).  
Despite this loss of resolution, the serpentine shape was maintained after 5 days incubation and 
cells were highly viable (Figure 3-12B). From the observation of fluorescence images, the 
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average line width of the extruded gel was 750±150 µm. Figure 3-12C-D displays higher 
magnification images of respectively PCL and PLGA-based composite scaffolds, demonstrating 
the high maintenance of the bioprinted morphology. 
This capability of Bioprinted gel to keep the aligned shape for at least 5 days, in range with our 
pre-conditioning period before implantation, led us to choose this technique to generate the 
final prototype of patterned scaffold for limb ischemia model. 
 
 
Figure 3-12: Schematic representation of Bioprinting gel onto Synthetic scaffold and 
immunofluorescent images of gel patterning maintainance. 
A) 3D render representing the assembly of the Co-culture-laden AG/PL gel onto the first layer of 
PCL or PLGA-based composite scaffold already seeded with adventitial progenitor cells. B) 
Images obtained with tiles reconstruction (assembling different images) showing the successful 
printing with the shape of “serpentine” onto scaffold. C-D) Representative images of the 
maintained pattern of the Co-culture in the AG/PL gel extruded onto scaffold, after 5 days of 
incubation. Adventitial progenitor cells stained with Dil (red), HUVECs with DiO (green) and 




3.5.2.2 Ultrasonic trapping 
 Evaluation of adventitial progenitor cells alignment on coverslips 
The fabricated acoustic device demonstrated the capability to align cells on coverslips (Figure 
3-13A). Adventitial progenitor cells were aligned successfully with both f1=6.77MHz and 
f2=2.011MHz frequency of the transducers, even though from qualitative analysis of the images 
f1 had higher resolution of alignment pattern. 
Then, I analyzed the influence of the coating solutions on cell adhesion and patterning. Cells 
seeded on coverslips coated with bovine GL (0.0025%), fibronectin (0.01%) in PBS showed low 
ratio of cells attached on the surface after 12 hours, resulting in a complete loss of cell 
organization. For this reason, we further analysed GL 1%(w/v) (Figure 3-13B-C). The analysis of 
pictures obtained from time-frames showed high adherence property, but cells seeded on 
coverslips coated with GL lost the spatial organization after 5 hours.  
Proliferation assay (Figure 3-13D-E) demonstrates that cells proliferate after the US seeding, 
thus suggesting that the procedure does not affect the viability. 
Despite this loss of alignment of cells, the test allowed us to verify the design of the acoustic 





Figure 3-13: Ultrasound cell patterning onto coverslips. 
A) Optical microscopy picture of adventitial progenitor cells aligned on coverslips. B-C) Optical 
microscopy pictures of cells aligned onto coverslips snapped with time distance of 5 hours and 
obtained varying the parameters B): Coating of gelatin 1%; f=2.011MHz; C): Coating of gelatin 
1%; f=6.77MHz. D-E) Bar graphs and fluorescence images of showing proliferation rate after 48 
hours of adventitial progenitor cells cultured on gelatin 1% coated petri-dish without application 





 Evaluation of Co-culture (adventitial progenitor cells- HUVECs) alignment 
on scaffold 
US device showed the possibility to align cells even onto scaffolds. Then the experiment to align 
co-culture of adventitial progenitor cells and HUVECs on scaffold’s surface was carried out as 
described in the previous paragraph. 
A cell suspension with co-culture of adventitial progenitor cells and HUVECS [1:4] was prepared 
and added in the middle of the seeding chamber (where the scaffold was located) with 
transducers activated at 6.77MHz with 10Vpp. To allow living cell tracking, adventitial progenitor 
cells were stained with DIl (Red), HUVECs with DIO (green) and nucleus of both cell type with 
Hoechst (blue). 
We verified the long-lasting maintenance of the pattern. At 1, 2, 3 days samples were fixed and 
evaluated. The images obtained from IF microscopy confirmed an initial spatial patterning (day 
0), and the images showed the capability of aligning cell o top of scaffolds surface (Figure 3-14A-
D). 
 From day-1, instead, the spatial organization was lost. Images displayed traces of alignment 
especially on the edges of the wall of the Channel-shaped scaffolds, visible also at the 3rd day 
(day of last-time-point) (Figure 3-14E-I).  
Despite this slight improvement in organization, I concluded it was not efficient to confer the 





Figure 3-14: Ultrasound trapping of co-culture onto scaffold. 
 A-D) Fluorescence images of Co-culture seeded with US trapping on scaffold at day 0. HUVECs 
stained with DiO (green), adventitial progenitor cells with Dil (red) and nucleus of both cell with 
Hoechst (blue). White dashes show the thickness of the extruded lines of synthetic polymer (in 
this example PLGA). E-I) Fluorescence images at day 3 showing the wide spreading of cells and 




3.5.3 Results of in vivo work 
Laser Doppler analysis of blood flow recovery and immunohistochemistry assessment of the 
muscular vascularization were the endpoint measurements of this final in vivo investigation. 
Mice were treated with PLGA-AG/PL and PCL-AG/PL, with and without adventitial progenitor 
cells and HUVECs, while the control did not receive any treatment. Figure 3-15A shows that all 
the groups, including the control group, reached the same plateau of blood flow recovery. 
However, calculation of the time necessary to reach the maximum recovery showed that the 
group implanted with cellularized PLGA-AG/PL recovered faster as compared with vehicle (11 
vs. 18 days, respectively, p=0.01). This parameter was also close to statistical significance 
(p=0.07) in the comparison between cellularized PLGA-AG/PL and acellular PLGA-AG/PL (11 vs. 
16 days, p=0.07).  Power calculation indicates that it would be necessary to increase the group 
size from the actual number of 9 mice used in this study to 11 mice to have a chance to reach 
statistical significance with a power of 0.80 and  of 0.05. In contrast, the comparison between 
cellularized PLGA-AG/PL and vehicle showed the former group had a trend toward a faster 
recovery, but the difference did not reach the statistical significance (14 vs. 18 days, p=0.15). 
Again, a calculation of power suggests that it would require at least 22 mice per group to have 
a chance that the difference becomes significant. 
Both the microCT procedures demonstrated to be not efficient in our investigation. 3D 
reconstruction after the acquisition highlighted the insufficient perfusion of the contrast agent 
in the legs and low reproducibility. So additional refinements of the methodology are necessary, 
in particular higher concentration of the contrast medium and injection via the abdominal aorta 
instead of the heart cavity. In addition, at conclusion of these thesis the immunohistochemical 




Figure 3-15: Outcomes of Laser doppler and microCT assessment. 
A-B) Time course of blood flow recovery calculated from by laser Doppler flowmetry results; C) 
Bar graph showing the velocity of blood flow recovery.  D-E) Representative microCT 3D 
reconstruction obtained from our experiment, showing a sample with good (D) and not efficient 






The aim of the work described in this chapter was to create pattern-enhanced composite 
scaffolds cellularized with vascular cells able to promote organized collateralization for 
therapeutic application in a model of peripheral artery disease. 
 
PLGA-based composite scaffold fabrication. A first successful milestone was the fabrication of 
composite scaffolds with Bioprinted PLGA and nanofibers of GL, matching the features of the 
scaffolds composed of PCL. To this aim, I converted a commercially available 3D printer into a 
Bioprinter able to extrude polymeric gel solution. The process of scaffold fabrication was 
established assessing the repeatability and consistence of physical features, including width, 
geometry and mechanical properties. In particular, results from mechanical test showed no 
significant difference in mechanical properties between structures fabricated with previous 
system (PAM2) and the novel customized bioprinter. The second milestone was the 
demonstration of the biocompatibility of the PLGA-based scaffold when seeded with adventitial 
progenitor cells.   
 
Characterization of PLGA-based scaffold 
In tissue engineering applications, the identification of the clinical target is essential to define 
the material best suited for scaffold microfabrication. As mentioned previously, the scaffold has 
to be designed to have a material that will match the mechanical and remodelling features of 
the host tissue. Rohman et al. showed that bladder epithelial and smooth muscle cells 
proliferate better on substrates that had similar mechanical property to the native bladder 
(Rohman et al., 2007). Also, other studies showed the effect of degradation rate on cell viability 
(Sung et al., 2004). The balance between those two properties are important. Zimmerman et al. 
demonstrated the improvement provided by porous scaffold fabricated in laboratory over a 
commercially available substrate developed for general purpose. Despite this advancement, 
foam scaffolds with high porosity but random microstructure showed limitations in myocardial 
patches application, a model in which the mechanical stress becomes relevant (Zimmermann et 
al. 2006). Other studies showed how a scaffold specifically designed to reproduce myocardial 
tissue resulted in therapeutically significant benefit (Engelmayr et al., 2006; Freed et al., 2009).  
In this study, I achieved the fabrication of PLGA-based scaffolds with the same geometrical 
features of PCL-based scaffolds, which were designed, as described Chapter 2, to reproduce an 
ideal ECM for aligned arteriogenesis. Mechanical tests showed the more rigid behaviour of PLGA 
compared with PCL, in line with the literature (Middleton and Tipton, 2000; Sung et al., 2004). 
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In vitro assay comparing different patterns, Woodpile and Channels, showed high values in all 
biological assays, including cell density, viability and proliferation. The only difference observed 
between channels and woodpile geometries was cell proliferation. Looking at the data from the 
literature, PLGA showed lower values of proliferation compared to PCL, which matched better 
the native mechanical stiffness (Baker et al., 2009; Rohman et al., 2007; Tan and Teoh, 2007). 
This apparent discrepancy could be explained by the presence of GL nanofiber in our scaffold, 
which acts like a biomimetic substrate and allows cells to have improved functional behaviour. 
Overall, the data indicate the excellent biocompatibility of the adopted multi-material approach. 
 
Pattern-enhanced scaffold fabrication. Here, the milestone was the assessment of bioprinting 
and ultrasound trapping technologies to improve spatial organization of cells on the scaffold 
surface. Moreover, I demonstrated the feasibility of combining the cell patterning method with 
fabrication of the PLGA-GL scaffold.  
In recent years, bioprinting had a rapid development for cell encapsulation and tissue 
engineering applications (Bertassoni et al., 2014; Gao et al., 2015; Saunders et al., 2008). In 
contrast, alignment of cells by ultrasound trapping is less popular in this field of research (Habibi 
et al., 2017). A previous study assessed the capability of alignment of neuronal cells (Gesellchen 
et al., 2014). The analysis of the results from US trapping showed that adventitial progenitor 
cells, both on coated coverslips and scaffold, lose the initial alignment after few hours. Co-
culture of adventitial progenitor cells and HUVECs patterned on scaffolds displayed a slightly 
better trend of alignment assisted by the geometry. This better result may be attributable to 
stronger interactions provided by the two different cell populations, as shown previously in a 
study of cell sheet (Mendes et al., 2012) . In conclusion, we did not find an optimal method to 
increase the conservation of the cell pattern over time by the use of ultrasound trapping.  
Bioprinting methodology was therefore used for the production of pattern-enhanced composite 
scaffolds. Several studies explored the use of bioprinting or cell-suspended in gel for cardiac 
tissue engineering (Gaetani et al., 2012, 2015). Endothelial cells and stem cells were patterned 
by Gaebel et al. with laser printing for cardiac regeneration (Gaebel et al., 2011), while in another 
study cardiac progenitor cells were implanted in mice for epicardial regeneration (Gaetani et al., 
2015). The limitations of this trial were mainly due to poor mechanical properties (Duan, 2017; 
Gao et al., 2015; Hwang et al., 2010). To overcome this problem, the new trend is to use hydrogel 
in combination with synthetic material (Shim et al., 2011; Yeo et al., 2011). A recent study 
proposed the use of cell-laden alginate-based in combination with PCL to deliver osteoblast-like 
cell for bone tissue engineering (Lee and Kim, 2014).  
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In the present study, bioprinted AG/Pl gel had less line width resolution as compared with the 
bioprinted synthetic polymer (PCL and PLGA). Nevertheless, the method was highly reproducible 
and allowed me to successfully combine the cell-laden AG/PL gel onto the cellularized composite 
scaffolds. The pattern chosen for the extruded gel was a “serpentine”, which creates repeated 
parallel lines of cell-laden gel. This pattern combines and synergizes with the geometry of the 
PLGA-GL core, where the referential direction provided by channels aimed to stimulate the 
formation of collaterals in parallel direction with the occluded femoral artery.  
Another original aspect of the present study is the use of two cooperative vascular cell 
populations. At the best of my knowledge, this is the first attempt to incorporate adventitial 
progenitor cells and endothelial cells into a gel within a multi-material, multi-scale scaffold for 
implantation in limb ischemia model. The resulting 3D biomaterial represents a candidate 
therapeutic product for promotion of reparative arteriogenesis.  
 
In vivo study.  Due to time constrain, I could not finish all the analyses of the in vivo study, which 
aimed at comparing two different materials, PLGA-AG/PL and PCL-AG/PL, with and without 
adventitial progenitor cells and HUVECs, and determining a potential improvement vs. the 
control untreated group in a murine limb ischemia model.  
I was able, however, to obtain some relevant results in one of the two imaging methods 
employed to determine the clinical outcome from ischemia. The most important result was the 
recognition that the cellularized PLGA-AG/PL scaffolds significantly shortened the time to reach 
the maximum recovery. Not having completed the histological analysis of muscles, I cannot 
attribute this effect to an improvement of arteriogenesis or vasodilation. Implantation of 
cellularized PCL-AG/PL scaffolds also reduced the time to reach maximum perfusion recovery, 
but this reduction was less than the result obtained with cellularized PLGA-AG/PL scaffolds and 
did not reach a statistical significance when compared with vehicle. Again, in the absence of 
histological data, I cannot make any comment on vascularization produced by the two materials. 
However, a possible key of interpretation comes from the analysis of changes induced by 
embedding adventitial progenitor cells in 3D systems made by PLGA or PCL. Importantly, I found 
that the embedding of adventitial progenitor cells into a 3D structure modified significantly their 
profile and paracrine activity. Some differences were also the consequence of the scaffold 
manufacture with PCL or PGLA. The former led to a 2.5-fold increase in the BAX/BLC2 ratio, 
which is an index of cell apoptosis, with respect to a correspondent material planar film, whereas 
3D PGLA scaffold did not alter the ratio. In tissue engineering of 3D cell-scaffold constructs, 
gradients of nutrients and oxygen from the periphery toward the centre can affect cell 
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behaviour. Perfusion bioreactors reduce cell death but they do not completely eliminate the 
reduction in oxygen (Volkmer et al., 2008).  Also, reducing the scaffold inner surface and 
increasing perfusion rate in bioreactors resulted in improved oxygen supply in a 3D bone scaffold 
model (Volkmer et al., 2012). Although I did not measure the oxygen levels in the studied 
scaffolds, it is likely that the two polymers had the same diffusion due to the high porosity. A 
study using hydrogen peroxide encapsulated in a PGLA matrix system produced oxygen at a 
controlled release manner to sustain the survival of muscle cells under hypoxic (Abdi et al., 
2013). 
The presence of hypoxia in the 3D scaffolds is supported by the observed upregulation of VEGF 
mRNA and protein. Hypoxia inducible factor (HIF) is the central mediator of hypoxic response 
and VEGF is one of the primary target genes. We previously showed that hypoxia is a potent 
stimulus for adventitial progenitor cells production of VEGFA (Gubernator et al., 2015). Further 
investigation is necessary to determine levels of HIF in the scaffolds.  It should be noted that 
VEGF mRNA level and VEGF secretion in conditioned media showed similar increases in both 
cellularized 3D PLGA and PCL scaffolds compared with correspondent 2D films (from 4 to 6-fold). 
On the other hand, still in conditioned media, Angpt-1 was downregulated in the 3D transition 
of PCL but not of PLGA. Angpt-1 is an oligomeric secreted glycoprotein that plays a key role in 
the organization and maturation of newly formed vessels, promoting the quiescence and 
structural integrity of adult vasculature (Brindle et al., 2006). We have previously shown 
adventitial progenitor cells produce and release Angpt-1. Taken together, the data that VEGFA, 
an initiator of angiogenesis and vascular sprouting, is increased in adventitial progenitor cells 
embedded in 3D PCL and 3D PLGA, while Angpt-1, a vascular stabilizer, was decreased in the 
former may suggest that 3D polymers could modify the cell secretome in favour of 
neovascularization. Intriguingly, Bach-1, a hypoxia-inducible repressor of Angpt-1 expression 
and regulator of important biological processes including oxidative stress, inflammation, 
apoptosis, cell proliferation, fibrosis, and angiogenesis (Slater et al., 2018), was downregulated 
in the 3D transition of the two materials, thus suggesting the occurrence of complex as yet 
unexplained modifications in gene expression in adventitial progenitor cells exposed to different 
geometrical cues. It is tempting to speculate that these phenomena may have had a role in the 
therapeutic effect of cellularized PLGA scaffold. In vitro angiogenesis assays using conditioned 





This study represents a significant advancement in the pathway toward the production of a 
scaffold engineered with vascular cells to promote therapeutic angiogenesis. The production 
system has been simplified with the introduction of a novel Bioprinter that can be used in 
substitution of Pam2 for the extrusion of PCL or PLGA, while retaining compatibility with 
electrospinning for the deposition of GL fibers. The PLGA-GL scaffolds so generated show good 
biocompatibility. Furthermore, I demonstrated the transition to 3D induces significant 
expressional changes in the embedded cells. Finally, I succeeded in using the same bioprinter 
for improvement of cell patterning and retention. Also, I demonstrated the possibility to bioprint 
two vascular cell populations into the scaffold. A significant therapeutic benefit was observed 
when using the new cell engineered product made by PLGA to accelerate the perfusion of 
ischemic limbs. Its superiority over a similar product made of PCL suggests that the polymer 
composition plays a key role in the therapeutic outcome of the perivascular scaffold 
implantation. The reasons for the observed superiority are still not clear but they could depend 
on the interaction of the material with the embedded cells, through stimulation of a more 







4 Tissue Engineering Vascular Grafts 
4.1 Rationale and aim of the study 
Vascular grafts are used in cardiovascular reconstructive surgery for the treatment of ischaemic 
heart disease, critical limb ischemia, congenital heart disease, and haemodialysis. In the US only, 
400,000 coronary artery bypass grafting procedures are performed each year. Current grafts 
have an enormous clinical impact but require further optimization. Tissue engineering has been 
proposing to overcome the limited availability of autologous grafts. 
I hypothesize that the production of an ideal tissue engineered vascular graft (TEVG) requires 
assembling all the structural components of an artery. 
To this aim, here, I propose a novel approach based on three main goals: (i) Fabrication of a 
tubular scaffold, (ii) Cellularization with all essential component populations of an artery, (iii) 
Automatization of the manufacture process. 
4.2 Comparison with competitive approaches and conceptual novelties 
Autologous vessels, such as the saphenous vein and internal thoracic artery, represent the gold 
standard for grafting small-diameter vessels. However, they require invasive harvesting and are 
often unavailable. Moreover, the patency rate remains suboptimal, with coronary 
reconstructions showing failure rates from 50 to 80% at 8-10 years' follow-up (Angelini et al., 
2009; Harskamp et al., 2013).   
Synthetic vascular grafts showed satisfactory long-term results for replacement of large- and 
medium-diameter arteries, such as the carotid or common femoral artery (Chlupac et al., 2009) 
but have poor patency rates when applied to small-diameter vessels (<6 mm), such as coronary, 
infra-inguinal, and infra-geniculate arteries (Ballotta et al., 2003; Pampaloni et al., 2007; Seifu et 
al., 2013). Decellularized native tissues have been also considered. However, incomplete 
decellularization may provoke an immunogenic reaction from the host, whereas an excessive 
treatment could lead to the loss of mechanical properties and aneurysmal dilatation (Shojaee 
and Bashur, 2017).  
As consequence, there is increasing clinical requirements for design and development of living, 
functional small-calibre vascular grafts. TEVG fabricated with biodegradable materials, able to 
confer a temporary support for cell growth, could provide a solution for the lack of autologous 
grafts. In the last decade, a great variety of acellular and cellularized grafts have been proposed. 
Encouraging results were reported by L’Heureux, who applied an autologous cell-sheet based 
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graft in clinical trials. Despite the promising outcome, the main limitation was represented by 
the production time which turned out to be around 7.5 months (McAllister et al., 2009). 
Synthetic conduits seeded with endothelial cells (ECs) showed improved patency rate but did 
not surpass autologous grafts (Deutsch et al., 2009; Pashneh-Tala et al., 2015).  
Recently, hybrid TEVGs, which combine properties of both synthetic and natural materials, are 
emerging as a promising approach. Hybrid TEVGs fabricated by reinforcing decellularized native 
vessels with Polycaprolactone (PCL) (Gong et al., 2016) and PCL-collagen grafts seeded with ECs, 
vascular smooth muscle cells (VSMCs) and fibroblasts (Ju et al., 2017), were patent over a 
maximum follow-up of 6 months. However, the long conditioning period was a major limitation 
(Carrabba and Madeddu, 2018).  
Therefore, none of current TEVGs possess the properties of a natural artery, including proper 
compliance, resistance to burst pressure, and anastomotic strength. 
There are distinctively innovative aspects in this study: We propose to construct a novel small-
diameter TEVG, which will match the physiologic structure of natural arteries. The TEVG is 
fabricated and tested through three steps: (1) Production of a tubular structure comprising an 
internal layer of gelatin (GL) nanofibers (the intima), surrounded by PCL nanofibers (the 
basement membrane), and two concentric layers of bio-printed gel (the media and adventitia), 
(2) Precise topographic decoration of the conduit with specialized vascular cells, and (3) 
Assessment of the TEVG physical properties and biocompatibility. The whole process is 
optimized to reduce the manipulation of the graft thus limiting the possibility of contamination. 
The following paragraphs provided details of the approach  
4.2.1 Manufacture of the multi-layer hybrid TEVG 
The inner part of the TEVG conduit was fabricated using an electrospinning system. In a pilot 
test, the tubular scaffold core was made by extruding a jet of nanometric GL filaments onto the 
charged collector. Limitations of physical properties convinced me on using a composite system 
to increase robustessness. This was achieved by electrospinning PCL around the GL structure, 
thereby generating two concentric layers of porous nanofibers.  I decided to use a GL/PCL 
composition since it is proven to have good biocompatibility, confirmed in our hands when 
manufacturing planar scaffolds (Carrabba et al., 2016). In addition, I cross-linked GL with 3-
glycidyloxy-propyl-trimethoxy-silane (GPTMS) to improve the nanofibers property in aqueous 




Next, I focused on the manufacture of the outer component of the proposed TEVG. To this aim, 
using a commercially available 3D printer, I coated the GL/PCL conduit with two concentric layers 
of sodium alginate (AG) and Pluronic F127 (PL) gel.  
4.2.2 Cellularization 
4.2.2.1 Rotating seeding approach for endothelialization of the TEVG 
The luminal decoration of the scaffold was performed by seeding ECs by a custom-made rotating 
bioreactor. The system uses gravity to settle the cells onto the inner part of the TEVG, thus 
avoiding complex manipulation and reducing the risk of rupture.  
It is known that thrombus formation is one of the most important adverse events after graft 
implantation. Among the techniques to avoid this problem, the generation of a biomimetic 
surface covered with a layer of ECs is the most acknowledged. Static seeding has been developed 
over decades and employed in many laboratories (Villalona et al., 2010). Flat fabricated grafts 
offer an easy platform to populate the scaffold under static conditions. In a subsequent step, 
the scaffold is stitched into a tubular structure, with the cells on the luminal side. However, 
stiches often constitute areas of failure for implanted grafts. A preformed tubular structure 
alleviates the problem, although seeding tubular scaffolds remains a challenge, with limitations 
in efficiency, cell distribution and penetration.  
4.2.2.2 Bioprinting seeding approach for muscolarization of the TEVG 
Next, proceeding to the outer cellularization, I printed a suspension of human vascular mural 
cells in AG/PL onto the PCL conduit, which remained locked around rotating mandrel. 
In recent years, improvement in rapid-prototyping systems and automatization technologies 
allowed the introduction of bioprinting systems for tissue engineering. These devices allow 
precise extrusions of hydrogels and cell-laden gel. The success of the bioprinting approach was 
demonstrated by good cell viability and wide variety of cell patterning in 2D and 3D (Bertassoni 
et al., 2014; Gaetani et al., 2015; Kamei et al., 2006).  
Many attempts have been done to build a complex 3D structures, but as introduced in Chapter 
1, artificial blood vessels fabricated with hydrogels are usually too weak compared with native 
vessels and are not suitable to sustain blood pressure (Borovjagin et al., 2017; Duan, 2017; 
Mironov et al., 2009a; Norotte, 2009). In this project, we exploited the hydrogel feature of 
retaining the cells precisely into a specific geometry, conferring stability and strength to the cell-
laden gel with a support layer made by nanofibers.  
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4.3 Work-packages of the study 
Figure 4-1 illustrates the three activities of the study. 
 
 





4.4 Material and methods 
4.4.1 Cell biology material and methods 
4.4.1.1 Human umbilical vein endothelial cells (HUVECs) 
Immortalized HUVECs (EAhy926) were used in the first stage of the work to optimize the seeding 
procedure of the luminal side of the scaffold. EAhy926 HUVECs was cultured at 37 °C with 20% 
oxygen and 5% carbon dioxide in high glucose Dulbecco’s Modified Eagle’s Medium (DMEM) 
(Gibco, LifeTechnology) supplemented with 10% FBS (fetal bovine serum, Gibco) and a cocktail 
of 100U·ml-1 penicillin and 100µg/ml streptomycin (Lonza). Once reached 70% confluence, cells 
were further expanded by passaging. Cells were washed with PBS and incubated for 3 min at 
37°C in a solution of 0.05% (w/v) trypsin to detach them from the culturing surface. The trypsin 
activity was neutralized by adding a solution of 10% FBS at the ratio of 1:2, and the whole 
suspension was centrifuged at 300g for 5 min. At the end of centrifuging period, the supernatant 
was discarded and the HUVEC pellet was re-suspended in 1 ml of culturing medium. Cells were 
counted and seeded in new culturing plate at the density of 10,000 cell·cm-2. A cell-specific 
freezing media was prepared for EAhy926: 95% FBS, 5% DMSO. The process of storage and 
resuscitation is common for all cell types described in this section. HUVECs were used for seeding 
on the graft between passage 7 to 15.  
4.4.1.2 Coronary artery endothelial cells (CAECs) 
After the first stage of parameter tuning, EAhy926 cells were substituted with coronary artery 
endothelial cells (CAECs, from PromoCell) to replicate the structure of the Human Coronary 
Artery (HCA) in the production of the tubular graft. CAECs were cultured at 37 °C, 20% Oxygen, 
5% carbon dioxide in endothelial cell growth medium MV (PromoCell) supplemented with 0.05 
ml/ml Fatal Calf Serum (FCS), 0.004 ml/ml endothelial cell growth supplement, 10ng/ml 
epidermal growth factor, 90μg/ml heparin and 1μg/ml hydrocortisone. The expansion process 
splits the cells once 70% confluence was reached. Cells were washed with PBS and incubated 
with a solution of 0.05% (w/v) trypsin at RT to detach them from the culturing surface. Cells 
were counted and seeded in new culturing plate at the density of 8000 cell·cm-2. For cell storage, 
a cell-specific freezing media was prepared: 90% FBS, 10% DMSO. CAECs were used for graft 
endothelialisation between passage 5-7.  
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4.4.1.3 Vascular smooth muscle cells (VSMCs) 
Aortic smooth muscle cells (AoSMCs, from PromoCell) isolated from the human aorta were used 
for graft muscularization. They were cultured at 37 °C and 5% CO2 in PromoCell Smooth Muscle 
Cell Growth Medium 2 supplemented with 0.05 ml/ml FCS, 0.5ng/ml epidermal growth factor, 
2ng/ml basic fibroblast growth factor, and 5μg/ml insulin.  As described for the HUVECS, when 
cells reached 70% confluence they were expanded by passaging. Smooth Muscle Cell Growth 
Medium 2 was added to the trypsin (ratio of trypsin in medium: [1:2]) to neutralize the activity 
and the whole suspension was centrifuged at 300g for 3 min. AoSMCs were suspended in 1 ml 
medium, counted and seeded in new culturing plate at the density of 7,500 cell·cm-2. For cell 
storage, a cell-specific freezing media was prepared: 92.5% FBS, 7.5% DMSO. Cells were used 
between passage 5-7.  
 Adventitial    progenitor cells  
The cells were cultured following the protocol described at Chapter 2 (Cell Source). 
4.4.2 Material and methods of TEVG manufacture 
4.4.2.1 TEVG core material: PCL and GL 
PCL and GL were used for the fabrication of the graft inner layers. These polymers have been 
extensively described in Chapter 2. 
4.4.2.2 TEVG external layer material: Alginate and F127 Pluronic  
Alginate is a natural polymer extracted from seaweed through treatment with alkali solution, 
like NaOH (Clark et al., 1936; Smidsrød and Skja˚k-Br˦k, 1990). The commercially available 
Sodium Alginate powder is finally derived through a multiple process of filtration, purification, 
and conversion of the original extracted compound. Crosslinking methods include thermal 
gelation, cell-crosslinking, and chemical crosslinking (Lee and Mooney, 2012). However, the 
most common way of gelling is through ionic-crosslinking with CaCl2 (Crow and Nelson, 2006). 
Owing to its good biocompatibility and low costs, Alginate was widely employed in biomedical 
approaches, such as the delivery of small proteins (VEGF and PDGF) and chemicals improving 
skin wound healing and tissue repair (i.e. AlgiSite MTM (Smith&Nephew), AlgicellTM (Dema 
Sciences)) (Balakrishnan et al., 2006; Lee et al., 2003; Lee and Mooney, 2012; Murakami et al., 
2010; Silva and Mooney, 2010).  
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In this study, I used Sodium Alginate in combination with F127 Pluronic. This latter compound 
undergoes reverse thermal gelation, becoming a gel at higher temperature, conferring better 
printability. It has also the function of sacrificial material, when it is washed out, allowing 
generation of bigger pores that would improve cell interaction properties. 
4.4.3 Seeding and culturing devices  
4.4.3.1 Graft rotating support 
To address the technological challenge of seeding the external surface of the tubular graft I 
developed a new seeding system that will be indicated as Bioprinting rotating system. This 
system is composed by two distinct device as shown in Figure 4-2: 1) customized Bioprinter 
(described in Chapter 3) and 2) the graft rotating support.   
The graft rotating support is a custom-made system that allows the seeding of cells by a 
Bioprinting device. While the Bioprinter extrudes the cell-laden gel onto a tubular structure the 
rotating support keeps in rotation the graft and maintains cells in a controlled environment. I 
designed and assembled the device at Research Floor level 7, Faculty of Translational Health 
Science, University of Bristol. 
The system was designed to address requirements of biological safety, for example withstanding 
ethanol and UV sterilization, having surfaces easy to clean, and enclosing the electronic 
components within a waterproof container. 
 
Figure 4-2: 3D render of the Bioprinting roating system.  
The image shows the 3D render of the Bioprinter, the graft rotating seeding and the composition 
of both to form the bioprinting rotating system.  
 
The main body of the system is a 1550WKBK tank (Hammond Manufacturing Ltd) (22x14x10 cm 
LxWxH), which is an aluminium box, polyester painted, with an IP68 gasket that makes the 
system perfectly impermeable. This main box incorporates an electronic board, and it was 
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machined at the mechanical workshop University of Bristol to host a stepper motor NEMA14 
and a seeding tank. The components of the system are briefly described below:  
• Motor: a NEMA14 stepper motor, controlled by a driver (carrier Pololu a4988) and an 
Arduino Nano microcontroller (Arduino micro) (Arduino®, Italy), was used to guide the rotation 
of the graft (Figure 4-3, particular A). A plastic support was 3D printed to fix the motor at the 
appropriate height.  
• Electronic component: the microcontroller that manages the whole device is an Arduino 
micro (Figure 4-3, particular B). In addition to the controlling board, the motor driver A4988 
(Pololu, United States) drives the stepper engine rotation managing the phases of the motor and 
finely controlling its rotation. In fact, this driver has the ability to employ a microstepping control 
modality. The driver can implement the microstepping up to 1/16, so the required steps to 
complete a round can range from 200 (1.8°) to 3200 (7’). Arduino is open source and has its own 
programming software: the Arduino Integrated Development Environment (IDE), based on the 
language Java.  
• Seeding tank: the tank was made of a smaller 1550WKBK (Hammond Manufacturing 
Ltd) (11x6.5x4cm LxWxH) which was fitted on the upper surface of the main box (Figure 4-3, 
particular C). This box could be extracted allowing a cleaning process by sterilization in an 
autoclave.  
• Magnetic rotary coupling: a magnetic rotary coupling system was chosen to minimize 
the possibility of contamination (Figure 4-3, particular A-i). Two plastic components were 
fabricated with the 3D printer Ultimaker 2Go, using Nylon (680 FDA Nylon Resin Co-Polymer) 
which is autoclavable with a steamed cycle of 110°C. These components have 6 cylindrical holes, 
10mm deep around the main axis, to hold 6 magnets (Figure 4-3, A-i). One of the two 
components is connected to the shaft of the motor and remains outside the seeding tank, while 
the other is connected to the graft support (Figure 4-3, particular A-i) and remains inside the 
rotating tank. The magnetic attraction between the magnets inside and outside is strong enough 
to allow the magnets on one side to follow the movement of others. When the motor is 
activated, and its shaft rotates, the magnets move solidly with it and force the rotation of the 
graft support. The graft support consists in a 3D printed Nylon rod with diameter of 4 mm to 
allow the scaffold to slip in and out the support. 
• Temperature control: a temperature sensor was enclosed in the seeding tank (TSicTM 
506F, Innovative Sensor Technology) (Figure 4-3, particular A-ii). A hole was created drilling the 
tank to allow the fitting of the sensor. This hole was sealed to avoid leakage of culturing medium 
out of the tank and to avoid interaction with the electronic components. The sensor was 
137 
 
connected in retroactive feedback with the microcontroller, which drives a thermal pad (Thermo 
Technologies THERMC12V15W) (Figure 4-3, particular A-iii) attached on the external walls of 
the seeing tank to maintain the desired temperature that was fixed at 37°C. 
The electronic parts and the motor were enclosed within the aluminium box and provided with 
power supply and connection for the LCD control display. To keep all the components in their 




Figure 4-3: Graft Rotating Support.  
3A) 3D render of stepper motor NEMA 14; 3B) Representative images of electronic components; 
3C) Seeding Tank; 3C-i) Magnetic rotary coupling; 3C-ii) Temperature sensor; 3C-iii) Thermal pad. 
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4.4.3.2 Rotating bioreactor 
The Rotating Bioreactor is employed in my research to seed ECs on the luminal layer of a tubular 
graft, exploiting the rotating seeding approach described above. The system is a home-made 
device, result of previous work conducted in our laboratory. Also in this case, the biological 
safety was one of the main milestones and was guaranteed by the capability of working inside 
the incubator at 37°C and the system being sterilizable with ethanol and UV.   
The final design of the device is composed of a Polyvinyl-chloride (PVC) base, on which a box is 
fixed to contain the microcontroller, the motor driver, and the motor itself. The motor shaft pass 
through the box wall and is connected to a carrier with 6 tube locations, in which vascular grafts 
are positioned. Here, we describe the principal components of the system. 
• Control case: the main box (1550WKBK (Hammond Manufacturing Ltd)) ensures a 
waterproof enclosure, due to the presence on IP68 gasket (Figure 4-4A). The surfaces of the box 
have precisely designed holes to host the interfaces, the shaft, and various screws. On the box, 
a switch button, an USB interface, and a power input are also present (Figure 4-4A). O-rings 
ensured the sealing of the holes. An integrated battery (11.1V Li-Po), inside the control case, 
allows the device to be self-sufficient and avoids having cables coming out from the incubator, 
which could be a source of contamination.  
• Motor: the rotating bioreactor employed a NEMA17 motor to generate the rotation of 
the grafts (Figure 4-4B). The hole in the control case allows the shaft of the motor to be 
connected to the external components. To let the motor rotating freely and maintain the 
sealing, an oil seal was used. This was kept in position by an aluminium flange.  
• Electronic components: the rotation of the NEMA17 stepper motor is controlled by 
Arduino micro and motor driver A4988 (Figure 4-4B). The working principles are the same 
described for the graft rotating support (paragraph 4.4.1.).  
• Tube carrier:  this tool allows to hold 6 tubes and it is composed of two round shaped 
supports joined together by a hexagonal shaft (Figure 4-4C). To block the tubes during the 
rotation of the carrier, O-rings were placed in tube housing to gain static friction. Two different 
tube carriers were fabricated: one carved with six holes of the same size of 15ml Falcon tubes, 
while a second with the dimension of a 50ml Falcon tube. These two options provide flexibility 
to the system allowing to use two different Luer locks (1/8” female or 1/8” Luer locks) to block 
and connect the scaffold to different devices.  These tube carriers were designed to use sterile, 
disposable and commercially available Falcon tubes. The complete assembly of the Rotating 




Figure 4-4: Rotating Bioreactor: components and 3D renders. 
A) Representative images of the control case and connectors. Respectively from left to right: 
power plug, USB connection and switch. B) Electronics and mechanical components; C) F15 tube 
carrier; D) 3D render of Rotating Bioreactor and real picture of the fabricated device. 
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4.4.3.3 Tubular scaffold holder 
The scaffold holders have the function of keeping the TEVG straight and in the proper position 
during both the cell injection procedure and rotating seeding. The scaffold, in fact, has to be 
fixed inside the Falcon tube while the rotating bioreactor moves (Figure 4-5). In this thesis, I will 
refer to these tools as holders.  
 
Figure 4-5: Schematic 3D render of the set-up. 
 A) The scaffold is locked fitting the Luer locks into the holder traks; B) The scaffold is placed into 
a disposable Falcon tube (F15 in this example); C) Fitting of the Falcon into the Rotating 
Bioreactor. 
 
To hold the scaffold without risk of damaging its structural integrity, the holders were designed 
to have two connection trails that fit perfectly with the 1/8 Luer locks. These Luer locks are 
solidly connected with elastic rubber bands to the scaffold.  Two different holders were 
fabricated: F15 holder and F50 holder. The F15 holder was fabricated to allow a 1/8” female 
Luer lock to fit in the trail. It is 65mm long and has a diameter of 13.6mm, being able to fit tight 
into a F15 Falcon tube (Figure 4-6A). The F50 holder, instead, fits a 1/8” male Luer lock and its 
dimensions (90x26mm) were designed to fit into a F50 Falcon tube. Both types of holder allow 
the precise and stable positioning of a 5cm long tubular scaffold (Figure 4-6B).  
As it would be in contact with the biological component, the raw material used to build the 
holder must be biocompatible and sterilization compliant. For this reason, I used 
polyoxymethylene (POM) to fabricate the holders. POM is suitable as culture media wetted 
material, even after machining and repeated autoclaving (Penick et al., 2005). It has good 
machining characteristics, mechanical properties, and dimensional stability, and it is chemically 
resistant to solvents. Its melting point is 175°C, higher than the usual autoclaving temperatures, 
which is carried out at 130°C. Moreover, it has negligible porosity and low moisture absorption 
(0.9% at saturation). All these features make the POM an excellent material to build biomedical 
devices. 
The process of assembling the scaffold on the holder needs additional tools. In fact, during the 
scaffold mounting on the holder, it is essential to handle the structure as less as possible to 
prevent any damage and infection transmission. To help the operator in this passage, I have 
designed a scaffold mounting tools, machined with the CNC device as made for the holder. Also 
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in this case, I fabricated two different components for female and male Luer locks. All the 
fabricated POM components are shown in Figure 4-6C. The tools have a central hole, in which 
the Luer lock are placed, and 2 rubber bands, used to tighten the scaffold around the lock, 
positioned around the external central hole of the mounting tool (Figure 4-6D). Once the Luer 
lock fits the scaffold, the rubber bands are pushed with a pair of forceps, to jump on the scaffold 
(Figure 4-6E). Then, the scaffold, with the Luer locks secured to both ends, is snapped onto the 
holder (Figure 4-6F). 
 
Figure 4-6: Images of the whole set of tools for TEVG connection to the rotor system. 
A-B) F15 and F50 holders; C1) F15 scaffold mounting tools; C2) 1/8” female Luer lock; C3) Silicone 
lid for female Luer lock; C4) F15 holder; C5) F50 scaffold mounting tools; C6) 1/8” male Luer lock; 
C7) Silicone lid for male Luer lock; C8)F55 holder; D-E) Sequence of scaffold mounting set-up. 
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4.4.3.4 Perfusion bioreactor 
The conditioning phase under physiological stimuli before the implantation is essential for the 
maturation of the TEVG. In this study, I used the 3DCulturePro™ Bioreactor (TA Instruments, UK) 
to provide flow perfusion and support cell growth in the hybrid TEVG (Figure 4-7A). The 
perfusion bioreactor is a commercially available device. The system is composed of a peristaltic 
pump (Masterflex L/S digital 07528-20) (Figure 4-7B), a silicone tubing (3/175mm (1/8”) internal 
diameter (ID), 6.35mm (1/4“) outer diameter (OD)) to connect the various compartments of the 
chamber, a pump cassette tubing (PharMed BPT tubing, 2-stop, 2.79 mm ID) compatible with 
Ismatec, IDEX Health & Science GmbH (SC0736)) to withstand the cyclic action of the pump and 
perfuse the all system, a single or multi-chamber stand for sample setup, and six 3DCulturePro 
bioreactor chambers. Every single 3DCulturePro bioreactor chamber consists of two separated 
compartments (chamber-A and chamber-B). Chamber-A has the function of reservoir while 
chamber-B is designed to host the scaffold (Figure 4-7C). The flow rate is determined by the 
RPM selected on the pump interface and by the ID of the pump cassette tubing: with the ID of 
2.79 mm and RPM range of 3-300, the flow rate can be set between 1.1 and 100 ml/min. All the 
components are designed to withstand laboratory procedures, autoclavable sterilization (cycle 
of 121°C for 30 min), and long period in incubators.  
 
Figure 4-7: 3DCulturePro™ Bioreactor. 





4.4.4 Manufacturing process of hybrid three-layered TEVG 
4.4.4.1 Electrospinning device 
I fabricated the tubular scaffolds with an ND-ES lab electrospinning unit (Nadetech Innovations, 
Spain) (Figure 4-8), at Research Floor level 7, Faculty of Translational Health Science, University 
of Bristol. The equipment is an independent and automatized unit, in which the solution emitter 
is connected to a controllable high voltage source that can provide a voltage up to 30 kV. The 
Electrospinning device is equipped with its own control software, which allows a fine control of 
all the parameters. The system provides different set-up (vertical and horizontal extrusion) and 
collectors. In this stage of the work, I selected a rotating collector, consisting in a steel rod with 
controllable rotating speed. As the polymer jet leaves the needle of the loaded syringe and 
approaches the collector, the fibers wrap around the rod and create a cylindrical sheet. Since 
the aim of the work was to create a TEVG for replacement of small-diameter blood vessel (≤ 6 
mm), I designed the mandrel to have a diameter of 6 mm and a length of 200 mm. The pump 
was customized to allow the placement of multiple syringes and achieve a uniform deposition 
of the fibers along the length of the mandrel. 
 
Figure 4-8: Electrospinning Device 
 A) Nadetech-Innovations ND-Electrospinning Unit; B) Rotating mandrel for nanofiber 
deposition, with 6mm diameter; C) 3D printed tool for multi-syringe electrospinning; D) Graphic 




4.4.5 Single-material core of TEVG fabrication: electrospinning of GL fibers  
The production of the tubular core of the TEVG was carried out with the previously described 
set-up of the electrospinning machine. The polymer solution was composed of 15% w/v GL (Type 
A gelatin from porcine skin, Sigma Aldrich) dissolved in a liquid solution of 60/40 v/v acetic 
acid/deionized water. 200 μL GPTMS was added to each gram of GL and stirred for one hour. 
Then, the solution was poured into three 5 ml syringes and mounted in the syringe pump. The 
introduction of the new ND-ES lab electrospinning unit required me to perform additional tuning 
of the parameters in order to produce repeatable and robust features of the fibers. The process 
of tuning was carried out as described in Chapter 2 (paragraph “Tuning of Electrospinning 
process” and in supplementary data: A). Environmental conditions were also important for the 
production of the fibers. Below 20 °C, I noticed that the fibers started forming a thread of few 
mm in diameter that connected the needle to the collector thereby resulting in a scaffold poor 
in the amount of scaffold material. Furthermore, the structure had visible pores and, when 
dried, it was easy to break if handled. To overcome this issue, I used infra-red lamps (Beurer il 
35 infrared lamp) to keep the temperature at 24±1 °C.  For this new device the parameters were 
tested in the following range: 
• Voltage: 20, 25 and 30 kV; 
• Distance: 15, 20 and 25 cm;  
• Flow rate: 0.1, 0.2 and 0.5 ml·min-1. 
At the end of the electrospinning stage, the formed tubular structure was pulled out from the 
mandrel and dried for 48 h at 37°C to finalize the crosslinking process of the GL fibers. The 
tubular structure, with 6-mm inner diameter, was then cut in the required length measure, e.g. 
200 mm. 
4.4.5.1 TEVG characterization 
 Swelling assay 
One main factor that affects the biocompatibility of a biomaterial is its water content: in fact, as 
a biological tissue, a scaffold must include an optimal water amount. The process of water 
inclusion in a polymer matrix, when material is soaked in an aqueous solution, is called swelling. 
Obviously, this causes a variation of the sample physical size, weight, and mechanical properties. 
Furthermore, scaffolds showing a high degree of swelling have large surface area/volume ratio, 
which could favour the porous structures colonization by cells (Tonda-Turo et al., 2013). The 
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swelling assay was performed on 20mm long rings of the tubular scaffold. The samples were 
soaked in PBS solution and held within a cell culture 6 well-plate at 37°C. The samples’ weight 
was measured following a pre-set schedule: 1, 2, 5, 10 min. Before the weighing, the specimen 
was carefully dried on blotting paper and placed in a plastic container. The weigh was then 
registered, and the sample placed back in its well. The samples were monitored until the sample 
weight was stable. The relative weight change was calculated using the formula: 
(𝑤𝑒𝑡 𝑤𝑒𝑖𝑔𝑡ℎ − 𝑑𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡)
𝑑𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡
 
 Degradation assay 
The ideal scaffold has to be made of a biodegradable material and its degradation rate should 
match the regeneration phase of the hosting tissue. Moreover, the products of degradation 
should be nontoxic and be metabolized by the physiological metabolic pathways. I selected 
materials for this piece of work by taking into account both these features. Some synthetic 
polymers are biodegradable and, among those, several are widely used in tissue engineering, 
such as PGA, PLA, PLGA and PCL  (Velasco et al., 2015). Likewise, several natural polymers, such 
as collagen, gelatin, alginate, and agarose, are biodegradable. In this stage of the work, GL was 
used to build the core of the tubular scaffold electrospinning. The degradation study was 
composed of two different tests: the first one consisted in monitoring the weight loss of samples 
in phosphate buffer saline (PBS) at 37°C for a period of three weeks, whereas the second 
assessed the morphological modification of the GL fibers (durability and the maintenance of the 
nanofiber pattern in PBS solution) through SEM observation (Tonda-turo et al., 2011; Tonda-
Turo et al., 2013). SEM assessment was performed at 1, 2, 4, 7, 10 and 14 days. The final time-
point was at day 14, rather than 21 like for the weight loss monitoring, because of the gradually disruption of the material 
and the consequent difficulty in handling. 
 Weight loss assessment  
The weight loss test aimed at assessing the dissolution rate of the scaffold in an aqueous 
solution. It gave a quantitative parameter to study the stability of the material in wet conditions 
before using it in biological environments [8]. The samples (ring of 20mm long tubular scaffold) 
were soaked in PBS and held within a cell culture suitable 6 well-plate at 37°C. Before weighing, 
the specimen was carefully dried on blotting paper and placed in a plastic container, which had 
been previously weighed alone. The weigh was then registered, and the sample placed back in 
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its well. The weighing schedule was designed to last until the samples were too fragile to be 
handled. 
Morphology observation 
Samples for SEM analysis were processed as described in Chapter 2.  The scaffold specimens 
were dried in a vented oven for 48 h at 37°C and coated with a gold-palladium alloy. After the 
sputtering, the samples were placed in a specimen stand, and put on the sample stage of the 
SEM device. Pictures were taken at different magnifications.  
Mechanical characterization of single layer structure 
Mechanical properties of scaffolds were measured using Instron 3343 (© Illinois Tool Works Inc., 
US). The tensile machine was equipped with a BioPlus Bath, which allowed us to perform 
mechanical tests in wet and temperature-controlled conditions (37°C). The principal stress 
directions are longitudinal and circumferential (Figure 4-9). Young modulus, maximum strain 
and maximum load were calculated using Instron tensile machine which was set up in the same 
way planar scaffolds were tested, with a strain speed set at (0.01% ∗ 𝑙0) 𝑠𝑒𝑐⁄ . The samples were 
cut to stripes of 4.5 x 16 mm with 0.5±0.1 mm thickness. The directions of traction were both 
along the longitudinal scaffold axes and tangent to the circumferential one.  
 
Figure 4-9: Principal stress directions of TEVG. 
Images of fabricated grafts, red lines showing direction of cuts for tensile strength tests. A) 
longitudinal strips and B) circumferential rings. 
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4.4.6 Multi-material core of TEVG fabrication: electrospinning of Gelatin and PCL 
4.4.6.1 Tuning of PCL fibers 
Lack of durability and a mismatch of mechanical property led to the application of a second layer 
of synthetic material. PCL was identified as ideal material for this application. The 
electrospinning device was set as reported at chapter 2. (electrospinning set-up). Tuning of the 
machine parameters and analysis of the fibers analogous to the one described supplementary 
data A were performed for PCL solution. Time of electrospinning was set at 15 min while the 
other parameters of the Electrospinning unit were varied as follows: 
• Concentration of PCL solution: 7.5% (w/v), 10% (v/w) and 15% (v/w); 
• Voltage: 20, 25 and 30 kV; 
• Distance: 15, 20 and 25 cm;  
• Flow rate: 0.1, 0.2 and 0.5 ml·min-1. 
4.4.6.2 Swelling assay on PCL nanofibers 
The experiment was carried out following the protocol described previously for the GL scaffold. 
4.4.7 Electrospinning of GL and PCL 
The analysis of images obtained from SEM allowed us to define a range of parameters to 
electrospin both Gelatin and PCL nanofibers with optimal features for cells adhesion 
[REFERENCE from my Paper]. The manufacture of the multi-material scaffold was carried out in 
three consecutive stages of electrospinning process: I) production of gelatin fibers alone, II) 
production of a layer composed of both fibers of gelatin and PCL, III) finally a third layer made 
only of PCL nanofibers. During the first stage, three 5 ml syringes were loaded with the solution 
of 15% (w/v) Gelatin and electrospun for 45 min. The following stage saw the addition of three 
more syringes, loaded with PCL 15% (w/v) extruding simultaneously for 45 min. Finally, the third 
stage consisted of electrospinning for 1 h the PCL solution, extruded from 6 syringes. The 
rationale behind the simultaneous electrospinning of Gelatin and PCL was to create a transition 
layer made of a mesh of both materials to avoid the delamination of the two layers. This 
behaviour that was visible without the stage 2. We also removed the formed tubular structure 
from the mandrel and placed it in a ventilated oven for 48 h at 37°C to allow the final crosslinking 
of the gelatin fibers. 
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4.4.7.1 Permeability assay 
Porosity is very import when designing a scaffold in tissue engineering. This feature depends on 
the pore size, density, and interconnectivity. The presence and characteristics of the pores have 
a dramatic impact on cell infiltration and tissue growth in a scaffold (Seyednejad et al., 2012). 
Moreover, it is important for soluble molecule diffusion, for example nutrients, metabolites, and 
waste products (Rnjak-Kovacina and Weiss, 2011). Furthermore, a scaffold with interconnected 
pores promotes vascularization, which is a key feature to create 3D tissue substitutes. 
Permeability reflects the pore distribution and morphology. As such, it is widely used as an 
indirect parameter, owing to the difficulty of exactly measuring the pore topology in the 
scaffolds (Greenwald, 2000; Nasrollahzadeh and Pioletti, 2016; Rnjak-Kovacina and Weiss, 
2011). The permeability of a porous scaffold is calculated using Darcy’s Law, which states that 





where 𝐾𝑝 is the permeability, ΔP𝑓 is the pressure drop, µ𝑓 is the dynamic viscosity and w is the 
porous material thickness. From this formula, we can find the permeability: 
𝐾𝑝 =
𝑉𝑓 ∗ µ𝑓 ∗ 𝑤
𝛥𝑃
 
if the structure has a fluid column on it: 
𝛥𝑃 = ρ
𝑓




where 𝜌𝑓 is the fluid density, 𝑔 is the gravitational acceleration and ℎ𝑓 is the fluid column height 
whereas, for the fluid average speed, Q is the volumetric flow rate, and S is the cross-section 
area of the porous scaffold perpendicular to the flow. Gathering all the components, the final 
permeability formula used in this thesis is: 
𝐾𝑝 =
𝑄 ∗ µ𝑓 ∗ 𝑤
𝑆 ∗ 𝜌𝑓 ∗ 𝑔 ∗ ℎ𝑓
 
The scaffold permeability was measured using a custom-made flowmeter. The sample was 
enclosed between two layers of prespex (PMMA) and compressed by silicon gasket on both sides 
to ensure the sealing, avoiding any liquid leakage that could result in less accurate 
measurements. Above the sample slot, a graduated flask filled with liquid acted as the fluid 
column. The liquid flows through the porous scaffold into a 50 ml Falcon tube during a pre-set 
time. 
The chosen fluid was water with the following parameters: 
• 𝜇𝑓=0.89 Pa*s at 25°C. 
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• 𝜌𝑓 =0.997 g/cm3 at 25°C. 
Before mounting the samples, the scaffolds were soaked in water for 5 min to allow the 
stabilization of the structure in humid conditions. The experiment was performed filling the flask 
with a water column of 40 mm allowing flow through the scaffold for 15 min. The thickness of 
the scaffolds was evaluated in wet conditions. 
4.4.7.2 Mechanical characterization of bi-layered scaffold 
I characterized the mechanical properties of the multi-layer (GL/PCL) scaffold and thus assess its 
proper composition. Mechanical properties were measured using Instron 3343 (© Illinois Tool 
Works Inc., US) with BioPlus Bath as described in the previous sections. The experiment was set 
up following ISO 7198:2016 specifications. GL and GL/PCL tubular samples were cut and 
longitudinal stripes of 10 x 20 mm with 0.5±0.1 mm of thickness were prepared. The comparison 
of mechanical properties was carried out on longitudinal scaffold axes, setting a steady strain 
speed of ± 50 mm·min-1. 
4.4.8 Three-layered structure fabrication: bioprinting alginate and pluronic onto 
the GL/PCL core 
The focus of the following TEVG fabrication step was the manufacture of the external layer of 
the graft. To this aim, I coated the GL/PCL conduit with two concentric layers of AG and PL gel 
using a semi-automatized bioprinting system for gel deposition. This system is composed of a 
Bioprinter and a graft rotating support. The Bioprinter has been extensively described in chapter 
3. 
4.4.8.1 Gel production and crosslinking tuning 
The production of the stock solution of gel was carried out following the protocol described in a 
previous work (Armstrong et al. 2016). Solution of PL F127 40%(w/v) (Sigma, UK) in serum free 
DMEM (Gibco, life TechnologiesTM) was made by adding powder PL, while stirring at 4°C to allow 
the solution maintaining the liquid state. The solution was sterilized by autoclave process and 
kept in sterile condition up to 4 weeks. Stock solution of AG was freshly prepared the day before 
the experiment. The powder was placed onto a sterile petri dish and exposed to UV lights for 15 
min. Sodium AG 10% (w/v) in DMEM was added under a biological safety hood, to keep sterile 
conditions, and maintained in agitation for 30 min, at 37°C, under exposure of UV lights. The 
final working solution of 13% (w/v) F127 PL and 6% (w/v) Sodium AG was derived from the 
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combination of these two highly concentrated stock solutions. As mentioned previously, the 
distinctive property of this gel is that appears in liquid state at 4°C while it becomes a gel at 
higher temperature, thereby providing the possibility to stack different layers and build a 3D 
structure. Nevertheless, the addition of a crosslinking agent is needed to give water resistance 
to the gel. The crosslinking process is important because our application required two 
consecutive bioprinting steps around the external surface of the electrospun tubular structure. 
In fact, the leakage of gel or the loss of shape of the extruded gel would lead to the failure of the 
manufacturing process.  Calcium Chloride (CaCl2) was used as a cross-linking agent for the AG/PL 
gel. A tuning of the concentration was performed to optimize the adhesion of the two layers of 
gel. For this test, carried out without cells, the GL/PCL tubular structure was fixed on the Nylon 
rod of the graft rotating support and the gel was extruded while the scaffold was rotating until 
all the surface was covered. The structure was submerged with CaCl2 solution and subsequently 
a second layer of gel was extruded onto the previous one to form two concentric layers. Finally, 
the whole complex was submerged again with CaCl2 solution. Solutions with different 
concentration of CaCl2 (5, 10, 20, 30, 40, 50, 70 and 100 mM) were prepared and tested in all 
the combinations. 
4.4.9 Scaffold cellularization 
I performed the cellulariziation of the electrospun tubular structures in the laboratories of the 
Bristol Heart Institute, Faculty of Translational Health Sciences, the University of Bristol.  
I employed a custom-made rotating bioreactor, described above, to seed cells in the lumen of 
the tubular structure. The first step was to set up a rotary protocol to obtain a homogenous 
distribution of seeded cells. Immortalized HUVECs (EAhy926) were used to define a motion 
pattern of the rotating bioreactor. Once this protocol step was defined, the following phase was 
to assess the seeding duration and the cell seeding number to maximize the number of attached 
cells. At the end of the tuning procedures, the EAhy926 cell line was substituted with CAECs to 
use a tissue-specific cell type relevant to the purposed clinical application.  
Once the protocol of lumen seeding was tuned, the focus moved to coating the external layer 
of the graft with a gel loaded with vascular cells (adventitial    progenitor cells and VSMCs). This 
step saw the fabrication of an ad-hoc device for seeding the tubular structure. Tuning of the gel 





4.4.10.1 Scaffold set-up for rotating bioreactor and scaffold sterilization 
The mounting and sterilization of the scaffold are treated together because interconnected and 
sequential. The whole procedure can be divided in three phases: 1) pre-sterilization; 2) mounting 
procedure; 3) deep sterilization. Since the scaffolds were made of electrospun GL crosslinked 
with GPTMS and PCL, they could not be sterilized with the autoclave due to the low resistance 
to high temperature: PCL melting point is 65°C (Mondal et al., 2016)). This sterilization process 
used a more aggressive approach compared to the one employed for the planar scaffolds. 
Moreover, the seeding system I developed required a pre-phase, in which the scaffolds were 
mounted on custom-made holders that kept the structures in position during the process. The 
procedure for F15 and F50 scaffold holders was maintained exactly the same. Here I describe 
the subsequent steps of the procedure: 
1) Phase 1:  the 20cm long electrospun tube was cut in 5cm long pieces in order to fit into 
the POM holders (F15 or F50) (Figure 4-10B). The first step of the procedure had the 
tubular structure washed in PBS three times for 30 min at 37°C. These washes allow the 
removal of fabrication debris trapped inside the lumen of the scaffold but also the 
expulsion of additional residue that could be trapped inside the parous nanofibers mat. 
The incubation at working condition (37°C) also allowed the stabilization of the multi-
layer core of the TEVG that naturally incurs after swelling remodelling.  At this point, the 
scaffolds were washed for 5 min in 70% (v/v) Ethanol in distilled water and washed twice 
with PBS. The scaffolds were then exposed to UV, 15 min each side. 
2) Phase 2: Two 1/8” latex free brace rubber bands were placed on the external surface of 
POM assembling tool using sterile forceps and one 1/8” barbed Luer lock (female or 
male depending on the use of F15 or F50) was inserted in the central hole of the 
assembling tool. At this point, the scaffold was placed into a Polyethilene (PE) petri dish 
(Grenier), soaked with PBS, together with the sterile POM assembling tool, and the luer 
lock. The lock tip was fitted into one of the scaffold ends using sterile forceps, and rubber 
bands were pushed towards the edge of elliptical surface allowing them to jump over 
the scaffold to compress and fix it around the Luer lock (Figure 4-10C). This was then 
pushed out of the assembling tool. New rubber bands and a new 1/8’’ Luer lock were 
fitted on the assembling tool and the mounting procedure was repeated for the other 
extremity of the scaffold. The Luer locks were then fitted into the POM holder tracks, 
being careful that the scaffold was not twisted (Figure 4-10D).  
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3) Phase 3: The tubular scaffold mounted on the appropriate holder was fit into a Falcon 
tube. The Falcon tube was then loaded with a cocktail solution of 1 μg/ml of 
Amphotericin B (Gibco), and 1000 units/ml of Penicillin-Streptomycin (Sigma-Aldrich) in 
PBS and incubated overnight at 37°C. After this period of incubation, the scaffold was 
soaked in culture medium for 2 h before the seeding procedure.  
 
 
Figure 4-10: Sequence of graft enclosure on POM holder. 
A) A 20cm long scaffold derived from the complete fabrication procedure; B) A 5cm long 
scaffold; C) Procedure of locking the scaffold with elastic rubber bands to the Luer locks; D) Final 
assembly of the scaffold on the holder. 
 
4.4.10.2 Cell application 
The issue of seeding the internal surface of a tubular scaffold has been already discussed. The 
dynamic seeding chosen in this project exploits the settling action of gravity to make the cells 
adhere on the bottom surface part. As a consequence of rotation, this will change continuosly 
so that the inner surface will be completely colonized. The cells used were HUVECs (EAhy926) 
for the tuning procedure and CAECs for the final assembly. HUVECs detached from the flask, 
were resuspended in 1 ml culturing media and cells number was counted. The number of cells 
was fixed at 150,000 cells/scaffold. The sterilized scaffold was extracted from the Falcon tube 
filled with PBS and the bottom extremity of the scaffold was closed by fitting a silicone lid onto 
the Luer-lock to avoid the leakage of cells during the seeding process. Then, the scaffold was 
placed into a new Falcon tube with 10ml of DMEM high glucose (Figure 4-11A). A sterile 1ml 
syringe and an autoclaved stainless-steel needle (18 G), or alternatively a 200µl tip and the 
associated pipette (Gilson), were used to collect the cell suspension from the Falcon tube and 
inject it through the upper Luer lock (Figure 4-11B). The upper extremity was sealed with a 
silicone lid and the scaffold was inserted into the Falcon tube by pushing the rigid POM holder, 
paying attention that the whole scaffold was submerged. The 15ml Falcon tube was closed and 






Figure 4-11: Sequence of cell injection and set-up of the rotating seeding system. 
 A) The F15 holder is took out from the F15 Falcon tube with sterile forceps; B) The cells are 
inoculated in the inner volume of the scaffold which remains closed with custom made silicone 
lid. C) The Falcon tubes are placed in the seeding device. 
4.4.11 Optimization of rotating seeding protocols 
4.4.11.1 Rotary protocol optimization 
To reach the seeding homogeneity, the system exploits the gravitational force in combination 
with a pre-set rotation of the scaffolds. Briefly, the scaffolds were held in 15 ml Falcon tubes and 
kept in position by a custom-made holding system. Inside the tubes there were two separated 
volumes, one was the space outside the scaffold whereas the other was within the scaffold, 
which was filled with the cell suspension. Several rotating protocols were tested (Table 4-1), 
resulting in different cell distribution outcomes. The rotation phase was followed by a rest phase 
to allow the cells to establish a first bond with the scaffold. A rotation cycle was defined as a 
time span that ranged from the beginning of a rotation phase to the end of a rest phase. 
Moreover, the rotation was either clockwise or anti-clockwise. The overall duration of the 
protocol was fixed at 4 h. Once the procedure was completed, the scaffolds were removed from 
the device and placed in tubes filled with 4% PFA for fixation. To check the cell distribution, the 






Rotation phase Rest 
phase 
Initial phase Duration 
test 
A 105 20 s clockwise 
30 s anticlockwise 
@ 13.4 rpm 
15 min none 4  h 
B 105 20 s clockwise 
30 s anticlockwise 
@ 13.4 rpm 
15 min 1h @ 3rpm 
continuous 
rotation 
4  h 
C 105 20 s clockwise 
30 s anticlockwise 
@ 13.4 rpm 
5 min none 4  h 
D 105 20 s clockwise 
30 s anticlockwise 
@ 13.4 rpm 




4  h 
Table 4-1: Tested rotating protocols. 
 
4.4.11.2 Seeding duration protocol 
The following phase of the work was focused on the optimization of the seeding duration. 
EAhy926 HUVECs were seeded into the tubular scaffold as described above, and rotated for 2, 
4, 6, 8, 10 and 12 h. DAPI solution was used for the nuclei staining, while a mix of Anti-Vimentin 
antibody (Ab92547, Abcam) and Phalloidin (Conjugated Alexa Fluor 555 Phalloidin A34055, Life 
Technologies) was used to stain the cytoskeleton of the cells. At the end of the procedure, the 
scaffold was extracted from the holder, washed in PBS and the cells were fixed in 4% PFA. The 
samples were soaked in 0.1% Triton (Sigma-Aldrich) for 5 min to permeabilize the membrane 
and washed twice with PBS. At this point, the scaffolds were sliced along the axial direction to 
make plain sheets and incubated for 20 min in Phalloidin solution (25 μL/ml in PBS solution) at 
RT. They were washed with PBS and incubated overnight at 4°C in a new solution of Vimentin 
(5μL/ml in blocking solution, namely 5% FBS in PBS filtered). The following day, the scaffolds 
were washed in PBS and incubated for 1h at RT with the secondary antibody (Alexa Fluor 568 
(Life technologies) and then incubated for 5 min in DAPI solution.  At the end, the scaffold was 
washed with PBS and placed in 6-well plate with Glycerol 80% for image acquisition. The samples 
stained with these markers were observed under the fluorescence microscope Zeiss Axio 
observer Z1 (Zeiss). The internal media and the external media were collected and examined for 
the possible presence of cells. 
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4.4.11.3 Calibration of number of injected cells 
The number of cells to achieve a uniform distribution using the rotating seeding was then 
assessed. The experiment was carried out as described in the previous paragraph, but the 
rotating time was fixed at 6h and different number of cells were seeded: 150000, 300000, 
450000 and 600000.  
4.4.11.4 Cell quantification 
I then acquired micro-photographic images to determine the distribution of cells and quantify 
the percentage of attached cells with respect to the total injected amount. The images resulting 
from the fluorescence microscope observation represent an area of around 2x3 cm, acquired at 
2.5X magnification, and stitched together through tiles system. The microscope Zeiss Axio 
Observer Z1 with its managing software gives the possibility to create bigger pictures by joining 
different pictures together. In this study, 70 tiles were stitched together (Figure 4-12). 
 
 
Figure 4-12: Fluorescent microscope and graphic interface used for multi-field acquisition of IF 
pictures. 
a) The Zeiss Axio Observer Z1 used for the images acquisition. b) A screenshot of the managing 
software during the creation of a tile image reconstruction with the scaffold shape and its cut 
line which is showed in (c). 
 
 
After the acquisition, the images were post-processed with Matlab R2017a (Mathworks, United 
States software) as follows (Figure 4-13). The process for quantification of adhered cells started 
from dividing the pictures in smaller sectors, 1 x 1 mm, in order to have at least 20 sectors each 
side. The thresholding algorithm imbinarize was used to binarize the image, and imfindcircles to 
recognize the cells over the threshold images. Finally, the number of objects recognized for each 
sector were counted and combined to obtain the total number. To estimate the distribution of 
the cells on the surfaces, I have divided the surface in smaller sectors 0,476 mm2 wide (0.69 x 
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0.69 mm) and calculated mean and standard deviation of the estimated cell number in each 
sector. In addition, to confirm the data of the image processing, the cells that were found 
suspended in the media at the end of the procedure were counted and subtracted for the 




Figure 4-13: Image processing procedure on the DsRed channel fluorescence images. 
 a) The original cells seeded on scaffold image. b) The image is binarized. c) The located cells are 
marked with red circles on the original image. 
 
4.4.11.5  Static culture 
To assess the biocompatibility of the scaffold, cells were fixed and assessed after 5 days static 
culturing.  150,000 HUVECs were seeded in the lumen of the tubular structures, as described in 
the previous paragraph, and kept in rotation for 6 h. Then, they were detached from the holder 
and moved into a 100x100 mm petri dish for static culture. The scaffolds were cultured in 
DMEM, supplemented with 10% FBS and 1% P/S, and held submerged by the media by custom-
made frame of Poly(methyl methacrylate) (PMMA)  (Figure 4-14). The scaffolds were kept in 
static culture for 5 days, with culture media being changed every 2 days. At end of the culture 
period, the Luer locks were removed using sterile forceps, and the scaffold was cut using sterile 
scissors in two rings. The first one was washed in PBS, fixed in 4% PFA, and permeabilized with 
Triton solution. After the permeabilization, the scaffold ring was included in the Optimal Cutting 
Temperature (OCT, Fisher Scientific) compound and stored at -20°C to cut histologic slices and 
used for immunofluorescent staining.  A cryostat was used to obtain 8-10 µm thin slices. Grafts 
sections were stained with a conjugated Anti-Vimentin (647 nm emission wavelength) and CD31 
antibody. A viability assay (viability/cytotoxicity assay kit, Biotium Inc, US), described before, 
was performed to detect living cells on the second scaffold ring. The specimen was sliced, 
opened along the longitudinal axis, and incubated for 30 min with a solution of Calcein [1:2000], 
158 
 
EthD-III [1:500] and Hoechst [1:100] in serum free medium. At the end of the incubation period, 
the scaffold was visualized with fluorescence microscopy.  
 
 
Figure 4-14: Scaffolds cultured under static conditions after endothelialization and held in place 
by a laser cut PMMA frame. 
 
4.4.12 Muscularization 
While endothelialization of the lumen is fundamental to create a biomimetic scaffold and avoid 
thrombus formation, patency and compliance of a natural vessel is provided by the elastic and 
muscular layers. As mentioned in the introduction, the proposed novel approach consists of 
seeding the scaffold with all the cell types that compose the tunica media and adventitia.  VSMCs 
and adventitial progenitor cells were used to generate these layers, but to ensure the 
appropriate localization of the cells, they were enclosed in a gel. A novel methodology based on 
rotating bioprinting was designed and fabricated to allow the concentric extrusion of two layers 
of gel with VSMCs and adventitial progenitor cells, respectively from the inside to the outside. 
4.4.12.1 Cell seeding and static culture 
In this part of the experimental validation, I carried out separate experiments in which VSMCs 
or adventitial progenitor cells in AG/PL gel were seeded on the external surface of the tubular 
structure. This allowed a better visualization of the success of the seeding procedure through 
fluorescence microscopy and also assess the viability and proliferation for each cell type.  
159 
 
These experiments involved the use of the designed and fabricated Bioprinting rotating system. 
The system, like described in previous paragraph, was composed by the graft rotating support 
and the customized Bioprinter. The two components cooperate simultaneously to regulate the 
extrusion of the cell-laden gel and the rotation of the graft to allow the formation of an uniform 
layer. They were sterilized with Eth 70%(v/v), exposed under UV light for at least 1 hour and kept 
in the biological safety cabinet in sterile condition until the moment of the use. The graft rotating 
support was positioned on the deposition plate of the Bioprinter and the seeding tank of the 
graft support was filled with CaCl2-culturing medium until half of his height. The thermal pad 
was then activated and set the temperature at 37°C. The system was ready, and the focus of the 
process moved on the loading of the cell in the gel. 
Briefly, the AG and Pl F127 gel stocks were used to create the working solution. To create 1g of 
final solution of AG 6% (w/v) and PL 13% (w/v) in DMEM, 0.6g of AG and 0.325g of PL were 
added into a small sterile glassware and mixed for 1h at 4°C and another 15 min at RT before 
using for the experiment (the missing 0.075g of solution to reach 1g is the weight of cells that 
were added subsequently). VSMCs at passage 5-6 were detached from T175 flask following the 
standard procedure, counted to have the right amount, and centrifuged to obtain a 
concentrated pellet. Then, a sterile 5ml syringe was loaded with AG/PL gel, the pellet of VSMCs 
was collected in 75µl of DMEM and added in the syringe, with a concentration of 4millions 
cells·ml-1. The cell-laden gel was carefully mixed with a sterile stainless-steel spatula to obtain a 
homogenized gel. One end of the syringe was closed with a female Luer cap and the syringe was 
centrifuged for 10 sec at 200g to compact the gel and remove the big bubbles. When the gel was 
ready, and the syringe was placed in the Bioprinter, the GL/PCL scaffold was inserted into the 
sterile Nylon support and the components were fitted into the seeding tank of the seeding 
system. The g-code file for the Bioprinter was uploaded and run through the MatterControl 
software, while the rotation was activated through the control buttons of the LCD display. The 
rotating system was set to rotate 10° every extrusion, to allow a complete coverage of the 
surface of GL/PCL scaffold. When the whole surface was covered by a layer of cell-laden gel, the 
seeding tank was then fully filled with 100mM CaCl2 PromoCell Smooth Muscle Cell Growth 
Medium 2 culture media, for 10 min at 37°C. For this particular experimental set-up, the 
scaffolds were pulled off from the Nylon support and sliced in 7x7mm square structures and 
cultured in static condition in 48-well plate with CaCl2-free culture media for 15 days. Viability 
assay (viability/cytotoxicity assay kit, Biotium Inc, US) was performed at 1, 5, 10 and 15 days to 
evaluate the trend of cell viability in the gel. Different time points (5, 10 and 15 days) were also 
fixed to evaluate the proliferation of cells (Click-iT® EdU Assay, Invitrogen).  
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The same procedure was performed for adventitial progenitor cells using EBM2. 
4.4.13 Assembling and perfusion of the three-layered TEVG 
Assembly of the whole structure was carried out starting with the Bioprinting process and 
subsequently seeding the luminal side. The AG/PL gel was prepared as explained previously to 
obtain a final concentration of AG 6% (w/v) and PL 13% (w/v) in DMEM. VSMCs (4millions 
cells·ml-1) were loaded in the AG/PL gel and added in a sterile 5ml syringe. The GL/PCL sterilised 
scaffold was inserted into the sterile Nylon support and the components were fitted into the 
seeding tank and the first layer of VSMC-laden-gel was extruded. The gel was crosslinked for 1 
min in a solution of 20mM CaCl2 in DMEM. After this first stage, a second gel with adventitial    
progenitor cells was prepared and bioprinted in the same way. The final structure was 
crosslinked with 100mM CaCl2 solution in DMEM for 10min. The procedure was carried out in a 
biological safety hood to maintain the sterile environment. At this stage, the GL/PCL scaffold 
loaded with two layers of AG/PL was pulled off from the Nylon support and placed in a petri dish 
with PBS culturing media. The process of mounting the scaffold onto the rotating bioreactor was 
then performed. New POM holders were fabricated to allow the enclosure of the new tubular 
graft and also to be able to fit into a 50ml Falcon tube. These components were fabricated at 
the Chemistry Workshop, University of Bristol. As described previously, male 1/8’ Luer locks 
were secured with rubber bands at the scaffold’s extremities and then locked in the holder. The 
bottom Luer lock was closed with a silicone lid and the whole assembly was moved into a 50ml 
Falcon tube filled with endothelial cell growth medium. For this final experiment we applied all 
the outcomes derived from the tuning of rotating seeding. In fact, 450,000 CAECs were injected 
in the lumen of the scaffold, the other Luer lock was closed, and then, the whole Falcon tube 
was placed in the rotating bioreactor for a rotation period of 6h.  At the end of the rotational 
period, the complete hybrid TEVG was moved into a 3DCulturePro™ Bioreactor (TA Instruments, 
UK) for perfusion conditioning. The TEVG was kept in the bioreactor withstanding 10ml/min flow 
for 5 days, and at the end of the period an integrity check of the multiple layers was performed, 




Figure 4-15: Scaffold preparation and culturing systems for structure conditioning. 
 A) TEVG assembled with its three final layers and locked on the F50 holder. B) Rotating 




4.5 Results and discussion 
4.5.1 Single-material core fabrication and assessment: layer of GL nanofibers 
The fabrication of the first layer of nanofibers was achieved by electrospinning the 15% (w/v) GL 
solution through three loaded 5ml syringes. After the tuning process, the electrospinning 
parameters were set as follow: voltage 25 kV, distance between the needle and the collector 20 
cm, flow rate 0.2 ml/hour, rotating speed 1000 rpm, and total duration of procedure 2h. 
Temperature of the environment was monitored and maintained at 24±1°C. After the 
production process, the scaffolds were dried in oven at 37 °C for 48 h. The dry tubular scaffolds 
had a diameter of 6 mm and were cut in 5 cm chunks. From the analysis of SEM pictures, the 
fibers showed a section diameter of 90±18 nm, pore size of 290±23 nm, porosity of 27±2 % and 
a scaffold thickness of 180μm (Figure 4-16). The pictures displayed a fiber random distribution. 





Figure 4-16: First layer of GL nanofibers, SEM images. 
SEM images of the dry scaffold. a) A 35x picture of the scaffold internal surface. b) 20000x picture 
of the internal surface useful to estimate the fibers diameter. c) a 52x picture of a scaffold cross-
section. d) A 700x picture of the scaffold cross section used to calculate the scaffold thickness. 
 
4.5.1.1 Swelling assessment 
Since the GL scaffolds were used in wet conditions, determining the swelling properties of the 
structure was essential to understand the behavioural changes of the structure in those 
circumstances. The swelling assay was performed soaking 3 scaffold pieces of 20 mm dry length 
and their weight was monitored until stabilization. The following graph (Figure 4-17) showed 
the relative weight change, which over time during the swelling test is equal to: 
(𝑊𝑒𝑡 𝑤𝑒𝑖𝑔ℎ𝑡 − 𝐷𝑟𝑦 𝑤𝑒𝑖𝑔ℎ𝑡)
𝐷𝑟𝑦 𝑊𝑒𝑖𝑔ℎ𝑡
 
The weight change stabilized after 5 min. After the swelling period, I calculated the dimension 
variation that resulted in a thickness increase of +90,8% and decrease in length and diameter of 
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-14.8% and -21.1% respectively. The scaffolds showed a quick adaptation to the wet 
environment, reaching a plateau between 2 and 5 min (Figure 4-17). The superficial topography 
was evaluated through SEM pictures, taken from dry scaffold and swollen scaffolds (Figure 
4-18). The changes in dimensions and superficial topography were relevant and thus need to be 
considered when this kind of scaffolds are employed. In line with what was expected, this result 
was due to the remodelling of the fibres of GL in water solution. 
 
Figure 4-17: Swelling test of GL nanofibers. 
The graph shows the behaviour of GL nanofibers in water condition. The weight gain is stable 




Figure 4-18: Swelling of GL nanofibers, SEM images.  
SEM images comparison of the dry and swollen GL scaffolds. a) A 875x picture of the scaffold 
internal surface and an enlarged (b) 5000x version compared with an 875x picture of a swollen 
scaffold (c) with a 5000x view (d). 
 
4.5.1.2 Permeability assessment 
The permeability assessment was performed on the GL tubular scaffolds (N=3). Before the test, 
every sample was soaked in distilled water for 5 min to reach the wet condition stability. The 
permeability coefficient (Kp) was calculated following the Darcy’s law described previously. The 




4.5.1.3 Degradation assessment 
 Weight loss 
A weight loss test was performed on the GL tubular scaffold to evaluate degradation in wet 
conditions. The scaffolds were incubated in PBS at 37 °C for all the test length. The test was 
ended when the samples were dissolved. 
 
Figure 4-19: Degradability, Weight loss assay.  
The data are normalized by the swollen scaffolds at day 0. Values expressed as mean ± standard 
deviation. n=3.  
 
Data showed in Figure 4-19 indicate that the degradation became relevant, in terms of weight 
loss, after 10 days. In addition, at 18 days, the level of deterioration of scaffolds resulted in the 
collapse of the structure. It is important to highlight that the test was carried out in PBS in 
absence of cells component and therefore indicates the intrinsic degradation characteristics of 
the GL structure. 
 Morphology assessment 
To evaluate the surface modification over the degradation period, scaffolds were soaked in PBS 
at 37 °C and held in this condition for 1, 2, 4 and 7 days. Then, they were dried in vented oven 
for 48 h at 37 °C. The SEM images showed that the fibers remained intact until the second day 
of the assay (Figure 4-20). The fibers started to melt together from day 4 until forming one 





Figure 4-20: Degradation of GL nanofibers, SEM images. 
 SEM images of degrading GL tubular scaffolds. The pictures were taken after 1 (a), 2 (b), 4 (c), 7 
(d), 10 (e), 14 (f) days in PBS.  
 
4.5.1.4 Mechanical characterization of single layer structures 
From the stress-strain curves, ultimate stress, ultimate strain, and elastic modulus of the tubular 
scaffolds were extracted. The samples were cut into strips of almost 4.5 x 16 mm with around 
0.5 mm of thickness (N=3). The direction of traction was both along the longitudinal scaffold 
axes and tangent to the circumferential one. Thin films of the same material, GL crosslinked with 
GPTMS, were produced by casting, and tested along with the scaffolds (Figure 4-21A-B). The 
results (Figure 4-21C-D-E) showed that the GL nanofiber scaffolds had a longitudinal elastic 
modulus of 0.131±0.045 MPa, and a circumferential one of 0.098±0.026 kPa. GL film had an 
elastic modulus of 0.338±0.009 MPa, which is higher than the tubular scaffolds in both the 
tensile directions. The evaluation of the ultimate stress showed a statistical difference (P<0.05) 
between the longitudinal and the circumferential tensile direction, with 0.61±0.105 and 
0.37±0.040 MPa. High variability and no significant difference were observed for ultimate strain. 
These tensile tests showed a mismatch between the elastic modulus of the GL and the reported 
values of native cerebral and coronary artery (0.22±0.06 and 1.48±0.24 MPa, respectively (Ciszek 
et al., 2013; Karimi et al., 2013)), thus confirming the need of improving the physical features of 





Figure 4-21: Mechanical Test, single layer of GL nanofibers 
Examples of the tensile tests. A) GL tubular scaffold sample. B) GL thin film. 
From tensile tests on the tubular scaffolds (longitudinal (Long.) and circumferential (Circ.) 
direction) and films. I calculated the elastic moduli, statistical test used, *P<0.05, ***P<0.0001 
vs GL film (C), the ultimate stress, statistical test used, *p<0.05 vs longitudinal (D) and strain (E) 
before the rupture (all experiments performed with n=3). The data refer to the thin gelatin films 
and the gelatin tubular scaffolds with traction direction both along the longitudinal axes 
(Longitudinal) and tangent to the scaffold axes (Circumferential). Values expressed as mean ± 
standard deviation. n=3. 
 
4.5.2 PCL nanofibers tuning 
To improve the durability and to reduce the gap of mechanical properties between the native 
coronary arteries and the graft, I next adopted a multi-layer approach for the fabrication of the 
core of the TEVG. As mentioned before, this goal was achieved by elecrospinning PCL around 
the GL nanofibers layer.  
The analysis of SEM images allowed an evaluation of the features of PCL nanofibers and 
definition of the process parameters. The PCL solution at 7.5% (w/v) and 10% (w/v) showed 
defects and beads, while the highly concentrated 15% (w/v) PCL solution avoided the presence 
of beads. Overall, PCL electrospun layers showed bigger fibers diameter dimensions compared 
to GL. The set-up configuration of 25 kV voltage, 20 cm distance between the needle and the 
169 
 
collector, 0.2 ml/hour flow rate, and 1000 rpm rotating speed allowed me to obtain the smallest 
fiber diameter (1.13±0.15 µm) and it was selected as a default configuration (also for the 
corresponding GL parameters). In this set-up, PCL fibers showed porosity of 36.08±8.49 % and 
pore size of 3.64±0.44 µm. This value of porosity, even if bigger that GL’s one, does not allow 
the migration of SMCs, feature that is important for us since in this stage of the investigation we 
want to avoid mixture of different cell type. 
4.5.2.1 Swelling assay of PCL nanofibers  
The swelling assay was performed soaking 3 pieces of 20 mm long PCL scaffolds (dry length) and 
monitoring their weight until stabilization. Results (Figure 4-22) showed that PCL did not absorb 
much water. This is due to its hydrophobic behaviour. The PCL matrix was stable after 5 min with 
a weight increased 1.5-fold. The data showed in Figure 4-22 points out the critical point of 
different behaviour of GL and PCL in wet condition.  
 
Figure 4-22: Swelling Test, PCL vs GL.  
The graph shows the relative gain weight of GL and PCL nanofibers, showing the different 
behaviour in wet condition. Values expressed as mean ± standard deviation. n=3.  
4.5.3 Multi-material core: intima-like structure made of GL/PCL 
The results from the assessment of single material convinced me to introduce an intermediate 
step during the fabrication, in which GL and PCL were electrospun together to avoid 
delamination in wet conditions. With this final configuration, the fabrication of the inner layer  
of the scaffold, aiming at reproducing the intima, was carried out electrospinning two materials 
following the three stages described in the methods section, for an overall time of fabrication of 
12.5hours. After the production process, the 20cm long scaffold was pulled out of the rotating 
rod and dried in oven at 37 °C for 48 h. The dried tubular scaffolds had a diameter of 6 mm and 
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were cut in 5 cm smaller scaffold. The result of this fabrication procedure was a nanofiber 
tubular structure with an inner layer of GPTMS-crosslinked GL able to provide cell adhesion, a 
middle layer of PCL and GL fibers to avoid delamination of the structure and a third layer of PCL 
fibers to confer the final mechanical strength to the graft. Even though, this product was derived 
by the combination of two different material and in three subsequent steps, it formed a merged 
compact layer of nanofibers, that we considered as unique core of the scaffold. 
4.5.3.1 Mechanical Characterization of Intimal part of the graft 
The newly fabricated GL/PCL scaffold and GL scaffold were compared to determine differences 
in mechanical strength of the new fabrication approach. The results of the tensile test carried 
out following the ISO specification showed that the Young Modulus of GL/PCL scaffold was 
1.70±0.66 MPa while GL’s one was 0.38±0.14MPa (results expressed in mean±standard 
deviation, Figure 4-23). The difference between the two type of scaffold was significant, but 
more important was that the new type of GL/PCL raised the mechanical strength reducing the 
gap with the values of Young Modulus found in literature of the native coronary artery 
(1.48±0.24 MPa) (Karimi et al., 2013). In fact, the mismatch between commercial grafts and 
native blood vessels is one of the main reasons for grafts failure.  
 
Figure 4-23: Mechanical comparison of tubular structures of GL, GL/PCL and human coronary 
artery  
A) Graph bar of Elastic Modulus; the value of the human coronary artery was retrieved from 
study of Karimi et al. B) Stress-strain curve of GL and GL/PCL scaffold. N=3; values mean±SD. 
 
4.5.4 Three-layered structure fabrication made of GL/PCL+AG/PL 
The tuning of the crosslinking process was performed. AG/PL gel was extruded with Bioprinter 
onto GL/PCL structure kept at 37°C thanks to the heated tank. This resulted in an instantaneous 
solidification via the sol-gel transition of the PL (Armstrong et al., 2016). The crosslinking process 
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was finalized by submerging the scaffold in CaCl2 solution. The PL constituent also served as a 
sacrificial template, being completely expelled during crosslinking with CaCl2, which drove the 
formation of micron-sized pores that can accommodate cells (Armstrong et al., 2016). The first 
layer of AG/PL (dyed in blue, Figure 4-24) was printed around the above described GL/PCL 
tubular structure and incubated for 1 min in a crosslinking solution of 20mM CaCl2.This was 
followed by a second extrusion of AG/PL gel (dyed in orange, Figure 4-24) and a final crosslinking 
in a 100mM of CaCl2 solution for 10 min. Sections were observed under optical microscope to 
verify stability and absence of layer detachment. 
 
 
Figure 4-24: Result from tuning of gel crosslinking 
 
4.5.5 In vitro assessment of endothelialization 
4.5.5.1 Rotary protocol optimization 
 
Figure 4-25: Representative images showing the sequence for mounting the scaffolds in the 
bioreactor (movie available upon request).   
 
HUVECS (EAhy926) seeding distribution was assessed to identify the optimal seeding rotation. 
The sterilized scaffold was locked into the POM holder and prepared to be seeded with HUVECs 
as describe in the methods section (Figure 4-25). Anti-Vimentin and Phalloidin, which bind 
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respectively Vimentin and the F-actin of the cytoskeleton component, were used to visualise 
cells.  
The combination of rotating and steady periods allowed the cells to drop, thanks to the gravity, 
on a different section of the scaffold during each cycle. With the optimized rotary pattern and 
cell amount, we obtained a good cell distribution over the entire scaffold inner surface. The 
following pictures (Figure 4-26) show the results of the rotary protocol optimization. Four 
protocols were assessed as described in methods section. 
 
Figure 4-26: Protocol optimization.  
Images show distribution of HUVECs stained with the Dil (red), a membrane marker. A) Protocol 
A. B) Protocol B. C) Protocol C. D) Protocol D. All the images show a longitudinal stripes 
distribution. Scalebar: 5 mm. Tiles obtained by stitching 2.5X images. 
 
Since the bottom and the top part were in close contact with the Luer locks and the cell 
suspension does not circulate properly in these locations, we analysed the central part of the 
scaffold to understand better the cells distribution. From image analysis, protocol D (20sec 
clockwise, 30sec anticlockwise, rotational speed of 13.4rpm, with 5 min rest and an initial step 
of 1min rotation at 20rpm) showed the best results (Figure 4-27). This protocol resulted to rotate 




Figure 4-27: Lumen of GL/PCL scaffold seeded with ECs.  
A) Fluorescence images of GL/PCL scaffold seeded with EAhy926 using protocol D. b), c), d), e) 
are enlarged sections of picture a to highlight the cell presence. B) Magnification of the c) area 





4.5.5.2 Seeding duration optimization 
The optimal seeding duration was tested from 2 to 12 h with time points of 2 h (Figure 4-28A-
F).  
 
Figure 4-28: Seeding duration experiments.  
The scaffolds were stained with Anti-Vimentin and Phalloidin. On the images a thresholding 
algorithm (Bernsen) was applied using the Fiji image processing software. The images were 
taken at 2h (a), 4h (b), 6h (c), 8h (d), 10h (e), 12h (f) after the seeding process (magnification 
2.5x). 
 
The images showed the cell distribution on the seeded surfaces comparing the negative 
controls, which were experiments without any rotation (static seeding, Figure 4-29A) or without 






Figure 4-29: Comparison with negative control images.  
A) The 12h of seeding without cell injection. B) The 12h of seeding without any rotation.  




Another investigated aspect was the cell morphology, which is an indicator of cell adhesion 
(Figure 4-30). The morphology comparison with a control (Figure 4-31), which is made of the 
same cell line seeded on 48 multi-wells (CellStar), showed that a protocol 6 h long, or more, 
allowed the cells to have a good spread shape. 
 
Figure 4-30: Morphological assessment of ECs seeded in the lumen of the scaffold by 
immunofluorescence. 
Cell morphology on the seeded scaffolds. The nuclei were stained in blue (DAPI) whereas the 
cytoskeleton in red (Phalloidin and Vimentin). The images are taken from a 2h (Figure 30A), 4h 
(B), 6h (C), 8h (D), 10h (E), 12h (F) seeding process (magnification 20x). 
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Morphological comparison between endothelial cells seeded on multi-well (G) and on GL 
scaffold (H) with a 6-hour protocol (10X magnification). The spread shape is assumed in both the 
pictures. Red staining Vimentin and Phalloidin, blue staining DAPI. All scalebars are 100 µm. 
 
The pictures of the entire scaffold were used to perform image processing for cell quantification, 
as described in methods. The analysed surface is 2 x 3 cm, divided in sectors of 1 x 1 mm.  
Figure 4-31A showed that the percentage of total cell number tended to increase as the seeding 
duration is higher, from 13% (2h) to 44% (12h). 
In the same experiments, at the end of the rotating periods, the culture media was collected, 
and the presence of cells floating was determined. The number of adhered cells was then 
estimated following the formula: 
((𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑 − 𝑐𝑒𝑙𝑙𝑠 𝑓𝑙𝑜𝑎𝑡𝑖𝑛𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑒𝑑𝑖𝑢𝑚) 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑) ∗ 100⁄ . 
 The result displayed a higher percentage of adhered cells compared with the analysis performed 
with image processing. Anyway, even in this case after a 6h period of seeding the number of 
cells attached on the lumen of the scaffold reached a plateau (Figure 4-31B).  
The observation of the data showed that the graphs in Figure 4-31A and Figure 4-31B follow the 
same trend, but with a consistent offset (roughly 25% in each time-point of the investigation). 
We believe that this discrepancy is due to the disruption of the scaffold during manipulation at 
the level of the rubber bands at the moment of the termination of the experiment.  
To reduce the variability of the counting due to the defects of the edges, I decided to focus the 
analysis on the central area of the scaffold (13.5 x 13.5mm divided in sectors of 0.69 x 0.69mm). 
The reduction of the area of investigation allowed to increase the magnification and the 
resolution of the images, producing a more accurate image processing analysis. Again, the cell 
density increased with the seeding duration reaching a plateau after 6h (Figure 4-31C-D). These 
results match with the trend showed from the two previous counting method and help us to 
define the optimal time point to stop the rotating seeding. Anyway, I have to highlight that this 
last result was based on the assumption that the cells are distributed in the same way in the 
central part and on the connection areas. The values of adhered cells higher that 100% are the 
result of this approximation. 
While the period of rotation of 12h shows the best features in terms of adherence rate, 
variability (lowest standard deviations), and morphology, the evaluation of the cell morphology 
indicates optimal cells spreading on the nanofiber surface already after 6h. One critical point in 
clinical product manufacture is shortening the process to a level that still guarantees optimal 
fabrication.  After 6 h seeding period, the efficiency of cells attachment did not increase further, 
and the cells demonstrated to be well attached and start spreading their cytoskeleton. For this 
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reason, the 6h rotating period was chosen as an optimal period, after which the cellularized graft 
could be moved into the perfusion bioreactor for the dynamic maturation.  
 
Figure 4-31: Graphs of adhered cells in the graft lumen.  
A) The graph shows the percentage of adhered cells derived from Image processing on the whole 
scaffold area; B) The graph shows the percentage of adhered cells derived from the cell counting 
in the medium. The estimated adhered cells were calculated by: 
(( 𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑 − 𝑐𝑒𝑙𝑙𝑠 𝑓𝑙𝑜𝑎𝑡𝑖𝑛𝑔 𝑖𝑛 𝑡ℎ𝑒 𝑚𝑒𝑑𝑖𝑢𝑚)  𝑡𝑜𝑡𝑎𝑙 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛𝑗𝑒𝑐𝑡𝑒𝑑) ∗ 100⁄ ; C) 
and D) show the results of the same analysis and the data are expressed in terms of adhered 
cells/mm2 (C) or percentage of adhered cells (D). These results derive from calculation, with 
image processing, of the number of ahered cells in the central part of the scaffold, after an highly 
magnified acquisition. n=3, mean±SD. 
 
4.5.5.3 Cell injection optimization 
The calibration of the number of cells to use for the endothelialization was tested seeding 
150,000, 300,000, 450,000 and 600,000 cells. The rotating period was fixed at 6 h and the 
evaluation procedure was carried out following the protocol described in the paragraph 
“Seeding Duration Optimization”. Image processing was inaccurate for this specific test. In fact, 
increasing the number of cells and creating areas of cell overlapping meant many artefacts were 
introduced, which made the analysis not precise. The calculation of the seeding efficiency was 
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therefore based on the counting of residual cells in the medium. These data suggested that when 
the injected cell number was increased to 600,000 cells, efficiency slightly decreased (Figure 
4-32). This could be explained by the reduction of adhesion sites for cells, with the increased 
number of cells not be able to attach in the designed time span. Translated into clinical 
application this suggests we can minimize cell quantities, which is a key point when using 
autologous cells from the patient. The optimal seeding number was set as 450,000 cells. 
 
Figure 4-32: Cell injection optimization: bar graph. 
Percentage of adhered cells after 6 hour rotating protocol varying the initial cell amount. Values 
expressed as mean ± standard deviation. n=3. 
 
4.5.5.4 static culture of the tubular scaffold  
The next in vitro experiment aimed to determine the evolution of the construct when kept in 
static culture for 5 days. The scaffolds underwent three kind of assays: the first one was a 
repetition of the Anti-Vimentin staining with a different fluorophore, which has an emission 
wavelength of 647 nm that decrease the scaffold autofluorescence; the second one was a 
viability staining (live & dead); the third one was the immunofluorescence, with Anti-Vimentin 
and Anti-CD31, on histology slices. 
Figure 4-33A, and especially its magnification Figure 4-33B, show cells with elongated bodies 
following the morphology of the fibers and with a visible spread cytoskeleton.  
The analysis of the fluorescent images showed high viability (Figure 4-33C-D): the percentage of 
living cells on the scaffolds was 97% and the value complies with the control (24 multi-well).  
The histology slices were stained with two different antibodies (Figure 4-33E-F): Anti-CD31 with 
DAPI and Anti-Vimentin with DAPI. The pictures were made by stacking the fluorescence images 
over the bright-field ones. 
Results indicate ECs have formed a discontinuous layer on the scaffold internal surface. Since 
the aim is to reproduce an endothelial layer, it is good to notice that the cells are well distributed 
180 
 
around the whole surface and that they have not infiltrated inside the scaffolds. On the other 
hand, there should not be gaps in the cell layers; this issue could be overcome injecting more 
cells during the seeding procedure or allowing longer stating maturation before applying the 
flow in the bioreactor. 
 
 
Figure 4-33: Static Culture of endothelialised graft lumen.  
A-B) Static culture of EAhy926 cells on the GL/PCL scaffold. Figure A is obtained assembling 2.5X 
images of different fields of the scaffold. B) Higher magnified field of the lumen of the scaffold 
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(10X). DAPI (blue) was used to mark the nuclei and Anti-Vimentin (red) to mark the cytoskeleton 
(magnification 10x. Cells stained with Anti-Vimentin using a fluorophore with emission 
wavelength of 647nm). C-D) Calcein (green) and EthD-iii (red) were used to stain respectively 
living and dead cells on control (24-well plate) (C) and GL lumen of the scaffold (D). E-F) Histology 
slices of the GL/PCL scaffolds seeded with endothelial cells, demonstrating the localization of 
the cells. E) The cells are stained with Anti-CD31 (green) and DAPI (blue). F) The cells are stained 
with Anti-Vimentin (red) and DAPI (blue). The images are obtained merging the fluorescence 
and the bright-field pictures 
4.5.6 Static culture muscularization:  
The Bioprinting procedure on the outer surface of the tubular graft was performed by seeding 
only one cell type per time (adventitial    progenitor cells or VSMCs) and evaluating cell behaviour 
in parallel experiments. The cell-laden gel was bioprinted on the external layer of the tubular 
structure connected to the bioprinting rotating support and crosslinked as previously described. 
The cellularized scaffold was then cut in smaller pieces and cultured in static conditions in 24-
well plate, using endothelial cell growth cell medium for adventitial progenitor cells and smooth 
muscle growth medium 2 for AoSMCs. I demonstrated the feasibility of the procedure, in which 
the gel layer showed integrity and adhesion to the PCL external layer. In addition, I observed the 
spread distribution of cells through the whole thickness of the gel, without migration into the 





Figure 4-34: Static culture of muscularized graft outer surface 
A-B) Schematic representation of the bioprinting system and the analysed section. B) Cross-
sectional images of the AG/PL+GL/PCL prototype: bright field image highlights the multi-layer 
structure and its magnification. The fluorescence image shows the adventitial    progenitor cells 
stained with DAPI within the AG/PL gel. Blue staining, DAPI. 
 Biocompatibility and capability of adventitial progenitor cells and VSMCs to proliferate in the 
AG/PL-GL/PCL assembled scaffold was evaluated at fixed time-points. Analysis of images derived 





Figure 4-35: Viability assessment of adventitial progenitor cells and AoSMC seeded on the outern 
layer of the bioegnineered graft. 
A-B) Schematic representation of the bioprinting system and the analysed section (outer layer). 
B) Viability assay at different time-points of adventitial progenitor cells and VSMCs. Red staining 




Figure 4-36: Proliferation assessment of adventitial progenitor cells and AoSMC seeded on the 
outern layer of the bioegnineered graft. 
Proliferation assay at different time-points of adventitial progenitor cells and VSMCs. Both 
adventitial progenitor cells were stained as follow: cytoskeleton with Vimentin (red), nuclei of 
proliferative cell with EdU (green) and nuclei of the total cells with DAPI (blue). 
 
Results showed that adventitial progenitor cells maintained a viability rate of around 70% along 
the whole period of 15 days, while VSMCs, that at day 1 were 78±2% viable, decreased to 57±3% 
of viability at day 15 (Figure 4-35 and Figure 4-36). 
Adventitial progenitor cells showed a ratio of proliferative cells below 20% along the 15 days 
evaluation. On the other hand, VSMCs showed no proliferative ability (below 1%). This is 
compatible with contractile phenotype of VSMCs. Moreover, mechanical stimuli which usually 
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the blood vessel receive in-vivo are absent in static conditions and this lack of pulsatile pressure 
could also limit the activation of VSMCs. An additional staining with Vimentin was performed on 
the cells stained with EdU kit for proliferation assessment. This allowed the evaluation of the 
morphology and the spreading of the cytoskeleton of the cells (Figure 4-37). From this visual 
analysis is evident that in the two-week period both adventitial progenitor cells and VSMCs have 
the possibility to spread and develop contacts with other cells, which is an important indicator 




Figure 4-37:Viability and proliferation bar graphs of adventitial progenitor cells and AoSMCs. 
Bar graphs show the percentage of proliferating and viable bioprinted adventitial progenitor 
cells and VSMCs after 5, 10 and 15 days maturation in  static conditions. Values expressed as 
mean ± standard deviation. n=3. 
 
4.5.7 Perfusion conditioning of the TEVG 
Finally, I tested the TEVGs that underwent the whole process of seeding and culturing (6 h 
rotation and 5 days perfusion using a dynamic bioreactor, with omission of static culturing). The 
integrity of the structure was assessed by visual observation under optical microscopy. At the 
end of the perfusion phase, some areas of detachment between the AG/PL and GL/PCL layers 
were visible after the slicing of the samples at the termination of the experiment, but the 
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structure did not show evidence of collapsing during the period of culturing. Immunofluorescent 
images showed the presence of the adventitial progenitor cells and AoSMCs labelled 
respectively with DiO (green dye) and Dil (red dye), in the different compartment of the graft, 
without clear migration (Figure 4-38A-D). A confluent layer of CAECs (also stained with DiO) was 
visible and covered the whole lumen without infiltration of the underneath GL/PCL layer, 
confirming the right tuning of GL fibers (Figure 4-38E-F). The observation of the images 
demonstrates the feasibility of the fabrication procedure of the three-layered hybrid TEVG, 
maintaining the adventitial progenitor cells and AoSMCs separated. But it is highlighted the need 
of increasing the cell density in the AG/PL gel to create dense layer of cells and also to improve 
the cell-to-cell contact, fundamental for the assembly of a tissue (Guillotin et al., 2010)(Guillotin 
and Guillemot, 2011; Norotte, 2009). Also, Dil staining of AoSMCs showed low efficiency of 
binding, suggesting a more specific marker for future validation. As far as regard the luminal side 
of the graft, the efficacy of seeding of the rotating bioreactor system and the tuning procedure 
were demonstrated by the achievement of a uniform layer of CAECs. The increase of the initial 
number of cells inject and the dynamic conditioning showed beneficial effects to the endothelial 




Figure 4-38: Immunofluorescent images of assembled three-layered TEVG.  
A-C) The images show the three channels ((A) blue, (B) red and (C) green) of immunofluorescent 
images obtained on cross-section of three-layered TEVG.  A) Blue channel: nuclei stained with 
DAPI; B) Red channel: AoSMCs stained with Dil; C) Green channel: DiO dye stained the adventitial 
progenitor cells in the external layer and the CAECs in the lumen of the graft. The scaffold 
analysed underwent the entire procedure including: Rotating Bioprinting of cell-laden-AG/PL, 
CAECs injection in the lumen, 6h rotating seeding and 5 days dynamic conditioning in flow 
perfusion bioreactor. D) Channel merged in a unique image, showing the different compartment 
of the scaffold. E-F) Endothelialized lumen of the TEVG. Figure (E) and (F) show the confluent 
layer of CAECs on the luminal side of the graft (magnification 2.5X) and a magnified field (10X) 





Main milestones. The aim of the work described in this chapter was to create a small diameter 
vascular graft (<6 mm) able to fill the gap between clinical demand and availability of autologous 
material for CABG. A first successful milestone was the manufacturing of different layers of the 
candidate TEVG and assembling them in a composite structure mimicking the complexity of the 
backbone of a native artery. In the scaffold manufacture, I used sterilization protocols necessary 
to reduce the risk of cell contamination. The second milestone was the successful incorporation 
of specialized vascular cells to populate the provisional scaffold. To this aim, I generated a new 
rotating system devoted to endothelialization while I used a bioprinter system to cellularize the 
layers corresponding to the media and the adventitia. I used human cells, either commercial 
lines or adventitial progenitor cells derived from human veins, to obtain proof of principle. 
Finally, I demonstrated the feasibility of the entire process of assembling polymers and cells into 
a first TEVG prototype.  
 
Overview of acellular scaffolds 
The main properties of an ideal TEVG is to have an anti-coagulation internal surface, appropriate 
mechanical features, and capability to be integrated in the host tissue (Gong et al., 2016; 
Niklason, 1999; Seifu et al., 2013). Biodegradable artificial grafts have been explored as a 
promising approach. Among those, the preference for acellular grafts or pre-cellularized grafts 
is still a topic of debate (Stowell and Wang, 2018). Table 1-1 in Chapter 1 provides a list of TEVG 
applied in human studies.  
Acellular TEVGs are expected to stimulate an in situ cell recruitment from surrounding tissue, 
after the implantation. This category of scaffolds has the advantage of constituting an off-the-
shelf product that could be stored and be readily available for any type of emergency and patient 
(Mahara et al., 2015; Muylaert et al., 2016; Shafiq et al., 2016; Stowell and Wang, 2018; Wang 
et al., 2015). However, the absence of the cellular component introduces some major 
drawbacks: I) the time for the endogenous endothelium to spread and cover the implanted graft 
exposes the patient to the risk of thrombogenic events; II) the resistance to mechanical stress 
depends exclusively on the artificial graft strength, which, being intrinsically unable to remodel, 
could lead to aneurysm formations. In fact, the graft would need the colonization of exogenous 
stromal cells able to differentiate into VSMCs to support structural integrity and provide 
contractile responsiveness. Acellular tubular grafts, named Humacyte (Humacyte Incorporated, 
RTP, NC), were tested in a series of small and large animal models, showing 100% patency after 
24 days and 88% after 6 months in dogs and baboons, respectively (Dahl et al., 2011, 2013). 
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These promising results led to a clinical trial that got underway in 2012, in which the acellular 
PGA scaffolds were used for vascular access in patients with end-stage renal disease (Gui and 
Niklason, 2014; Lawson et al., 2016). This study involved 60 patients recruited in Poland and the 
US with an average of follow-up period of 16 months, during which 4 patients died, although 
none were associated with the failure of the graft (Lawson et al., 2016). Additionally, no immune 
response or aneurysm formation was detected. In term of efficacy, the TEVGs were successfully 
patent (63%) at 6 months, while the patency rate dropped to 28% after 12 months. This led to 
numerous interventions of thrombectomy to restore the patency (Lawson et al., 2016). 
 
Production of an advanced acellular scaffold 
Although our final aim was to generate a cellularized TEVG, the intermediate step of the 
production process resulted in an advanced multi-layered acellular TEVG that could be 
considered as an immediate therapeutic product. Importantly, the implementation of using an 
AG/PL and GL/PCL composite system allowed us to approximate some mechanical properties of 
the native human artery. It would be interesting to compare this acellular prototype with 
existing ones in an in vivo model of arterial grafting and also investigate whether the subsequent 
cellularization step does increase biocompatibility and therapeutic efficacy, while not 
compromising mechanical properties.  
The first attempt to fabricate the tubular acellular graft made with nanofibers was performed 
electrospinning GL crosslinked with GPTMS. This material was chosen for its high 
biocompatibility and cell adhesion properties (Kang et al., 1999; Tonda-Turo et al., 2013; Yeo et 
al., 2011). I assessed the feasibility of producing a tubular structure with 6 mm diameter and 
specific surface characteristics. The surface showed a fiber size of 90±18 nm, and a pore size of 
290±23 nm. Since the eukaryotic cell’s diameter range is around a few microns, they cannot get 
inside the scaffold. This is an important specification because the vessels have a single layer of 
ECs, and therefore their migration to the media would be undesired (Powell and Boyce, 2008).  
The swelling assessment showed that the structure undergoes a self-remodelling in wet 
conditions (length: -15%, thickness: +91% and diameter: -21%). Despite the good properties 
achieved, a degradation test highlighted that weight loss was relevant after 10 days in wet 
conditions, which represents a short period for a vascular conduit. Mechanical tests showed no 
statistical difference between the longitudinal and the circumferential elastic modulus 
(respectively 0.131±0.009 MPa and 0.098.7±0.006 MPa), suggesting an isotropic behaviour of 
the scaffold due to the complete random organization of the nanofibers. On the other hand, a 
relevant difference between GL scaffolds (both directions) and native coronary artery (1.48±0.24 
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MPa (Karimi et al., 2013)) was detected. Generally, the mismatch of mechanical properties 
between the graft and the host vasculature is highly associated with implant failure. Moreover, 
it has been noticed that the long-term patency has a close relationship with the mechanical 
properties of a graft. Furthermore, the compliance, which  is the ability of a vessel to increase 
its volume with the increase of transmural pressure, is function of the elastic modulus and the 
geometry of the structure (Emmott et al., 2016).  
To overcome these limitations, I decided to focus my attention on producing a hybrid TEVG, 
made of natural and synthetic polymers to synergize the cell interaction features of the former 
with mechanical properties of the latter. The new core of the hybrid TEVG was fabricated with 
an inner layer of GL surrounded by a second of PCL. A previous study demonstrated the 
combination of these two materials had good biocompatibility and showed that the resulting 
nanofiber network had adhesive features similar to those of the natural extracellular matrix 
(Carrabba et al., 2016).  
A swelling test performed on samples of PCL nanofibers showed a slight reorganization of the 
fibers in aqueous environment, with a maximum relative gain weight of 1.87±0.32, which 6.2 
times less than GL. This behaviour led to delamination of the nanofiber layer of the two 
polymers. To avoid problems of delamination, a transition layer was added, in which 
simultaneously both PCL and GL were electrospun. This addition of the new GL/PCL core solved 
the limitations associated with the single material-tubular structure. The resistance to 
degradation of PCL is well described in literature (Mondal et al., 2016), while mechanical 
properties vary depending on the structure and fabrication techniques (Carrabba et al., 2016; 
Eshraghi and Das, 2010; Kim, 2008; Lee et al., 2008). New mechanical tests, comparing GL and 
GL/PCL scaffolds showed a significant increase in the Young modulus in the GL/PCL scaffold 
(1.70±0.66 MPa) as compared to the GL alone (0.38±0.14MPa). Furthermore, this new 
composite material now showed a value comparable with the native coronary artery (1.48±0.24 
MPa) (Karimi et al., 2013).  
 
Overview of cellularized grafts 
Early efforts to build cellularized TEVGs were based on rolling confluent VSMCs and fibroblast 
sheets onto a rod, the so called  ‘cell-sheet method’, to create an artery-resembling vessel 
(L’Heureux et al., 2006). The fabrication process lasted 7-9 months and reproducibility was poor 
(Gauvin et al., 2011; McAllister et al., 2009). This limited clinical translation urged the 
development of new methods, including seeding cells onto bio-degradable scaffolds. ECs-
seeded TEVGs reportedly reduce the risk of intravascular clot formation and neointima 
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hyperplasia (Davies and Hagen, 1993; Kakisis et al., 2005; Wu  K. K. and Thiagarajan  P., 1996). 
Moreover, VSMCs confer tonicity and elasticity, due to their contractile phenotype and ability 
to produce ECM proteins, such as collagen and elastin (Chan-Park et al., 2009). Moreover, the 
cross-talk between VSMCs and ECs is fundamental for long-lasting patency, regulating ECM 
production and remodelling (Korff et al., 2001; Tschoeke et al., 2008). ). Currently, production 
time and selection of clinically relevant cell source represent persistent problems in creating 
successful TEVG (Carrabba and Madeddu, 2018; Koch et al., 2010; Wystrychowski et al., 2011). 
 
Incorporation of specialized vascular cells to generate a living artery 
In order to create a TEVG able to grow, remodel, and integrate with surrounding host tissue, I 
developed a cellularized graft which replicates the native artery organization with high fidelity. 
I succeeded in the first objective to create a tubular scaffold homogeneously colonized at its 
luminal surface by ECs and at the outer layer by VSMCs and adventitial progenitor cells. In the 
majority of studies from the literature, one or a maximum of two cell types were considered and 
no publication reported the use of adventitial progenitor cells, which are typically resident 
around the adventitial vasa vasorum. These cells have important regenerative (Campagnolo et 
al., 2010)  but also control remodelling processes in the media and intima (Tigges et al., 2013; 
Zhang et al., 2018).  
The use of different cell types required distinct seeding methods to address the difficulties 
related to tubular geometry. Reviewing the literature, I recognized different approaches have 
been used so far for cell seeding of TEVGs.  They can be mainly categorized as static, hydrogels-
based, electrostatic, magnetic, pressure-based, and rotational seeding (Villalona et al., 2010). 
The latter two strategies attracted my attention. To the twofold aim of endothelialization and 
muscularization, I designed and constructed two new distinct seeding systems: a rotating 
bioreactor and a bioprinting rotating system. Material and fabrication techniques were chosen 
considering the following requirements: sterilization compliance of the parts that would be in 
contact with the biological matter, manufacturing simplicity, possibility of performing 
simultaneous and segregated experiments, use of tools and containers currently employed in 
the biology laboratories, ability to withstand the incubator environment without getting 
damaged or causing contamination. The rotating bioreactor was designed to hold 6 scaffolds 
simultaneously and was programmed to employ different seeding protocols. The bioprinting 
system, instead, cellularizes one tubular structure per time but allows the operator to achieve a 
precise and semi-automatized homing of cells in the designed area.  
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HUVECs were employed for the endothelialization set-up. The first experiment series was 
performed to find the right rotary protocol, which would give us cell presence over the entire 
surface. Once the protocol was tuned, tests were made to find the right protocol duration. 
Several durations were tested from 2 to 12 h, at intervals of 2 h, while maintaining fixed the 
number of cells injected. The number of attached cells was measured in two ways: performing 
cell counts in culture media at the end of the experiments and on the images of the graft taken 
with the fluorescence microscope. From the former method, an unattached cell rate between 
18-43% was registered, whereas, from the visual quantification, the attached cells ranged from 
13% to 44%. In addition, the images were analysed to estimate the homogeneity of the 
distribution by dividing the images in smaller sectors. The average cell number was from 87 
cells/mm2, in case of protocol duration of 2 h, to 220 cells/mm2, for 12 h of seeding time, with a 
standard deviation/mean ratio from 0.43- 0.66. The last in vitro experiment was the static 
culture of the seeded scaffolds for 5 days. At the end, a viability assay indicated a viable cell rate 
of 97%. From the histology analysis, I verified that no cells had infiltrated the scaffold. 
The attached cells rate was aligned to the average found in literature (Villalona et al., 2010). 
However, the visual quantification was difficult because of the scaffold dimensions, its 
autofluorescence and the problem of quantification associated with the edges. Therefore, it 
cannot be excluded that some cells were not detected.  
For the muscularization procedure, AoSMC and adventitial progenitor cells were used. The 
assessment of the procedure showed a good accuracy in cell homing around the synthetic 
nanofibers layer. Both cell type had high viability rate (both above 70%), though percentage of 
viable AoSMCs decreased significantly below 60% at day 15. A proliferation assay highlighted 
the absence of proliferation in AoSMCs, which is compatible with their contractile phenotype, 
while adventitial progenitor cells maintained a proliferation capacity. A morphological 
assessment after 2 weeks of static culturing suggested that cells spread their cytoskeleton and 
formed contacts, finding space within the gel in the process of degradation. This analysis also 
showed that the both ECs and mural cells did not form a confluent layer in their respective 
location, suggesting that an increase in the number of cells or culture time might be considered 
in the future. Noteworthy, these experiments were performed in static conditions, thus future 
experiments will assess the organization and spreading of the cells into the gel under pulsatile 
flow stimulation. Finally, I was able to assemble a three-layered TEVG confirming the feasibility 
of recreating the morphology of a native artery. For this experiment, a more tissue-specific cell 
type was used, substituting immortalized HUVECs with CAECs.  
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In conclusion, I gained evidence that the adopted seeding methods were effective and can be 
integrated. The seeding machineries were capable to operate in tissue culture environment 
without malfunctions or inducing infections. 
 
Time for production 
In terms of production time, from the bioprinting of the first AG/PL layer to the application of 
the flow, the whole procedure lasted less than 7 h. Previous rotational seeding approaches 
present in literature showed a range of seeding period between 12h and 72 h (Villalona et al., 
2010). In their preclinical study in large animals, Ju YM et al. showed that the period of seeding 
lasted 48h, followed by a conditioning period in pulsatile bioreactor of 7 days. In other studies, 
a polyglycolic-acid (PGA) scaffold was seeded with VSMCs for 24h (Godbey et al., 2004) while a 
small-diameter polyurethane (PU) graft was seeded for 12h using rotational seeding, but the 
process needed a post-seeding period of static culture to allow the stabilization of cells in the 
internal layer (Hsu et al., 2005). 
Differences become even more emphasized if our method is compared with static seeding 
methodologies, in which the efficiency decrease to a level of 25% (Villalona et al., 2010). 
Although this strategy reduces the procedural complexity, it needs prolonged phases of seeding, 
at least 7 days (Roh et al., 2007)) with regular turning which introduces a higher risk of 
contamination. On the other hand, if the period is too short, ECs may not reach a spread and 
well adhered morphology with risk of detachment after flow application. From the analysis of 
data present in literature, I can claim having achieved the goal of reducing the time of 
cellularization process, while maintaining the efficiency in a valuable range (up to 75%), as well 
as consistent sterility. Moreover, the increase in the technological complexity was moderated 
by introduction of operator-friendly procedures. As a result, the newly fabricated rotating 
bioreactor and rotating bioprinting device allow the seeding of cells to be carried out by a single 
investigator, performing all the protocol steps under biological safety hood in sterile conditions 





4.7 Future development 
The prototype graft could be improved further. In the current work, we used commercial adult 
cells from specific origin tissue to assess the feasibility of the TEVG cellularization approach, but 
for a translational application, the choice of clinically relevant cell source represents a 
fundamental implementation. During the last stages of development of the graft prototype, we 
already hypothesised different alternatives:  
i) One option investigated in the present study would be using autologous tissue-specific cells 
extracted from the patient’s body. This strategy bases its advantages on the absence of 
immune reaction but implies big disadvantages connected to the harvesting and expanding 
different cell types, which would require larger amounts of tissue sources and longer time 
for graft production. In addition, cells expanded from patients that need revascularization 
may have intrinsic dysfunctions (Figure 4-39-A). 
ii) A second option would be using immune-compatible allogeneic cells from human donors, 
in which the allogenic cells would be treated to avoid immunogenic reaction (Figure 4-39-
B).  
iii) Another prospect to consider for future development involves the use of induced 
Pluripotent Stem (iPS) cells to create the three different cell types. The tuning of the 
differentiation procedure would allow to generate a patient-specific TEVG (Figure 4-39-C).  
iv) The high request of creating a ready-available graft open the doors for an alternative 
scenario which involves the final decellularization of the TEVG. The complex step of 
cellularization, which represents the most innovative step of the approach, will still remain 
the key of the process. Following this maturation procedure, necessary to remodel the entire 
structure and produce the ECM protein fundamental for the stability of the structure, the 
graft will be decellularized and stored to be used as an off-the-shelf product available for 
any patient (Figure 4-39-D). 
Another aspect in the developmental route to the clinic is the optimization of the period of 
dynamic conditioning. Extending the period of exposure to flow into a perfusion Bioreactor 
might improve the maturation of the cellular components. It would also be interesting to assess 
and implement the production of specific ECM proteins, like elastin, and the contractile activities 
of the VSMCs layer. 
From the fabrication point of view, the electrospinning process still presents issues which could 
affect its reproducibility, due to the high sensibility of the system to changes in temperature and 
humidity, which we plan to control implementing the device with temperature and humidity 
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control unit. In addition, mechanical testing, suturability, coagulation assays, and in vivo 
preclinical studies should be performed before planning a first in human clinical trial.  
Finally, as far as regards clinical purpose, together with the coronary artery and femoropopliteal 
bypass grafting that we already widely described, we consider paediatric application as a 
potential alternative (Figure 4-39-E-F). Paediatric patients with congenital diseases, in fact, often 
require reconstruction of main arteries, with problem of lack of autologous vessel and multiple 
surgical intervention. The developed graft, because of its dimension and the potentiality of 





Figure 4-39: Schematic illustration of future developments and clinical targets.  
A) Tissues obtained from biopsies of a patient are treated and cells are isolated (adventitial 
progenitor cells (APCs in the figure), SMCs and ECs), expanded in vitro and used to cellularize 
the TEVG. The graft is finally implanted with the use of autologous cells. (B) Tissues obtained 
from biopsies of a patient are treated and cells are isolated, expanded and treated to avoid 
immune-reaction. Allogenic immune-compatible cells are used to cellularize the scaffold and the 
graft is implanted. C) Cells are isolated, expanded reprogrammed to be pluripotent (iPS). Cells 
are then differentiated in the desired cell type and autologous differentiated cells are used to 
cellularize the TEVG before implantation. D) Cells of different origin can be used to cellularize 
the scaffold and remodel the scaffold under dynamic conditioning. Once the graft is mature, it 
will undergo to decellularization process. Finally, the TEVG will be sterilized and stored ready for 
the surgical intervention. E-F) Schematic illustration of hypothesized clinical target: E) adult 







Potential clinical impact 
 In the US alone, the direct and indirect costs of coronary artery disease were estimated $177 
billion, with a substantial proportion attributable to revascularization. In addition, bypass graft 
maintenance has relevant economic implications. The vascular graft market was evaluated at 
$2.5 billion in 2016 and is expected to reach 3.8 billion in 2022, growing in CAGR of 7.3% during 
the forecast period. Therefore, the successful application of a durable TEVG could substantially 
reduce the NHS costs, especially if the new strategy is implemented through the automatized 
manufacturing of an off-the-shelf product. The proposed solution could have a relevant impact 
into the field by demonstrating the feasibility of generating and implanting a multi-layered 
synthetic small-size conduit containing an elastic lamina to separate the intima from the media 
and functionalized with topographically printed vascular cells.  
Three routes to commercial exploitation could be considered: 1. Partnership with a company. 
The technology is likely to be of interest to the increasing number of companies who see the 
potential of the untapped cell therapy market. 2. Technology license to a medical company. It is 
anticipated that a potential licensee will fund pilot therapy studies for the product and, if 
successful, enter into a research collaboration to provide further proof of concept data for 












5 Conclusive remarks 
The work described in this thesis represents part of the general translational program being 
developed at the Bristol Heart Institute, University of Bristol, under the leadership of by 
supervisors Prof Madeddu and Prof Drinkwater. The program has the ambition to generate new 
tissue engineering solutions for the definitive correction of occlusive vascular disease in adults 
and congenital heart disease in children.  
In this context, I attempted to reach two principal goals: to design and manufacture composite 
hybrid scaffolds cellularized with human vascular cells for perivascular promotion of 
arteriogenesis in a murine model of limb ischemia and to generate three-layered small-size 
conduits resembling the complexity of an artery to address the unmet clinical need and shortage 
of natural arterial grafts. I also contributed to the design and realization of a new GLP facility 
dedicated to tissue engineering. I designed and fabricated new instruments that represent the 
technological core of this project and the overall program of research. 
At the beginning of my PhD studies, I had knowledge and expertise in engineering. Joining a 
clinically oriented laboratory has given me the possibility to apply my engineering skills to 
translational cardiovascular medicine, thus developing a multidisciplinary curriculum. I learnt 
and applied several molecular and biological technique instrumental to my work and 
investigated how cells react to the exposure to synthetic materials. Ultimately, I applied animal 
models of disease to investigate how these newly developed tissues engineered products 
interfere with and potentially improve the recipient response to tissue engineering products. I 
also contributed to the publication of review articles covering the topic of tissue engineering. 
My original article “Design, fabrication and perivascular implantation of bioactive scaffolds 
engineered with human adventitial progenitor cells for stimulation of arteriogenesis in peripheral 
ischemia” published in Biofabrication and reported in Chapter 2 of this thesis opens new 
avenues for targeted delivery of therapeutic cells in patients with critical limb ischemia. I 
employed the synthetic polymer polycaprolactone for fabrication of 3D woodpile- or channel-
shaped scaffolds by a computer-assisted writing system (pressure assisted micro-syringe 
square), followed by deposition of gelatin nanofibers by electro-spinning. Scaffolds were then 
cross-linked with natural or synthetic GPTMS agents to improve mechanical properties and 
durability in vivo. The composite scaffolds were next fixed by crown inserts in each well of a 
multi-well plate and seeded with adventitial progenitor cells, which were isolated/expanded 
from human saphenous vein surgical leftovers. Cell density, alignment, proliferation and viability 
were assessed 1 week later. Data from in vitro assays showed channel-shaped/GPTMS-
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crosslinked scaffolds confer cells with best alignment and survival/growth characteristics. Based 
on these results, channel-shaped/GPTMS-crosslinked scaffolds with or without adventitial 
progenitor cells were implanted around the femoral artery of mice with unilateral limb ischemia. 
Perivascular implantation of scaffolds increased arterial collaterals around the femoral artery 
and in limb muscles compared with non-implanted controls. Perivascular arteriogenesis were 
additionally incremented by cell-engineered scaffolds.  
Continuing on the same line of research, I attempted to refine some limitation of the present 
study with the ultimate aim of succeeding in improving reperfusion. I have substituted the 
backbone polymer of PCL with PLGA to better tune degradability and then introduced a 
bioprinter for easy production of the scaffold and patterned cellularization. I produced a multi-
layered cellularized scaffold containing two types of vascular cells and studied the influence of 
the 3D architecture on the cell profile and paracrine activity. I completed a new in vivo study, 
although histological data are still under examination. Importantly, I succeeded in my goal of 
manufacturing a new cell engineered product capable of improving reperfusion of the implanted 
ischemic limb. 
Finally, I engaged with a new ambitious project that will be the topic of my post doc. The project 
represents a novel attempt to generate a biocompatible living vascular conduit with the ability 
to remodel in a physiologic manner following implantation in vivo. The candidate product 
consists of two intermediates (INT) which are combined in the final Investigational Medicinal 
Product (IMP). INT1: autologous vascular cells competent to address the specific functions of 
the different sheets of an artery and INT2: a synthetic hybrid conduit mimicking the structural 
complexity of an artery, including concentric superimposition of layers with different mechanical 
properties and an elastic lamina delimiting the intima and preventing it from invasion of 
neointima-forming cells. INT1 is incorporated into INT2 through novel bioprinting 
methodologies allowing an automatized fabrication process. The IMP is intended for the 
revascularization of small-diameter vessels, which remains an unmet clinical need. The primary 
target is atherosclerotic vascular disease, but additional clinical applications include the 
correction of congenital heart disease. 
Initially, I have used mature vascular cells extracted from a patient’s tissue. The protocol for 
production of adult vascular cells has been already upgraded to meet clinical standards. In a 
mutually non-exclusive approach, an off-the-shelf IMP could be manufactured using allogeneic 
vascular cells from immune-compatible healthy donors and iPS or embryonic stem cells 
differentiation. This solution would allow mass production of an INT1 that retains functional 
properties superior to a patient-derived INT1. With regard to INT2, the material used in this 
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project has been already approved by the FDA. Hence, the next step in the impact pathway is to 
upgrade an automatized prototype in order to obtain approval for a first-in-human study.   
This studentship has projected me into a clinical reality and fostered a great deal of interest and 
enthusiasm in medical science. I am fully committed to persevere in this endeavour hoping to 
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6.1 Supplementary data: A 
Evaluate of nanofibers characteristics: fibers density and fibers defects 
As far as nanofibers is concerned, the aim of the process was to evaluate fibers density and fibers 
defects with ImageJ software. 
• Enhancement of focus; 
• Thresholding; 
• Binarization; 
• Close (dilate then erode); 
• Counting of pixel through histogram and calculation optical porosity; 
• Calculation average fiber diameter (in pixels), and evaluation of variance and standard 
deviation; 
• Application of the function maximum (erosion) with a value equal to the average 
diameter + 2*(Standard deviation). This is done to erode the 95.45% of the fibers leaving 
only the defects. 
• the last post-processing also involves an erosion of defects that will be restored to their 
original size with a minimum function (expansion), in which input will be given the same 




6.2 Supplementary data: B  
Channel structure 
The supplementary data provide with the Phyton code which was used to generate the g.code 
file used to fabricate the “channel” structure with the customized Bioprinter as described in 
section 3.4.1.4.2. The file could be imported Python, run, and the .gcode produced could be 
imported in any software able to drive a 3D printer (i.e. MatterControl).  
 
1. #imports this library for maths later on   
2. import numpy as np   
3.    
4. #title just sets the filename output   
5. #desc is put at the top of the file so you know what setup you used   
6. #change whenever you change variables!   
7. title="Channels.gcode"   
8.                        
9. #set variables here   
10. #units are mm   
11. #yellow 0.5; 21G 0.514, 27G 0.2, 30G 0.159,  32G 0.108   
12. gauge=32   
13. nozzle_diameter=0.108   
14. layer_height=0.5*nozzle_diameter   
15. line_width=float(nozzle_diameter)   
16. filament_diameter=13   
17. line_space=0.4   
18. lines=16   
19. line_length=line_space*lines-0.4   
20. overall_line_length=49.3   
21. bed_centre_x=102.5   
22. bed_centre_y=100   
23. layers=6    
24. skirt_size=2*line_length   
25. #layers of the support grid are always 2   
26. layer_grid=2   
27. layers_tot=layers+layer_grid   
28. exspeed=700   
29. mspeed=2400   
30.    
31.    
32. #this inverts movements later on if there is an odd number of lines   
33. linemultiplier=int   
34. if lines % 2 == 0:   
35.     linemultiplier=1   
36. else:   
37.     linemultiplier=-1   
38.    
39.    
40. #this section defines a number of functions to make things easier later on   
41. ####################################################################   
42.    
43. def drawLine(direction, e, x=None, y=None, length=None,speed=None):      
44.     global xpos   
45.     global ypos   
46.     global line_length   
47.     if speed == None:   
48.         speed=exspeed   
49.     gFile.write("G1 F"+str(speed)+"\n")   
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50.     if x == None:   
51.         x=xpos   
52.     if y == None:   
53.         y=ypos   
54.     if length == None:   
55.         length=line_length   
56.     if direction == 'x':   
57.         gFile.write('G1 X'+str(x+length)+" Y"+str(y)+" E"+str(e)+"\n")        
  
58.         xpos=x+length   
59.     if direction == '-x':   
60.         gFile.write('G1 X'+str(x-
length)+" Y"+str(y)+" E"+str(e)+"\n")          
61.         xpos=x-length       
62.     if direction == 'y':   
63.         gFile.write('G1 X'+str(x)+" Y"+str(y+length)+" E"+str(e)+"\n")   
64.         ypos=y+length   
65.     if direction == '-y':   
66.         gFile.write('G1 X'+str(x)+" Y"+str(y-length)+" E"+str(e)+"\n")   
67.         ypos=y-length   
68.     gFile.write("G92 E0\n")   
69.     #retract(e,50)   
70.            
71. #moveTo just moves to a coordinate without extruding   
72. def moveTo(x=None,y=None,z=None,speed=mspeed):   
73.     global xpos   
74.     global ypos   
75.     global zpos   
76.     if x == None:   
77.         x=xpos   
78.     if y == None:   
79.         y=ypos   
80.     if z == None:   
81.         z=zpos   
82.     gFile.write("G1 X"+str(x)+" Y"+str(y)+" Z"+str(z)+" F"+str(speed)+"\n")   
83.     xpos=x   
84.     ypos=y   
85.     zpos=z   
86.       
87. #extrusion calculates the amount to extrude for a given line width and distanc
e   
88. def extrusion(width, length=line_length):   
89.     ex=(0.3)*(((width-
layer_height)*layer_height+np.pi*(layer_height/2)**2)*length)/filament_diamete
r   
90.     return(ex)   
91.       
92. def supportingGrid(startPos):   
93.     gFile.write(';Printing supporting grid\n')   
94.        
95.     for k in range(layer_grid):   
96.         moveTo(z=layer_height) # I removed (layer_height*(l+1) because I don't
 want that it would move up when change printing direction   
97.         if k%2==0:   
98.             moveTo(startPos[0],None,z=layer_height)   
99.             moveTo(y=startPos[1])   
100.             drawLine("x", extrusion(line_width))   
101.             drawLine("y", extrusion(line_width))   
102.             drawLine("-x", extrusion(line_width))   
103.             drawLine("-y", extrusion(line_width))   
104.             for i in range(lines-1):   
105.                 if i % 2 == 0:   
106.                     drawLine("x", extrusion(line_width))   
107.                     moveTo(xpos,ypos+line_space)   
108.                 else:   
109.                     drawLine('-x',extrusion(line_width))   
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110.                     moveTo(xpos, ypos+line_space)   
111.             if lines % 2 != 0:   
112.                 drawLine("x", extrusion(line_width))   
113.             else:   
114.                 drawLine('-x',extrusion(line_width))   
115.             #moveTo(startPos[0],startPos[1]+line_space*lines,zpos)   
116.             #gFile.write('; direction change\n')   
117.         else:   
118.             for i in range(lines):   
119.                 if i % 2 == 0:   
120.                     drawLine("-y", extrusion(line_width))   
121.                     moveTo(xpos+line_space*linemultiplier,ypos)   
122.                 else:   
123.                     drawLine('y', extrusion(line_width))   
124.                     moveTo(xpos+line_space*linemultiplier,ypos)   
125.         restartpos=[xpos,ypos,zpos]   
126.     gFile.write(';end of supporting grid\n')   
127.    
128.        
129. def Channels(startPos):   
130.     gFile.write(';y_direction\n')   
131.     moveTo(x=startPos[0],z=5)   
132.     moveTo(y=startPos[1], z=z_layer)   
133. #    for k in range(layers):   
134.            
135.     drawLine("x", extrusion(line_width))   
136.     drawLine("y", extrusion(line_width))   
137.     drawLine("-x", extrusion(line_width))   
138.     drawLine("-y", extrusion(line_width))   
139.       
140.     for i in range(lines):   
141.         if i % 2 == 0:   
142.             drawLine("y", extrusion(line_width))   
143.             moveTo(xpos+line_space*linemultiplier,ypos)   
144.         else:   
145.             drawLine('-y', extrusion(line_width))   
146.             moveTo(xpos+line_space*linemultiplier,ypos)   
147.    
148.     gFile.write(';end of y direction\n')   
149.    
150. #######################################################################
######   
151.    
152.    
153. #creates a new file and preps it for the gcode   
154. gFile=open(title,"w+")   
155. gFile.write("M190 S25\nG21\nG90\nG92 Z0 E0\nG28\n\n")   
156.    
157. #'homes' the script   
158. xpos=0   
159. ypos=0   
160. zpos=0   
161. speed_number=9   
162. k=0   
163. w=0   
164. travel_height=5   
165. pre_extrusion=0.05   
166. displacement=14.1   
167.    
168. #moves to start position of the skirt   
169.    
170. gFile.write("G1 Z"+str(layer_height)+" F"+str(mspeed)+"\n")   
171. moveTo(z=10)   
172.    
173. gFile.write("G1 E"+str(pre_extrusion)+"\n")   
174.    
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175. moveTo(bed_centre_x-(skirt_size/2)-20,bed_centre_y-(skirt_size/2))   
176.    
177. moveTo(bed_centre_x-(skirt_size/2)-15,bed_centre_y-(skirt_size/2))   
178.    
179. moveTo(z=layer_height)   
180.    
181. gFile.write("G1 F"+str(exspeed)+"\n")   
182. zpos=layer_height   
183.    
184.    
185. skirt(skirt_size)   
186. supportingGrid([bed_centre_x-(line_length/2)-15,bed_centre_y-
(line_length/2)])   
187.    
188. Channels([bed_centre_x-(line_length/2)-15,bed_centre_y-
(line_length/2)])   
189.    
190. #finishes up and saves the gcode file   
191. gFile.write("\n\n\nG92 E0\nM104 S0\nM106 S0\nM84")   






6.3 Supplementary data: C 
Woodpile structure 
The supplementary data provide with the Phyton code which was used to generate the g.code 
file used to fabricate the “woodpilel” structure with the customized Bioprinter as described in 
section 3.4.1.4.2. The file could be imported Python, run, and the .gcode produced could be 
imported in any software able to drive a 3D printer (i.e. MatterControl).  
 
1. #imports this library for maths later on   
2. import numpy as np   
3.    
4.    
5. title="woodpile.gcode"   
6. desc="Woodpile Scaffold"   
7. #set variables here   
8. #units are mm   
9. #yellow 0.5; 21G 0.514, 27G 0.2, 30G 0.159,  32G 0.108   
10. gauge=32   
11. nozzle_diameter=0.108   
12. layer_height=0.25*nozzle_diameter   
13. line_width=float(nozzle_diameter)   
14. filament_diameter=13   
15. line_space=0.400   
16. lines=16   
17. line_length=line_space*lines-0.5   
18. bed_centre_x=100   
19. bed_centre_y=100   
20. layers=6   
21. skirt_size=2*line_length   
22.    
23. layer_grid=2   
24. exspeed=500   
25. mspeed=2400   
26.    
27.    
28. #this inverts movements later on if there is an odd number of lines   
29. linemultiplier=int   
30. if lines % 2 == 0:   
31.     linemultiplier=1   
32. else:   
33.     linemultiplier=-1   
34.    
35.    
36.    
37. def drawLine(direction, e, x=None, y=None, length=None,speed=exspeed):      
38.     global xpos   
39.     global ypos   
40.     global line_length   
41.     gFile.write("G1 F"+str(speed)+"\n")   
42.     if x == None:   
43.         x=xpos   
44.     if y == None:   
45.         y=ypos   
46.     if length == None:   
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47.         length=line_length   
48.     if direction == 'x':   
49.         gFile.write('G1 X'+str(x+length)+" Y"+str(y)+" E"+str(e)+"\n")        
  
50.         xpos=x+length   
51.     if direction == '-x':   
52.         gFile.write('G1 X'+str(x-
length)+" Y"+str(y)+" E"+str(e)+"\n")          
53.         xpos=x-length       
54.     if direction == 'y':   
55.         gFile.write('G1 X'+str(x)+" Y"+str(y+length)+" E"+str(e)+"\n")   
56.         ypos=y+length   
57.     if direction == '-y':   
58.         gFile.write('G1 X'+str(x)+" Y"+str(y-length)+" E"+str(e)+"\n")   
59.         ypos=y-length   
60.     gFile.write("G92 E0\n")   
61.    
62. #moveTo just moves to a coordinate without extruding   
63. def moveTo(x=None,y=None,z=None,speed=mspeed):   
64.     global xpos   
65.     global ypos   
66.     global zpos   
67.     if x == None:   
68.         x=xpos   
69.     if y == None:   
70.         y=ypos   
71.     if z == None:   
72.         z=zpos   
73.     gFile.write("G1 X"+str(x)+" Y"+str(y)+" Z"+str(z)+" F"+str(speed)+"\n")   
74.     xpos=x   
75.     ypos=y   
76.     zpos=z   
77.       
78. #extrusion calculates the amount to extrude for a given line width and distanc
e   
79. def extrusion(width, length=line_length):   
80.     ex=(0.5)*(((width-
layer_height)*layer_height+np.pi*(layer_height/2)**2)*length)/filament_diamete
r   
81.     return(ex)   
82.    
83. #woodpileMesh prints a mesh of a number of layers (set with layers variable)   
84. #startPos is the bottom left corner coordinate   
85. def supportingGrid(startPos):   
86.     gFile.write(';Printing supporting grid\n')   
87.        
88.     for l in range(layer_grid):   
89.         moveTo(z=layer_height)    
90.         if l%2==0:   
91.             moveTo(startPos[0],None,z=layer_height)   
92.             moveTo(y=startPos[1])   
93.             drawLine("x", extrusion(line_width))   
94.             drawLine("y", extrusion(line_width))   
95.             drawLine("-x", extrusion(line_width))   
96.             drawLine("-y", extrusion(line_width))   
97.             for i in range(lines-1):   
98.                 if i % 2 == 0:   
99.                     drawLine("x", extrusion(line_width))   
100.                     moveTo(xpos,ypos+line_space)   
101.                 else:   
102.                     drawLine('-x',extrusion(line_width))   
103.                     moveTo(xpos, ypos+line_space)   
104.             if lines % 2 != 0:   
105.                 drawLine("x", extrusion(line_width))   
106.             else:   
107.                 drawLine('-x',extrusion(line_width))   
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108.    
109.         else:   
110.             for i in range(lines):   
111.                 if i % 2 == 0:   
112.                     drawLine("-y", extrusion(line_width))   
113.                     moveTo(xpos+line_space*linemultiplier,ypos)   
114.                 else:   
115.                     drawLine('y', extrusion(line_width))   
116.                     moveTo(xpos+line_space*linemultiplier,ypos)   
117.         restartpos=[xpos,ypos,zpos]   
118.         moveTo(*restartpos)   
119.     moveTo(x=xpos+5,z=5)   
120.     gFile.write('M226\n')   
121.     gFile.write(';end of the supporting grid\n')   
122.    
123.        
124. def woodpileMesh(startPos):   
125.     gFile.write(';woodpiling\n')   
126.        
127.     for l in range(layers):    
128.         moveTo(z=(layer_height+layer_height*(l+1)))   
129.         if l%2==0:   
130.             moveTo(startPos[0],None,z=layer_height+(0.01)*(l+1))   
131.             moveTo(y=startPos[1])   
132.             drawLine("x", extrusion(line_width))   
133.             drawLine("y", extrusion(line_width))   
134.             drawLine("-x", extrusion(line_width))   
135.             drawLine("-y", extrusion(line_width))   
136.             for i in range(lines-1):   
137.                 if i % 2 == 0:   
138.                     drawLine("x", extrusion(line_width))   
139.                     moveTo(xpos,ypos+line_space)   
140.                 else:   
141.                     drawLine('-x',extrusion(line_width))   
142.                     moveTo(xpos, ypos+line_space)   
143.             if lines % 2 != 0:   
144.                 drawLine("x", extrusion(line_width))   
145.             else:   
146.                 drawLine('-x',extrusion(line_width))   
147.               
148.         else:   
149.             moveTo(startPos[0],None,z=layer_height+(0.01)*(l+1))   
150.                
151.             for i in range(lines):   
152.                 if i % 2 == 0:   
153.                     drawLine("-y", extrusion(line_width))   
154.                     moveTo(xpos+line_space*linemultiplier,ypos)   
155.                 else:   
156.                     drawLine('y', extrusion(line_width))   
157.                     moveTo(xpos+line_space*linemultiplier,ypos)   
158.         restartpos=[xpos,ypos,zpos]   
159.         moveTo(*restartpos)   
160.         moveTo(x=xpos+10,z=10)   
161.         gFile.write('end of layer '+str(l+1)+'\n')   
162.         if l < layers:   
163.             gFile.write('M226\n')   
164.         else:   
165.             moveTo(z=layer_height*layers+15)   
166.             moveTo(x=0,y=150)   
167.     gFile.write(';end of woodpiling\n')   
168.                
169. def skirt(size):   
170.     gFile.write(';skirt\n')   
171.     moveTo(bed_centre_x-(size/2)-15,bed_centre_y-
(size/2),layer_height)       
172.     drawLine('x',extrusion(line_width,size),length=size)   
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173.     drawLine('y',extrusion(line_width,size),length=size)   
174.     drawLine('-x',extrusion(line_width,size),length=size)   
175.     drawLine('-y',extrusion(line_width,size),length=size)   
176.     gFile.write(';end of skirt\n')   
177.    
178.    
179.    
180. def retract(ex,percent):   
181.     gFile.write("G1 E"+str(-ex*(percent/100))+"\n")   
182.    
183. #end of functions, onto the script   
184. #######################################################################
######   
185.    
186.    
187. #creates a new file and preps it for the gcode   
188. gFile=open(title,"w+")   
189. gFile.write("M190 S25\nG21\nG90\nG92 Z0 E0\nG28\n\n")   
190.    
191. #'homes' the script   
192. xpos=0   
193. ypos=0   
194. zpos=0   
195. travel_height=10   
196. pre_extrusion=0.05   
197.    
198.    
199. gFile.write("G1 Z"+str(layer_height)+" F"+str(mspeed)+"\n")   
200. moveTo(z=10)   
201.    
202. gFile.write("G1 E"+str(pre_extrusion)+"\n")   
203.    
204. moveTo(bed_centre_x-(skirt_size/2)-20,bed_centre_y-(skirt_size/2))   
205.    
206. moveTo(bed_centre_x-(skirt_size/2)-15,bed_centre_y-(skirt_size/2))   
207.    
208. moveTo(z=layer_height)   
209.    
210. gFile.write("G1 F"+str(exspeed)+"\n")   
211. zpos=layer_height   
212.    
213.    
214. skirt(skirt_size)   
215. supportingGrid([bed_centre_x-(line_length/2)-15,bed_centre_y-   
(line_length/2)])   
216.    
217. woodpileMesh([bed_centre_x-(line_length/2)-15,bed_centre_y-
(line_length/2)])   
218.    
219.    
220.    
221. gFile.write("\n\n\nG92 E0\nM104 S0\nM106 S0\nM84")   
222. gFile.close()  
 
